CN101595219A - 作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物,其制备方法和用途 - Google Patents
作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物,其制备方法和用途 Download PDFInfo
- Publication number
- CN101595219A CN101595219A CNA2007800445766A CN200780044576A CN101595219A CN 101595219 A CN101595219 A CN 101595219A CN A2007800445766 A CNA2007800445766 A CN A2007800445766A CN 200780044576 A CN200780044576 A CN 200780044576A CN 101595219 A CN101595219 A CN 101595219A
- Authority
- CN
- China
- Prior art keywords
- toxin
- component
- microorganism
- raf
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 128
- 108091007433 antigens Proteins 0.000 title claims abstract description 120
- 102000036639 antigens Human genes 0.000 title claims abstract description 118
- 244000005700 microbiome Species 0.000 title claims abstract description 105
- 239000002773 nucleotide Substances 0.000 title claims abstract description 62
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 62
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 230000028327 secretion Effects 0.000 claims abstract description 90
- 230000033001 locomotion Effects 0.000 claims abstract description 25
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 25
- 230000004913 activation Effects 0.000 claims abstract description 23
- 239000013604 expression vector Substances 0.000 claims abstract description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 16
- 239000013600 plasmid vector Substances 0.000 claims abstract description 15
- 230000035772 mutation Effects 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 230000003834 intracellular effect Effects 0.000 claims abstract description 10
- 238000005336 cracking Methods 0.000 claims abstract description 9
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 9
- 210000002540 macrophage Anatomy 0.000 claims abstract description 9
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 6
- 231100000654 protein toxin Toxicity 0.000 claims abstract description 6
- 210000000172 cytosol Anatomy 0.000 claims abstract description 5
- 231100000765 toxin Toxicity 0.000 claims description 144
- 239000003053 toxin Substances 0.000 claims description 138
- 108700012359 toxins Proteins 0.000 claims description 137
- 206010028980 Neoplasm Diseases 0.000 claims description 88
- 210000004027 cell Anatomy 0.000 claims description 82
- 241000894006 Bacteria Species 0.000 claims description 77
- 108020001507 fusion proteins Proteins 0.000 claims description 66
- 102000037865 fusion proteins Human genes 0.000 claims description 66
- 108090000623 proteins and genes Proteins 0.000 claims description 62
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 claims description 51
- 101100381978 Mus musculus Braf gene Proteins 0.000 claims description 51
- 230000001580 bacterial effect Effects 0.000 claims description 51
- 235000018102 proteins Nutrition 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 241000588724 Escherichia coli Species 0.000 claims description 40
- 239000013612 plasmid Substances 0.000 claims description 40
- 108010049048 Cholera Toxin Proteins 0.000 claims description 36
- 102000009016 Cholera Toxin Human genes 0.000 claims description 35
- 101710154606 Hemagglutinin Proteins 0.000 claims description 33
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 33
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 33
- 101710176177 Protein A56 Proteins 0.000 claims description 33
- 239000000185 hemagglutinin Substances 0.000 claims description 33
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 23
- 108091000080 Phosphotransferase Proteins 0.000 claims description 21
- 108010055044 Tetanus Toxin Proteins 0.000 claims description 21
- 239000000370 acceptor Substances 0.000 claims description 21
- 239000003228 hemolysin Substances 0.000 claims description 21
- 208000037797 influenza A Diseases 0.000 claims description 21
- 102000020233 phosphotransferase Human genes 0.000 claims description 21
- 229940118376 tetanus toxin Drugs 0.000 claims description 21
- 241000607142 Salmonella Species 0.000 claims description 18
- 230000032258 transport Effects 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 17
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 16
- 101000697856 Rattus norvegicus Bile acid-CoA:amino acid N-acyltransferase Proteins 0.000 claims description 15
- 241000712461 unidentified influenza virus Species 0.000 claims description 15
- 241000192125 Firmicutes Species 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 231100000655 enterotoxin Toxicity 0.000 claims description 13
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 12
- 241000193738 Bacillus anthracis Species 0.000 claims description 12
- 241000186779 Listeria monocytogenes Species 0.000 claims description 12
- 239000000147 enterotoxin Substances 0.000 claims description 12
- 230000003612 virological effect Effects 0.000 claims description 12
- 108010006464 Hemolysin Proteins Proteins 0.000 claims description 11
- 108010079723 Shiga Toxin Proteins 0.000 claims description 10
- 101710146739 Enterotoxin Proteins 0.000 claims description 9
- 241000607768 Shigella Species 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 9
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 8
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 8
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 241000607598 Vibrio Species 0.000 claims description 7
- 230000000813 microbial effect Effects 0.000 claims description 7
- 244000052769 pathogen Species 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 claims description 6
- 101710092462 Alpha-hemolysin Proteins 0.000 claims description 6
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 claims description 6
- -1 Gp100 Proteins 0.000 claims description 6
- 108010081690 Pertussis Toxin Proteins 0.000 claims description 6
- 102100020814 Sequestosome-1 Human genes 0.000 claims description 6
- 102100039094 Tyrosinase Human genes 0.000 claims description 6
- 108060008724 Tyrosinase Proteins 0.000 claims description 6
- 239000002776 alpha toxin Substances 0.000 claims description 6
- 231100000776 exotoxin Toxicity 0.000 claims description 6
- 239000002095 exotoxin Substances 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 230000035479 physiological effects, processes and functions Effects 0.000 claims description 6
- 101710197219 Alpha-toxin Proteins 0.000 claims description 5
- 241000193163 Clostridioides difficile Species 0.000 claims description 5
- 108050006400 Cyclin Proteins 0.000 claims description 5
- 101710082714 Exotoxin A Proteins 0.000 claims description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
- 101710124951 Phospholipase C Proteins 0.000 claims description 5
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 claims description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 5
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 claims description 5
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 claims description 5
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims description 5
- 101710182223 Toxin B Proteins 0.000 claims description 5
- 101710182532 Toxin a Proteins 0.000 claims description 5
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 231100000518 lethal Toxicity 0.000 claims description 5
- 230000001665 lethal effect Effects 0.000 claims description 5
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 claims description 4
- 102100033806 Alpha-protein kinase 3 Human genes 0.000 claims description 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 4
- 102100040753 Casein kinase II subunit alpha' Human genes 0.000 claims description 4
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 4
- 241000193403 Clostridium Species 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 102100037916 Cyclin-dependent kinase 11B Human genes 0.000 claims description 4
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims description 4
- 101000892015 Homo sapiens Casein kinase II subunit alpha' Proteins 0.000 claims description 4
- 101001018978 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 claims description 4
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 4
- 101000585262 Homo sapiens Serine/threonine kinase-like domain-containing protein STKLD1 Proteins 0.000 claims description 4
- 101000628647 Homo sapiens Serine/threonine-protein kinase 24 Proteins 0.000 claims description 4
- 101000588553 Homo sapiens Serine/threonine-protein kinase Nek9 Proteins 0.000 claims description 4
- 101000864831 Homo sapiens Serine/threonine-protein kinase Sgk3 Proteins 0.000 claims description 4
- 101000693630 Homo sapiens Uncharacterized serine/threonine-protein kinase SBK3 Proteins 0.000 claims description 4
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims description 4
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 claims description 4
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 102100024924 Protein kinase C alpha type Human genes 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 102100029854 Serine/threonine kinase-like domain-containing protein STKLD1 Human genes 0.000 claims description 4
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 claims description 4
- 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 claims description 4
- 102100031398 Serine/threonine-protein kinase Nek9 Human genes 0.000 claims description 4
- 102100025559 Serine/threonine-protein kinase SBK2 Human genes 0.000 claims description 4
- 101710152798 Serine/threonine-protein kinase SBK2 Proteins 0.000 claims description 4
- 102100030071 Serine/threonine-protein kinase Sgk3 Human genes 0.000 claims description 4
- 102100028948 Serine/threonine-protein kinase TAO1 Human genes 0.000 claims description 4
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 claims description 4
- 241000607762 Shigella flexneri Species 0.000 claims description 4
- 108010002687 Survivin Proteins 0.000 claims description 4
- 102100025558 Uncharacterized serine/threonine-protein kinase SBK3 Human genes 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 4
- 241000607447 Yersinia enterocolitica Species 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 208000037976 chronic inflammation Diseases 0.000 claims description 4
- 230000009089 cytolysis Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 210000005075 mammary gland Anatomy 0.000 claims description 4
- 210000001672 ovary Anatomy 0.000 claims description 4
- 229930192851 perforin Natural products 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 229940098232 yersinia enterocolitica Drugs 0.000 claims description 4
- 231100000710 AB5 toxin Toxicity 0.000 claims description 3
- 101150082952 ACTA1 gene Proteins 0.000 claims description 3
- 101150019464 ARAF gene Proteins 0.000 claims description 3
- 101800000263 Acidic protein Proteins 0.000 claims description 3
- 102100032187 Androgen receptor Human genes 0.000 claims description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 3
- 108010062544 Apoptotic Protease-Activating Factor 1 Proteins 0.000 claims description 3
- 102100034524 Apoptotic protease-activating factor 1 Human genes 0.000 claims description 3
- 101100064323 Arabidopsis thaliana DTX47 gene Proteins 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 claims description 3
- 102000051819 Baculoviral IAP Repeat-Containing 3 Human genes 0.000 claims description 3
- 102100027522 Baculoviral IAP repeat-containing protein 7 Human genes 0.000 claims description 3
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 108030001720 Bontoxilysin Proteins 0.000 claims description 3
- 101150012716 CDK1 gene Proteins 0.000 claims description 3
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 claims description 3
- 101100439046 Caenorhabditis elegans cdk-2 gene Proteins 0.000 claims description 3
- 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 claims description 3
- 101100495324 Caenorhabditis elegans cdk-7 gene Proteins 0.000 claims description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 claims description 3
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 3
- 108010068192 Cyclin A Proteins 0.000 claims description 3
- 108010058546 Cyclin D1 Proteins 0.000 claims description 3
- 102000003909 Cyclin E Human genes 0.000 claims description 3
- 108090000257 Cyclin E Proteins 0.000 claims description 3
- 102000002495 Cyclin H Human genes 0.000 claims description 3
- 108010068237 Cyclin H Proteins 0.000 claims description 3
- 102100025191 Cyclin-A2 Human genes 0.000 claims description 3
- 101100499270 Drosophila melanogaster Diap1 gene Proteins 0.000 claims description 3
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 claims description 3
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 claims description 3
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 claims description 3
- 102000001301 EGF receptor Human genes 0.000 claims description 3
- 108060006698 EGF receptor Proteins 0.000 claims description 3
- 108010051542 Early Growth Response Protein 1 Proteins 0.000 claims description 3
- 102100023226 Early growth response protein 1 Human genes 0.000 claims description 3
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
- 241000588722 Escherichia Species 0.000 claims description 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 3
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 claims description 3
- 102100025614 Galectin-related protein Human genes 0.000 claims description 3
- 101100272587 Gallus gallus ITA gene Proteins 0.000 claims description 3
- 108090001053 Gastrin releasing peptide Proteins 0.000 claims description 3
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 3
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 3
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 claims description 3
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 3
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 3
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 3
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 claims description 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 claims description 3
- 101001046426 Homo sapiens cGMP-dependent protein kinase 1 Proteins 0.000 claims description 3
- 101150032161 IAP1 gene Proteins 0.000 claims description 3
- 108010042653 IgA receptor Proteins 0.000 claims description 3
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 3
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
- 102000004407 Lactalbumin Human genes 0.000 claims description 3
- 108090000942 Lactalbumin Proteins 0.000 claims description 3
- 102100034256 Mucin-1 Human genes 0.000 claims description 3
- 102000006386 Myelin Proteins Human genes 0.000 claims description 3
- 108010083674 Myelin Proteins Proteins 0.000 claims description 3
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 3
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 claims description 3
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 claims description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 claims description 3
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 3
- 108700012411 TNFSF10 Proteins 0.000 claims description 3
- 206010044248 Toxic shock syndrome Diseases 0.000 claims description 3
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims description 3
- 108010048992 Transcription Factor 4 Proteins 0.000 claims description 3
- 108091023040 Transcription factor Proteins 0.000 claims description 3
- 102000040945 Transcription factor Human genes 0.000 claims description 3
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 claims description 3
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 3
- 101710102803 Tumor suppressor ARF Proteins 0.000 claims description 3
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 claims description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 3
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 3
- 108010080146 androgen receptors Proteins 0.000 claims description 3
- 108700000711 bcl-X Proteins 0.000 claims description 3
- 102100022422 cGMP-dependent protein kinase 1 Human genes 0.000 claims description 3
- 230000032823 cell division Effects 0.000 claims description 3
- 208000019065 cervical carcinoma Diseases 0.000 claims description 3
- 230000006020 chronic inflammation Effects 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 3
- 239000002619 cytotoxin Substances 0.000 claims description 3
- 230000003619 fibrillary effect Effects 0.000 claims description 3
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 3
- 108010039551 hemorrhagic proteinase IV Proteins 0.000 claims description 3
- 108010071397 lactoferrin receptors Proteins 0.000 claims description 3
- 210000001165 lymph node Anatomy 0.000 claims description 3
- 210000001161 mammalian embryo Anatomy 0.000 claims description 3
- 238000012737 microarray-based gene expression Methods 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 3
- 210000005012 myelin Anatomy 0.000 claims description 3
- 210000000056 organ Anatomy 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 230000000737 periodic effect Effects 0.000 claims description 3
- 210000001550 testis Anatomy 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- 235000021241 α-lactalbumin Nutrition 0.000 claims description 3
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 claims description 2
- 102100022528 5'-AMP-activated protein kinase catalytic subunit alpha-1 Human genes 0.000 claims description 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims description 2
- 102100038079 AP2-associated protein kinase 1 Human genes 0.000 claims description 2
- 102100025995 AarF domain-containing protein kinase 1 Human genes 0.000 claims description 2
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 claims description 2
- 102100034134 Activin receptor type-1B Human genes 0.000 claims description 2
- 102100034135 Activin receptor type-1C Human genes 0.000 claims description 2
- 102100021886 Activin receptor type-2A Human genes 0.000 claims description 2
- 102100027647 Activin receptor type-2B Human genes 0.000 claims description 2
- 206010000830 Acute leukaemia Diseases 0.000 claims description 2
- 101710082399 Alpha-protein kinase 3 Proteins 0.000 claims description 2
- 102100039182 Ankyrin repeat and protein kinase domain-containing protein 1 Human genes 0.000 claims description 2
- 102100025511 Anti-Muellerian hormone type-2 receptor Human genes 0.000 claims description 2
- 101100243447 Arabidopsis thaliana PER53 gene Proteins 0.000 claims description 2
- 102100024003 Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 Human genes 0.000 claims description 2
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 claims description 2
- 102100039341 Atrial natriuretic peptide receptor 2 Human genes 0.000 claims description 2
- 102100035958 Atypical kinase COQ8A, mitochondrial Human genes 0.000 claims description 2
- 102100035952 Atypical kinase COQ8B, mitochondrial Human genes 0.000 claims description 2
- 102000004000 Aurora Kinase A Human genes 0.000 claims description 2
- 108090000461 Aurora Kinase A Proteins 0.000 claims description 2
- 102100032306 Aurora kinase B Human genes 0.000 claims description 2
- 102100026630 Aurora kinase C Human genes 0.000 claims description 2
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 claims description 2
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 claims description 2
- 108091005625 BRD4 Proteins 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 102100021738 Beta-adrenergic receptor kinase 1 Human genes 0.000 claims description 2
- 102100037281 Beta-adrenergic receptor kinase 2 Human genes 0.000 claims description 2
- 102100025423 Bone morphogenetic protein receptor type-1A Human genes 0.000 claims description 2
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 claims description 2
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 102100029894 Bromodomain testis-specific protein Human genes 0.000 claims description 2
- 102100033641 Bromodomain-containing protein 2 Human genes 0.000 claims description 2
- 102100033642 Bromodomain-containing protein 3 Human genes 0.000 claims description 2
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 claims description 2
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 claims description 2
- 102100025589 CaM kinase-like vesicle-associated protein Human genes 0.000 claims description 2
- 102100021535 Calcium/calmodulin-dependent protein kinase kinase 1 Human genes 0.000 claims description 2
- 102100021534 Calcium/calmodulin-dependent protein kinase kinase 2 Human genes 0.000 claims description 2
- 102100033086 Calcium/calmodulin-dependent protein kinase type 1 Human genes 0.000 claims description 2
- 102100033087 Calcium/calmodulin-dependent protein kinase type 1B Human genes 0.000 claims description 2
- 102100033088 Calcium/calmodulin-dependent protein kinase type 1D Human genes 0.000 claims description 2
- 102100033089 Calcium/calmodulin-dependent protein kinase type 1G Human genes 0.000 claims description 2
- 102100033093 Calcium/calmodulin-dependent protein kinase type II subunit alpha Human genes 0.000 claims description 2
- 102100025232 Calcium/calmodulin-dependent protein kinase type II subunit beta Human genes 0.000 claims description 2
- 102100025228 Calcium/calmodulin-dependent protein kinase type II subunit delta Human genes 0.000 claims description 2
- 102100025227 Calcium/calmodulin-dependent protein kinase type II subunit gamma Human genes 0.000 claims description 2
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 claims description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 claims description 2
- 102100034357 Casein kinase I isoform alpha Human genes 0.000 claims description 2
- 102100034356 Casein kinase I isoform alpha-like Human genes 0.000 claims description 2
- 102100037402 Casein kinase I isoform delta Human genes 0.000 claims description 2
- 102100037398 Casein kinase I isoform epsilon Human genes 0.000 claims description 2
- 102100037397 Casein kinase I isoform gamma-1 Human genes 0.000 claims description 2
- 102100023060 Casein kinase I isoform gamma-2 Human genes 0.000 claims description 2
- 102100023067 Casein kinase I isoform gamma-3 Human genes 0.000 claims description 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims description 2
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000009738 Connective Tissue Neoplasms Diseases 0.000 claims description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 2
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 2
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 claims description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 2
- 102100023263 Cyclin-dependent kinase 10 Human genes 0.000 claims description 2
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 claims description 2
- 102100038114 Cyclin-dependent kinase 13 Human genes 0.000 claims description 2
- 102100038113 Cyclin-dependent kinase 14 Human genes 0.000 claims description 2
- 102100033250 Cyclin-dependent kinase 15 Human genes 0.000 claims description 2
- 102100033245 Cyclin-dependent kinase 16 Human genes 0.000 claims description 2
- 102100033234 Cyclin-dependent kinase 17 Human genes 0.000 claims description 2
- 102100033144 Cyclin-dependent kinase 18 Human genes 0.000 claims description 2
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 2
- 102100034741 Cyclin-dependent kinase 20 Human genes 0.000 claims description 2
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 claims description 2
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 2
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims description 2
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims description 2
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims description 2
- 102100031679 Cyclin-dependent kinase-like 1 Human genes 0.000 claims description 2
- 102100031685 Cyclin-dependent kinase-like 2 Human genes 0.000 claims description 2
- 102100031684 Cyclin-dependent kinase-like 3 Human genes 0.000 claims description 2
- 102100031683 Cyclin-dependent kinase-like 4 Human genes 0.000 claims description 2
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 claims description 2
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 claims description 2
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 claims description 2
- 102100022204 DNA-dependent protein kinase catalytic subunit Human genes 0.000 claims description 2
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 claims description 2
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 claims description 2
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 claims description 2
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 claims description 2
- 102100038605 Death-associated protein kinase 2 Human genes 0.000 claims description 2
- 102100038606 Death-associated protein kinase 3 Human genes 0.000 claims description 2
- 102100029638 Dual serine/threonine and tyrosine protein kinase Human genes 0.000 claims description 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 claims description 2
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 claims description 2
- 102100023275 Dual specificity mitogen-activated protein kinase kinase 3 Human genes 0.000 claims description 2
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 claims description 2
- 102100023272 Dual specificity mitogen-activated protein kinase kinase 5 Human genes 0.000 claims description 2
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 claims description 2
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 claims description 2
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 claims description 2
- 102100040844 Dual specificity protein kinase CLK2 Human genes 0.000 claims description 2
- 102100040856 Dual specificity protein kinase CLK3 Human genes 0.000 claims description 2
- 102100040858 Dual specificity protein kinase CLK4 Human genes 0.000 claims description 2
- 102100036492 Dual specificity testis-specific protein kinase 1 Human genes 0.000 claims description 2
- 102100036498 Dual specificity testis-specific protein kinase 2 Human genes 0.000 claims description 2
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 claims description 2
- 102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 claims description 2
- 102100023115 Dual specificity tyrosine-phosphorylation-regulated kinase 2 Human genes 0.000 claims description 2
- 102100023114 Dual specificity tyrosine-phosphorylation-regulated kinase 3 Human genes 0.000 claims description 2
- 102100023112 Dual specificity tyrosine-phosphorylation-regulated kinase 4 Human genes 0.000 claims description 2
- 102100029505 E3 ubiquitin-protein ligase TRIM33 Human genes 0.000 claims description 2
- 102100029493 EKC/KEOPS complex subunit TP53RK Human genes 0.000 claims description 2
- 101150076616 EPHA2 gene Proteins 0.000 claims description 2
- 101150016325 EPHA3 gene Proteins 0.000 claims description 2
- 101150097734 EPHB2 gene Proteins 0.000 claims description 2
- 102100030011 Endoribonuclease Human genes 0.000 claims description 2
- 102100030013 Endoribonuclease Human genes 0.000 claims description 2
- 108010055211 EphA1 Receptor Proteins 0.000 claims description 2
- 108010055323 EphB4 Receptor Proteins 0.000 claims description 2
- 101150078651 Epha4 gene Proteins 0.000 claims description 2
- 101150025643 Epha5 gene Proteins 0.000 claims description 2
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 claims description 2
- 102100021600 Ephrin type-A receptor 10 Human genes 0.000 claims description 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 2
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 claims description 2
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 claims description 2
- 102100021605 Ephrin type-A receptor 5 Human genes 0.000 claims description 2
- 102100021604 Ephrin type-A receptor 6 Human genes 0.000 claims description 2
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 claims description 2
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 claims description 2
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 claims description 2
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 claims description 2
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 claims description 2
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 claims description 2
- 102100031984 Ephrin type-B receptor 6 Human genes 0.000 claims description 2
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 claims description 2
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 claims description 2
- 241000402754 Erythranthe moschata Species 0.000 claims description 2
- 101100071194 Escherichia coli hlyA gene Proteins 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 102100021808 Eukaryotic elongation factor 2 kinase Human genes 0.000 claims description 2
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 claims description 2
- 102100026130 Extracellular tyrosine-protein kinase PKDCC Human genes 0.000 claims description 2
- 108091008794 FGF receptors Proteins 0.000 claims description 2
- 102100029531 Fas-activated serine/threonine kinase Human genes 0.000 claims description 2
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims description 2
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 claims description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims description 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims description 2
- 102100023734 G protein-coupled receptor kinase 4 Human genes 0.000 claims description 2
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 claims description 2
- 102100023686 G protein-coupled receptor kinase 6 Human genes 0.000 claims description 2
- 101710113436 GTPase KRas Proteins 0.000 claims description 2
- 102100039788 GTPase NRas Human genes 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 2
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 claims description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 claims description 2
- 102100022662 Guanylyl cyclase C Human genes 0.000 claims description 2
- 101710121697 Heat-stable enterotoxin Proteins 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 claims description 2
- 102100032822 Homeodomain-interacting protein kinase 1 Human genes 0.000 claims description 2
- 102100032827 Homeodomain-interacting protein kinase 2 Human genes 0.000 claims description 2
- 102100032826 Homeodomain-interacting protein kinase 3 Human genes 0.000 claims description 2
- 102100022603 Homeodomain-interacting protein kinase 4 Human genes 0.000 claims description 2
- 101001080057 Homo sapiens 2-5A-dependent ribonuclease Proteins 0.000 claims description 2
- 101000677993 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-1 Proteins 0.000 claims description 2
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims description 2
- 101000742699 Homo sapiens AP2-associated protein kinase 1 Proteins 0.000 claims description 2
- 101000720055 Homo sapiens AarF domain-containing protein kinase 1 Proteins 0.000 claims description 2
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 claims description 2
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 claims description 2
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 claims description 2
- 101000970954 Homo sapiens Activin receptor type-2A Proteins 0.000 claims description 2
- 101000937269 Homo sapiens Activin receptor type-2B Proteins 0.000 claims description 2
- 101000889403 Homo sapiens Ankyrin repeat and protein kinase domain-containing protein 1 Proteins 0.000 claims description 2
- 101000693801 Homo sapiens Anti-Muellerian hormone type-2 receptor Proteins 0.000 claims description 2
- 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 claims description 2
- 101000961040 Homo sapiens Atrial natriuretic peptide receptor 2 Proteins 0.000 claims description 2
- 101000875771 Homo sapiens Atypical kinase COQ8A, mitochondrial Proteins 0.000 claims description 2
- 101000875775 Homo sapiens Atypical kinase COQ8B, mitochondrial Proteins 0.000 claims description 2
- 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 claims description 2
- 101000765862 Homo sapiens Aurora kinase C Proteins 0.000 claims description 2
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 claims description 2
- 101000751445 Homo sapiens Beta-adrenergic receptor kinase 1 Proteins 0.000 claims description 2
- 101000806653 Homo sapiens Beta-adrenergic receptor kinase 2 Proteins 0.000 claims description 2
- 101000934638 Homo sapiens Bone morphogenetic protein receptor type-1A Proteins 0.000 claims description 2
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 claims description 2
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 claims description 2
- 101000794028 Homo sapiens Bromodomain testis-specific protein Proteins 0.000 claims description 2
- 101000871850 Homo sapiens Bromodomain-containing protein 2 Proteins 0.000 claims description 2
- 101000871851 Homo sapiens Bromodomain-containing protein 3 Proteins 0.000 claims description 2
- 101000978379 Homo sapiens C-C motif chemokine 13 Proteins 0.000 claims description 2
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 claims description 2
- 101000990005 Homo sapiens CLIP-associating protein 1 Proteins 0.000 claims description 2
- 101000932896 Homo sapiens CaM kinase-like vesicle-associated protein Proteins 0.000 claims description 2
- 101000971625 Homo sapiens Calcium/calmodulin-dependent protein kinase kinase 1 Proteins 0.000 claims description 2
- 101000971617 Homo sapiens Calcium/calmodulin-dependent protein kinase kinase 2 Proteins 0.000 claims description 2
- 101000944250 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1 Proteins 0.000 claims description 2
- 101000944254 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1B Proteins 0.000 claims description 2
- 101000944258 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1D Proteins 0.000 claims description 2
- 101000944259 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1G Proteins 0.000 claims description 2
- 101000944249 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit alpha Proteins 0.000 claims description 2
- 101001077352 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit beta Proteins 0.000 claims description 2
- 101001077338 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit delta Proteins 0.000 claims description 2
- 101001077334 Homo sapiens Calcium/calmodulin-dependent protein kinase type II subunit gamma Proteins 0.000 claims description 2
- 101000974816 Homo sapiens Calcium/calmodulin-dependent protein kinase type IV Proteins 0.000 claims description 2
- 101000994700 Homo sapiens Casein kinase I isoform alpha Proteins 0.000 claims description 2
- 101000994694 Homo sapiens Casein kinase I isoform alpha-like Proteins 0.000 claims description 2
- 101001026336 Homo sapiens Casein kinase I isoform delta Proteins 0.000 claims description 2
- 101001026376 Homo sapiens Casein kinase I isoform epsilon Proteins 0.000 claims description 2
- 101001026384 Homo sapiens Casein kinase I isoform gamma-1 Proteins 0.000 claims description 2
- 101001049881 Homo sapiens Casein kinase I isoform gamma-2 Proteins 0.000 claims description 2
- 101001049879 Homo sapiens Casein kinase I isoform gamma-3 Proteins 0.000 claims description 2
- 101000892026 Homo sapiens Casein kinase II subunit alpha Proteins 0.000 claims description 2
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 claims description 2
- 101000749824 Homo sapiens Connector enhancer of kinase suppressor of ras 2 Proteins 0.000 claims description 2
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 claims description 2
- 101000908138 Homo sapiens Cyclin-dependent kinase 10 Proteins 0.000 claims description 2
- 101000738400 Homo sapiens Cyclin-dependent kinase 11B Proteins 0.000 claims description 2
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 claims description 2
- 101000884348 Homo sapiens Cyclin-dependent kinase 13 Proteins 0.000 claims description 2
- 101000884374 Homo sapiens Cyclin-dependent kinase 14 Proteins 0.000 claims description 2
- 101000944355 Homo sapiens Cyclin-dependent kinase 15 Proteins 0.000 claims description 2
- 101000944357 Homo sapiens Cyclin-dependent kinase 16 Proteins 0.000 claims description 2
- 101000944358 Homo sapiens Cyclin-dependent kinase 17 Proteins 0.000 claims description 2
- 101000944341 Homo sapiens Cyclin-dependent kinase 18 Proteins 0.000 claims description 2
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 claims description 2
- 101000945708 Homo sapiens Cyclin-dependent kinase 20 Proteins 0.000 claims description 2
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 claims description 2
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims description 2
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims description 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims description 2
- 101000777728 Homo sapiens Cyclin-dependent kinase-like 1 Proteins 0.000 claims description 2
- 101000777764 Homo sapiens Cyclin-dependent kinase-like 2 Proteins 0.000 claims description 2
- 101000777768 Homo sapiens Cyclin-dependent kinase-like 3 Proteins 0.000 claims description 2
- 101000777775 Homo sapiens Cyclin-dependent kinase-like 4 Proteins 0.000 claims description 2
- 101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 claims description 2
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 claims description 2
- 101000619536 Homo sapiens DNA-dependent protein kinase catalytic subunit Proteins 0.000 claims description 2
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 claims description 2
- 101000956149 Homo sapiens Death-associated protein kinase 3 Proteins 0.000 claims description 2
- 101000865739 Homo sapiens Dual serine/threonine and tyrosine protein kinase Proteins 0.000 claims description 2
- 101001115394 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 3 Proteins 0.000 claims description 2
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 claims description 2
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 claims description 2
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 claims description 2
- 101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 claims description 2
- 101000749291 Homo sapiens Dual specificity protein kinase CLK2 Proteins 0.000 claims description 2
- 101000749304 Homo sapiens Dual specificity protein kinase CLK3 Proteins 0.000 claims description 2
- 101000749298 Homo sapiens Dual specificity protein kinase CLK4 Proteins 0.000 claims description 2
- 101000714159 Homo sapiens Dual specificity testis-specific protein kinase 1 Proteins 0.000 claims description 2
- 101000714156 Homo sapiens Dual specificity testis-specific protein kinase 2 Proteins 0.000 claims description 2
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 claims description 2
- 101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 claims description 2
- 101001049990 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 2 Proteins 0.000 claims description 2
- 101001049991 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 3 Proteins 0.000 claims description 2
- 101001049983 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 4 Proteins 0.000 claims description 2
- 101000634991 Homo sapiens E3 ubiquitin-protein ligase TRIM33 Proteins 0.000 claims description 2
- 101001125560 Homo sapiens EKC/KEOPS complex subunit TP53RK Proteins 0.000 claims description 2
- 101001010787 Homo sapiens Endoribonuclease Proteins 0.000 claims description 2
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 claims description 2
- 101000898673 Homo sapiens Ephrin type-A receptor 10 Proteins 0.000 claims description 2
- 101000898696 Homo sapiens Ephrin type-A receptor 6 Proteins 0.000 claims description 2
- 101000898708 Homo sapiens Ephrin type-A receptor 7 Proteins 0.000 claims description 2
- 101000898676 Homo sapiens Ephrin type-A receptor 8 Proteins 0.000 claims description 2
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 claims description 2
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 claims description 2
- 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 claims description 2
- 101000895759 Homo sapiens Eukaryotic elongation factor 2 kinase Proteins 0.000 claims description 2
- 101000926508 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 3 Proteins 0.000 claims description 2
- 101000691796 Homo sapiens Extracellular tyrosine-protein kinase PKDCC Proteins 0.000 claims description 2
- 101000917570 Homo sapiens Fas-activated serine/threonine kinase Proteins 0.000 claims description 2
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims description 2
- 101000829481 Homo sapiens G protein-coupled receptor kinase 4 Proteins 0.000 claims description 2
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 claims description 2
- 101000829473 Homo sapiens G protein-coupled receptor kinase 6 Proteins 0.000 claims description 2
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 2
- 101000903717 Homo sapiens Glycogen synthase kinase-3 alpha Proteins 0.000 claims description 2
- 101000899808 Homo sapiens Guanylyl cyclase C Proteins 0.000 claims description 2
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 claims description 2
- 101001066404 Homo sapiens Homeodomain-interacting protein kinase 1 Proteins 0.000 claims description 2
- 101001066401 Homo sapiens Homeodomain-interacting protein kinase 2 Proteins 0.000 claims description 2
- 101001066389 Homo sapiens Homeodomain-interacting protein kinase 3 Proteins 0.000 claims description 2
- 101001045363 Homo sapiens Homeodomain-interacting protein kinase 4 Proteins 0.000 claims description 2
- 101100508538 Homo sapiens IKBKE gene Proteins 0.000 claims description 2
- 101000889893 Homo sapiens Inactive serine/threonine-protein kinase TEX14 Proteins 0.000 claims description 2
- 101000649963 Homo sapiens Inactive serine/threonine-protein kinase VRK3 Proteins 0.000 claims description 2
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 claims description 2
- 101000741965 Homo sapiens Inactive tyrosine-protein kinase PRAG1 Proteins 0.000 claims description 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 2
- 101001043764 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 claims description 2
- 101000852815 Homo sapiens Insulin receptor Proteins 0.000 claims description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 claims description 2
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 claims description 2
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 claims description 2
- 101000977768 Homo sapiens Interleukin-1 receptor-associated kinase 3 Proteins 0.000 claims description 2
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims description 2
- 101000852255 Homo sapiens Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 claims description 2
- 101001137640 Homo sapiens Kinase suppressor of Ras 2 Proteins 0.000 claims description 2
- 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 claims description 2
- 101001042360 Homo sapiens LIM domain kinase 2 Proteins 0.000 claims description 2
- 101000941877 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 1 Proteins 0.000 claims description 2
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 claims description 2
- 101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 claims description 2
- 101000573522 Homo sapiens MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 2
- 101001059429 Homo sapiens MAP/microtubule affinity-regulating kinase 3 Proteins 0.000 claims description 2
- 101001059427 Homo sapiens MAP/microtubule affinity-regulating kinase 4 Proteins 0.000 claims description 2
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims description 2
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 claims description 2
- 101001059535 Homo sapiens Megakaryocyte-associated tyrosine-protein kinase Proteins 0.000 claims description 2
- 101000687968 Homo sapiens Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Proteins 0.000 claims description 2
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims description 2
- 101001018259 Homo sapiens Microtubule-associated serine/threonine-protein kinase 1 Proteins 0.000 claims description 2
- 101001018300 Homo sapiens Microtubule-associated serine/threonine-protein kinase 2 Proteins 0.000 claims description 2
- 101001018294 Homo sapiens Microtubule-associated serine/threonine-protein kinase 3 Proteins 0.000 claims description 2
- 101001018298 Homo sapiens Microtubule-associated serine/threonine-protein kinase 4 Proteins 0.000 claims description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims description 2
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 claims description 2
- 101000628967 Homo sapiens Mitogen-activated protein kinase 11 Proteins 0.000 claims description 2
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 claims description 2
- 101000628968 Homo sapiens Mitogen-activated protein kinase 13 Proteins 0.000 claims description 2
- 101000976899 Homo sapiens Mitogen-activated protein kinase 15 Proteins 0.000 claims description 2
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 claims description 2
- 101001052477 Homo sapiens Mitogen-activated protein kinase 4 Proteins 0.000 claims description 2
- 101000950710 Homo sapiens Mitogen-activated protein kinase 6 Proteins 0.000 claims description 2
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 claims description 2
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 claims description 2
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 claims description 2
- 101000958409 Homo sapiens Mitogen-activated protein kinase kinase kinase 10 Proteins 0.000 claims description 2
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 claims description 2
- 101001005605 Homo sapiens Mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 claims description 2
- 101001005609 Homo sapiens Mitogen-activated protein kinase kinase kinase 13 Proteins 0.000 claims description 2
- 101001005550 Homo sapiens Mitogen-activated protein kinase kinase kinase 14 Proteins 0.000 claims description 2
- 101001005556 Homo sapiens Mitogen-activated protein kinase kinase kinase 19 Proteins 0.000 claims description 2
- 101001018141 Homo sapiens Mitogen-activated protein kinase kinase kinase 2 Proteins 0.000 claims description 2
- 101001018149 Homo sapiens Mitogen-activated protein kinase kinase kinase 21 Proteins 0.000 claims description 2
- 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 claims description 2
- 101001018147 Homo sapiens Mitogen-activated protein kinase kinase kinase 4 Proteins 0.000 claims description 2
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 claims description 2
- 101001055097 Homo sapiens Mitogen-activated protein kinase kinase kinase 6 Proteins 0.000 claims description 2
- 101001055092 Homo sapiens Mitogen-activated protein kinase kinase kinase 7 Proteins 0.000 claims description 2
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 claims description 2
- 101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 claims description 2
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 claims description 2
- 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 claims description 2
- 101001059989 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 3 Proteins 0.000 claims description 2
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 claims description 2
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 claims description 2
- 101000896657 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 Proteins 0.000 claims description 2
- 101000794228 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 beta Proteins 0.000 claims description 2
- 101001011663 Homo sapiens Mixed lineage kinase domain-like protein Proteins 0.000 claims description 2
- 101000584208 Homo sapiens Myosin light chain kinase 2, skeletal/cardiac muscle Proteins 0.000 claims description 2
- 101001022780 Homo sapiens Myosin light chain kinase, smooth muscle Proteins 0.000 claims description 2
- 101000635935 Homo sapiens Myosin-IIIa Proteins 0.000 claims description 2
- 101000583016 Homo sapiens Myosin-IIIb Proteins 0.000 claims description 2
- 101000654298 Homo sapiens N-terminal kinase-like protein Proteins 0.000 claims description 2
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 claims description 2
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 claims description 2
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 claims description 2
- 101001108314 Homo sapiens Nuclear receptor-binding protein Proteins 0.000 claims description 2
- 101000577339 Homo sapiens Nuclear receptor-binding protein 2 Proteins 0.000 claims description 2
- 101000585675 Homo sapiens Obscurin Proteins 0.000 claims description 2
- 101000598781 Homo sapiens Oxidative stress-responsive serine-rich protein 1 Proteins 0.000 claims description 2
- 101100244966 Homo sapiens PRKX gene Proteins 0.000 claims description 2
- 101000692672 Homo sapiens Phosphoinositide 3-kinase regulatory subunit 4 Proteins 0.000 claims description 2
- 101000731078 Homo sapiens Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Proteins 0.000 claims description 2
- 101001126783 Homo sapiens Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Proteins 0.000 claims description 2
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims description 2
- 101000836974 Homo sapiens Protein O-mannose kinase Proteins 0.000 claims description 2
- 101001051777 Homo sapiens Protein kinase C alpha type Proteins 0.000 claims description 2
- 101001051767 Homo sapiens Protein kinase C beta type Proteins 0.000 claims description 2
- 101001026854 Homo sapiens Protein kinase C delta type Proteins 0.000 claims description 2
- 101001026852 Homo sapiens Protein kinase C epsilon type Proteins 0.000 claims description 2
- 101000971400 Homo sapiens Protein kinase C eta type Proteins 0.000 claims description 2
- 101000971404 Homo sapiens Protein kinase C iota type Proteins 0.000 claims description 2
- 101000971468 Homo sapiens Protein kinase C zeta type Proteins 0.000 claims description 2
- 101000613717 Homo sapiens Protein odd-skipped-related 1 Proteins 0.000 claims description 2
- 101000983155 Homo sapiens Protein-associating with the carboxyl-terminal domain of ezrin Proteins 0.000 claims description 2
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 claims description 2
- 101000606502 Homo sapiens Protein-tyrosine kinase 6 Proteins 0.000 claims description 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims description 2
- 101001125116 Homo sapiens Putative serine/threonine-protein kinase PRKY Proteins 0.000 claims description 2
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims description 2
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 claims description 2
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 claims description 2
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 claims description 2
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 claims description 2
- 101001089266 Homo sapiens Receptor-interacting serine/threonine-protein kinase 3 Proteins 0.000 claims description 2
- 101001089248 Homo sapiens Receptor-interacting serine/threonine-protein kinase 4 Proteins 0.000 claims description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 2
- 101000899806 Homo sapiens Retinal guanylyl cyclase 1 Proteins 0.000 claims description 2
- 101001009847 Homo sapiens Retinal guanylyl cyclase 2 Proteins 0.000 claims description 2
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 claims description 2
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 claims description 2
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 claims description 2
- 101000829506 Homo sapiens Rhodopsin kinase GRK1 Proteins 0.000 claims description 2
- 101000871032 Homo sapiens Rhodopsin kinase GRK7 Proteins 0.000 claims description 2
- 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 claims description 2
- 101000944921 Homo sapiens Ribosomal protein S6 kinase alpha-2 Proteins 0.000 claims description 2
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 claims description 2
- 101000945093 Homo sapiens Ribosomal protein S6 kinase alpha-4 Proteins 0.000 claims description 2
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 claims description 2
- 101001051723 Homo sapiens Ribosomal protein S6 kinase alpha-6 Proteins 0.000 claims description 2
- 101001051706 Homo sapiens Ribosomal protein S6 kinase beta-1 Proteins 0.000 claims description 2
- 101001051714 Homo sapiens Ribosomal protein S6 kinase beta-2 Proteins 0.000 claims description 2
- 101001051707 Homo sapiens Ribosomal protein S6 kinase delta-1 Proteins 0.000 claims description 2
- 101000726974 Homo sapiens Ribosomal protein S6 kinase-like 1 Proteins 0.000 claims description 2
- 101001051709 Homo sapiens Ribosomal protein S6 kinase-related protein Proteins 0.000 claims description 2
- 101000654257 Homo sapiens SCY1-like protein 2 Proteins 0.000 claims description 2
- 101000617778 Homo sapiens SNF-related serine/threonine-protein kinase Proteins 0.000 claims description 2
- 101000826081 Homo sapiens SRSF protein kinase 1 Proteins 0.000 claims description 2
- 101000826077 Homo sapiens SRSF protein kinase 2 Proteins 0.000 claims description 2
- 101000826079 Homo sapiens SRSF protein kinase 3 Proteins 0.000 claims description 2
- 101000642656 Homo sapiens STE20-related kinase adapter protein beta Proteins 0.000 claims description 2
- 101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 claims description 2
- 101000654734 Homo sapiens Septin-4 Proteins 0.000 claims description 2
- 101000648174 Homo sapiens Serine/threonine-protein kinase 10 Proteins 0.000 claims description 2
- 101000628578 Homo sapiens Serine/threonine-protein kinase 16 Proteins 0.000 claims description 2
- 101000661821 Homo sapiens Serine/threonine-protein kinase 17A Proteins 0.000 claims description 2
- 101000661819 Homo sapiens Serine/threonine-protein kinase 17B Proteins 0.000 claims description 2
- 101000628575 Homo sapiens Serine/threonine-protein kinase 19 Proteins 0.000 claims description 2
- 101000628693 Homo sapiens Serine/threonine-protein kinase 25 Proteins 0.000 claims description 2
- 101000701393 Homo sapiens Serine/threonine-protein kinase 26 Proteins 0.000 claims description 2
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 claims description 2
- 101000701391 Homo sapiens Serine/threonine-protein kinase 31 Proteins 0.000 claims description 2
- 101000697591 Homo sapiens Serine/threonine-protein kinase 32A Proteins 0.000 claims description 2
- 101000697600 Homo sapiens Serine/threonine-protein kinase 32B Proteins 0.000 claims description 2
- 101000701396 Homo sapiens Serine/threonine-protein kinase 33 Proteins 0.000 claims description 2
- 101000701395 Homo sapiens Serine/threonine-protein kinase 35 Proteins 0.000 claims description 2
- 101000701405 Homo sapiens Serine/threonine-protein kinase 36 Proteins 0.000 claims description 2
- 101000701401 Homo sapiens Serine/threonine-protein kinase 38 Proteins 0.000 claims description 2
- 101000697608 Homo sapiens Serine/threonine-protein kinase 38-like Proteins 0.000 claims description 2
- 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 claims description 2
- 101000880461 Homo sapiens Serine/threonine-protein kinase 40 Proteins 0.000 claims description 2
- 101000771237 Homo sapiens Serine/threonine-protein kinase A-Raf Proteins 0.000 claims description 2
- 101000695043 Homo sapiens Serine/threonine-protein kinase BRSK1 Proteins 0.000 claims description 2
- 101000794043 Homo sapiens Serine/threonine-protein kinase BRSK2 Proteins 0.000 claims description 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims description 2
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 claims description 2
- 101001026885 Homo sapiens Serine/threonine-protein kinase D3 Proteins 0.000 claims description 2
- 101000885321 Homo sapiens Serine/threonine-protein kinase DCLK1 Proteins 0.000 claims description 2
- 101000885387 Homo sapiens Serine/threonine-protein kinase DCLK2 Proteins 0.000 claims description 2
- 101000885383 Homo sapiens Serine/threonine-protein kinase DCLK3 Proteins 0.000 claims description 2
- 101001006996 Homo sapiens Serine/threonine-protein kinase H1 Proteins 0.000 claims description 2
- 101001006988 Homo sapiens Serine/threonine-protein kinase H2 Proteins 0.000 claims description 2
- 101001047642 Homo sapiens Serine/threonine-protein kinase LATS1 Proteins 0.000 claims description 2
- 101001047637 Homo sapiens Serine/threonine-protein kinase LATS2 Proteins 0.000 claims description 2
- 101001038337 Homo sapiens Serine/threonine-protein kinase LMTK1 Proteins 0.000 claims description 2
- 101001038335 Homo sapiens Serine/threonine-protein kinase LMTK2 Proteins 0.000 claims description 2
- 101001038341 Homo sapiens Serine/threonine-protein kinase LMTK3 Proteins 0.000 claims description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims description 2
- 101000576901 Homo sapiens Serine/threonine-protein kinase MRCK alpha Proteins 0.000 claims description 2
- 101000576904 Homo sapiens Serine/threonine-protein kinase MRCK beta Proteins 0.000 claims description 2
- 101000576907 Homo sapiens Serine/threonine-protein kinase MRCK gamma Proteins 0.000 claims description 2
- 101001129076 Homo sapiens Serine/threonine-protein kinase N1 Proteins 0.000 claims description 2
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 claims description 2
- 101000600885 Homo sapiens Serine/threonine-protein kinase NIM1 Proteins 0.000 claims description 2
- 101001123846 Homo sapiens Serine/threonine-protein kinase Nek1 Proteins 0.000 claims description 2
- 101001123814 Homo sapiens Serine/threonine-protein kinase Nek10 Proteins 0.000 claims description 2
- 101001123812 Homo sapiens Serine/threonine-protein kinase Nek11 Proteins 0.000 claims description 2
- 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 claims description 2
- 101000601456 Homo sapiens Serine/threonine-protein kinase Nek3 Proteins 0.000 claims description 2
- 101000601460 Homo sapiens Serine/threonine-protein kinase Nek4 Proteins 0.000 claims description 2
- 101000601467 Homo sapiens Serine/threonine-protein kinase Nek5 Proteins 0.000 claims description 2
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 claims description 2
- 101000588545 Homo sapiens Serine/threonine-protein kinase Nek7 Proteins 0.000 claims description 2
- 101000588548 Homo sapiens Serine/threonine-protein kinase Nek8 Proteins 0.000 claims description 2
- 101001098464 Homo sapiens Serine/threonine-protein kinase OSR1 Proteins 0.000 claims description 2
- 101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 claims description 2
- 101000987315 Homo sapiens Serine/threonine-protein kinase PAK 3 Proteins 0.000 claims description 2
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 claims description 2
- 101000987295 Homo sapiens Serine/threonine-protein kinase PAK 5 Proteins 0.000 claims description 2
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 claims description 2
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 claims description 2
- 101000691614 Homo sapiens Serine/threonine-protein kinase PLK3 Proteins 0.000 claims description 2
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 claims description 2
- 101000577652 Homo sapiens Serine/threonine-protein kinase PRP4 homolog Proteins 0.000 claims description 2
- 101000756066 Homo sapiens Serine/threonine-protein kinase RIO1 Proteins 0.000 claims description 2
- 101000754913 Homo sapiens Serine/threonine-protein kinase RIO2 Proteins 0.000 claims description 2
- 101000709238 Homo sapiens Serine/threonine-protein kinase SIK1 Proteins 0.000 claims description 2
- 101000709250 Homo sapiens Serine/threonine-protein kinase SIK2 Proteins 0.000 claims description 2
- 101000864057 Homo sapiens Serine/threonine-protein kinase SMG1 Proteins 0.000 claims description 2
- 101000628562 Homo sapiens Serine/threonine-protein kinase STK11 Proteins 0.000 claims description 2
- 101000864806 Homo sapiens Serine/threonine-protein kinase Sgk2 Proteins 0.000 claims description 2
- 101000838579 Homo sapiens Serine/threonine-protein kinase TAO1 Proteins 0.000 claims description 2
- 101000838578 Homo sapiens Serine/threonine-protein kinase TAO2 Proteins 0.000 claims description 2
- 101000838596 Homo sapiens Serine/threonine-protein kinase TAO3 Proteins 0.000 claims description 2
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 claims description 2
- 101000607332 Homo sapiens Serine/threonine-protein kinase ULK2 Proteins 0.000 claims description 2
- 101000607339 Homo sapiens Serine/threonine-protein kinase ULK3 Proteins 0.000 claims description 2
- 101000809308 Homo sapiens Serine/threonine-protein kinase ULK4 Proteins 0.000 claims description 2
- 101000649929 Homo sapiens Serine/threonine-protein kinase VRK1 Proteins 0.000 claims description 2
- 101000649931 Homo sapiens Serine/threonine-protein kinase VRK2 Proteins 0.000 claims description 2
- 101000770770 Homo sapiens Serine/threonine-protein kinase WNK1 Proteins 0.000 claims description 2
- 101000770774 Homo sapiens Serine/threonine-protein kinase WNK2 Proteins 0.000 claims description 2
- 101000742982 Homo sapiens Serine/threonine-protein kinase WNK3 Proteins 0.000 claims description 2
- 101000742986 Homo sapiens Serine/threonine-protein kinase WNK4 Proteins 0.000 claims description 2
- 101001036145 Homo sapiens Serine/threonine-protein kinase greatwall Proteins 0.000 claims description 2
- 101000989953 Homo sapiens Serine/threonine-protein kinase haspin Proteins 0.000 claims description 2
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 claims description 2
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 claims description 2
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 claims description 2
- 101001001645 Homo sapiens Serine/threonine-protein kinase pim-3 Proteins 0.000 claims description 2
- 101000799194 Homo sapiens Serine/threonine-protein kinase receptor R3 Proteins 0.000 claims description 2
- 101000637839 Homo sapiens Serine/threonine-protein kinase tousled-like 1 Proteins 0.000 claims description 2
- 101000637847 Homo sapiens Serine/threonine-protein kinase tousled-like 2 Proteins 0.000 claims description 2
- 101000651178 Homo sapiens Striated muscle preferentially expressed protein kinase Proteins 0.000 claims description 2
- 101000625846 Homo sapiens TBC domain-containing protein kinase-like protein Proteins 0.000 claims description 2
- 101000662997 Homo sapiens TRAF2 and NCK-interacting protein kinase Proteins 0.000 claims description 2
- 101000759314 Homo sapiens Tau-tubulin kinase 1 Proteins 0.000 claims description 2
- 101000759318 Homo sapiens Tau-tubulin kinase 2 Proteins 0.000 claims description 2
- 101000772231 Homo sapiens Testis-specific serine/threonine-protein kinase 1 Proteins 0.000 claims description 2
- 101000772239 Homo sapiens Testis-specific serine/threonine-protein kinase 2 Proteins 0.000 claims description 2
- 101000794197 Homo sapiens Testis-specific serine/threonine-protein kinase 3 Proteins 0.000 claims description 2
- 101000794199 Homo sapiens Testis-specific serine/threonine-protein kinase 4 Proteins 0.000 claims description 2
- 101000794200 Homo sapiens Testis-specific serine/threonine-protein kinase 6 Proteins 0.000 claims description 2
- 101000596093 Homo sapiens Transcription initiation factor TFIID subunit 1 Proteins 0.000 claims description 2
- 101000596092 Homo sapiens Transcription initiation factor TFIID subunit 1-like Proteins 0.000 claims description 2
- 101000796673 Homo sapiens Transformation/transcription domain-associated protein Proteins 0.000 claims description 2
- 101000844519 Homo sapiens Transient receptor potential cation channel subfamily M member 6 Proteins 0.000 claims description 2
- 101000844518 Homo sapiens Transient receptor potential cation channel subfamily M member 7 Proteins 0.000 claims description 2
- 101000766332 Homo sapiens Tribbles homolog 1 Proteins 0.000 claims description 2
- 101000766349 Homo sapiens Tribbles homolog 2 Proteins 0.000 claims description 2
- 101000766345 Homo sapiens Tribbles homolog 3 Proteins 0.000 claims description 2
- 101000659324 Homo sapiens Twinfilin-1 Proteins 0.000 claims description 2
- 101000795921 Homo sapiens Twinfilin-2 Proteins 0.000 claims description 2
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 claims description 2
- 101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 claims description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 claims description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims description 2
- 101000661459 Homo sapiens Tyrosine-protein kinase STYK1 Proteins 0.000 claims description 2
- 101000587313 Homo sapiens Tyrosine-protein kinase Srms Proteins 0.000 claims description 2
- 101000820294 Homo sapiens Tyrosine-protein kinase Yes Proteins 0.000 claims description 2
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 claims description 2
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 claims description 2
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims description 2
- 101000720059 Homo sapiens Uncharacterized aarF domain-containing protein kinase 2 Proteins 0.000 claims description 2
- 101000720061 Homo sapiens Uncharacterized aarF domain-containing protein kinase 5 Proteins 0.000 claims description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims description 2
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 claims description 2
- 101000739853 Homo sapiens [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Proteins 0.000 claims description 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims description 2
- 101001117143 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Proteins 0.000 claims description 2
- 101000734338 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial Proteins 0.000 claims description 2
- 101000734339 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 claims description 2
- 101000994496 Homo sapiens cAMP-dependent protein kinase catalytic subunit alpha Proteins 0.000 claims description 2
- 101000944219 Homo sapiens cAMP-dependent protein kinase catalytic subunit beta Proteins 0.000 claims description 2
- 101000944207 Homo sapiens cAMP-dependent protein kinase catalytic subunit gamma Proteins 0.000 claims description 2
- 101001046427 Homo sapiens cGMP-dependent protein kinase 2 Proteins 0.000 claims description 2
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 claims description 2
- 108060006678 I-kappa-B kinase Proteins 0.000 claims description 2
- 102000001284 I-kappa-B kinase Human genes 0.000 claims description 2
- 102100040173 Inactive serine/threonine-protein kinase TEX14 Human genes 0.000 claims description 2
- 102100028288 Inactive serine/threonine-protein kinase VRK3 Human genes 0.000 claims description 2
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 claims description 2
- 102100038659 Inactive tyrosine-protein kinase PRAG1 Human genes 0.000 claims description 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 2
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 claims description 2
- 102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 claims description 2
- 108091006081 Inositol-requiring enzyme-1 Proteins 0.000 claims description 2
- 102100036721 Insulin receptor Human genes 0.000 claims description 2
- 102100039137 Insulin receptor-related protein Human genes 0.000 claims description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 claims description 2
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 claims description 2
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 claims description 2
- 102100023530 Interleukin-1 receptor-associated kinase 3 Human genes 0.000 claims description 2
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims description 2
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 2
- 102100021000 Kinase suppressor of Ras 2 Human genes 0.000 claims description 2
- 102100026023 LIM domain kinase 1 Human genes 0.000 claims description 2
- 102100021756 LIM domain kinase 2 Human genes 0.000 claims description 2
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 claims description 2
- 102100032656 Leucine-rich repeat serine/threonine-protein kinase 1 Human genes 0.000 claims description 2
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 claims description 2
- 108010068342 MAP Kinase Kinase 1 Proteins 0.000 claims description 2
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 claims description 2
- 108010068305 MAP Kinase Kinase 5 Proteins 0.000 claims description 2
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 claims description 2
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 claims description 2
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 claims description 2
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 claims description 2
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 2
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 claims description 2
- 108010041980 MAP-kinase-activated kinase 3 Proteins 0.000 claims description 2
- 108010041164 MAP-kinase-activated kinase 5 Proteins 0.000 claims description 2
- 102100028920 MAP/microtubule affinity-regulating kinase 3 Human genes 0.000 claims description 2
- 102100028913 MAP/microtubule affinity-regulating kinase 4 Human genes 0.000 claims description 2
- 108700012928 MAPK14 Proteins 0.000 claims description 2
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims description 2
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 claims description 2
- 101150003941 Mapk14 gene Proteins 0.000 claims description 2
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 claims description 2
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 claims description 2
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 claims description 2
- 102100024262 Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Human genes 0.000 claims description 2
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims description 2
- 102100033268 Microtubule-associated serine/threonine-protein kinase 1 Human genes 0.000 claims description 2
- 102100033253 Microtubule-associated serine/threonine-protein kinase 2 Human genes 0.000 claims description 2
- 102100033251 Microtubule-associated serine/threonine-protein kinase 3 Human genes 0.000 claims description 2
- 102100033252 Microtubule-associated serine/threonine-protein kinase 4 Human genes 0.000 claims description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 2
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 claims description 2
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 claims description 2
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 claims description 2
- 102100026930 Mitogen-activated protein kinase 13 Human genes 0.000 claims description 2
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 claims description 2
- 102100023483 Mitogen-activated protein kinase 15 Human genes 0.000 claims description 2
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 claims description 2
- 102100024189 Mitogen-activated protein kinase 4 Human genes 0.000 claims description 2
- 102100037801 Mitogen-activated protein kinase 6 Human genes 0.000 claims description 2
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 claims description 2
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 claims description 2
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 claims description 2
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 claims description 2
- 102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 claims description 2
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 claims description 2
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 claims description 2
- 102100025184 Mitogen-activated protein kinase kinase kinase 13 Human genes 0.000 claims description 2
- 102100025211 Mitogen-activated protein kinase kinase kinase 14 Human genes 0.000 claims description 2
- 102100025217 Mitogen-activated protein kinase kinase kinase 19 Human genes 0.000 claims description 2
- 102100033058 Mitogen-activated protein kinase kinase kinase 2 Human genes 0.000 claims description 2
- 102100033054 Mitogen-activated protein kinase kinase kinase 21 Human genes 0.000 claims description 2
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 claims description 2
- 102100033060 Mitogen-activated protein kinase kinase kinase 4 Human genes 0.000 claims description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 claims description 2
- 102100026889 Mitogen-activated protein kinase kinase kinase 6 Human genes 0.000 claims description 2
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 claims description 2
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 claims description 2
- 102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 claims description 2
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 claims description 2
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 claims description 2
- 102100028193 Mitogen-activated protein kinase kinase kinase kinase 3 Human genes 0.000 claims description 2
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 claims description 2
- 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 claims description 2
- 102100021691 Mitotic checkpoint serine/threonine-protein kinase BUB1 Human genes 0.000 claims description 2
- 102100030144 Mitotic checkpoint serine/threonine-protein kinase BUB1 beta Human genes 0.000 claims description 2
- 102100030177 Mixed lineage kinase domain-like protein Human genes 0.000 claims description 2
- 101100520190 Mus musculus Pkn3 gene Proteins 0.000 claims description 2
- 102100030788 Myosin light chain kinase 2, skeletal/cardiac muscle Human genes 0.000 claims description 2
- 102100030782 Myosin light chain kinase family member 4 Human genes 0.000 claims description 2
- 101710087570 Myosin light chain kinase family member 4 Proteins 0.000 claims description 2
- 101710198035 Myosin light chain kinase, smooth muscle Proteins 0.000 claims description 2
- 102100030743 Myosin-IIIa Human genes 0.000 claims description 2
- 102100030369 Myosin-IIIb Human genes 0.000 claims description 2
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 claims description 2
- 102100022437 Myotonin-protein kinase Human genes 0.000 claims description 2
- 102100031703 N-terminal kinase-like protein Human genes 0.000 claims description 2
- 102100029166 NT-3 growth factor receptor Human genes 0.000 claims description 2
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 claims description 2
- 241000772415 Neovison vison Species 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 claims description 2
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 claims description 2
- 102100021858 Nuclear receptor-binding protein Human genes 0.000 claims description 2
- 102100028790 Nuclear receptor-binding protein 2 Human genes 0.000 claims description 2
- 102100030127 Obscurin Human genes 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 101700056750 PAK1 Proteins 0.000 claims description 2
- 108091007960 PI3Ks Proteins 0.000 claims description 2
- 102000038030 PI3Ks Human genes 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 102100026481 Phosphoinositide 3-kinase regulatory subunit 4 Human genes 0.000 claims description 2
- 102100032391 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Human genes 0.000 claims description 2
- 102100030278 Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform Human genes 0.000 claims description 2
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims description 2
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims description 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims description 2
- 108091008611 Protein Kinase B Proteins 0.000 claims description 2
- 108010015499 Protein Kinase C-theta Proteins 0.000 claims description 2
- 108010003506 Protein Kinase D2 Proteins 0.000 claims description 2
- 102100028655 Protein O-mannose kinase Human genes 0.000 claims description 2
- 102100024923 Protein kinase C beta type Human genes 0.000 claims description 2
- 102100037340 Protein kinase C delta type Human genes 0.000 claims description 2
- 102100037339 Protein kinase C epsilon type Human genes 0.000 claims description 2
- 102100021556 Protein kinase C eta type Human genes 0.000 claims description 2
- 102100037314 Protein kinase C gamma type Human genes 0.000 claims description 2
- 102100021557 Protein kinase C iota type Human genes 0.000 claims description 2
- 102100021566 Protein kinase C theta type Human genes 0.000 claims description 2
- 102100021538 Protein kinase C zeta type Human genes 0.000 claims description 2
- 102100026829 Protein-associating with the carboxyl-terminal domain of ezrin Human genes 0.000 claims description 2
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 claims description 2
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 claims description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims description 2
- 102100029403 Putative serine/threonine-protein kinase PRKY Human genes 0.000 claims description 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 2
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 claims description 2
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 claims description 2
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 2
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 2
- 108010079933 Receptor-Interacting Protein Serine-Threonine Kinase 2 Proteins 0.000 claims description 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 claims description 2
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 claims description 2
- 102100033729 Receptor-interacting serine/threonine-protein kinase 3 Human genes 0.000 claims description 2
- 102100033734 Receptor-interacting serine/threonine-protein kinase 4 Human genes 0.000 claims description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 2
- 102100022663 Retinal guanylyl cyclase 1 Human genes 0.000 claims description 2
- 102100030847 Retinal guanylyl cyclase 2 Human genes 0.000 claims description 2
- 201000000582 Retinoblastoma Diseases 0.000 claims description 2
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 claims description 2
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 claims description 2
- 102100023742 Rhodopsin kinase GRK1 Human genes 0.000 claims description 2
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 claims description 2
- 102100033534 Ribosomal protein S6 kinase alpha-2 Human genes 0.000 claims description 2
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 claims description 2
- 102100033644 Ribosomal protein S6 kinase alpha-4 Human genes 0.000 claims description 2
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 claims description 2
- 102100024897 Ribosomal protein S6 kinase alpha-6 Human genes 0.000 claims description 2
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 claims description 2
- 102100024917 Ribosomal protein S6 kinase beta-2 Human genes 0.000 claims description 2
- 102100024913 Ribosomal protein S6 kinase delta-1 Human genes 0.000 claims description 2
- 102100030864 Ribosomal protein S6 kinase-like 1 Human genes 0.000 claims description 2
- 102100024914 Ribosomal protein S6 kinase-related protein Human genes 0.000 claims description 2
- 102100031698 SCY1-like protein 2 Human genes 0.000 claims description 2
- 102100022010 SNF-related serine/threonine-protein kinase Human genes 0.000 claims description 2
- 108060006706 SRC Proteins 0.000 claims description 2
- 102000001332 SRC Human genes 0.000 claims description 2
- 102100023010 SRSF protein kinase 1 Human genes 0.000 claims description 2
- 102100023015 SRSF protein kinase 2 Human genes 0.000 claims description 2
- 102100023017 SRSF protein kinase 3 Human genes 0.000 claims description 2
- 102100035929 STE20-related kinase adapter protein beta Human genes 0.000 claims description 2
- 102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 claims description 2
- 102100032743 Septin-4 Human genes 0.000 claims description 2
- 102100028900 Serine/threonine-protein kinase 10 Human genes 0.000 claims description 2
- 102100026758 Serine/threonine-protein kinase 16 Human genes 0.000 claims description 2
- 102100037955 Serine/threonine-protein kinase 17A Human genes 0.000 claims description 2
- 102100037959 Serine/threonine-protein kinase 17B Human genes 0.000 claims description 2
- 102100026757 Serine/threonine-protein kinase 19 Human genes 0.000 claims description 2
- 102100026737 Serine/threonine-protein kinase 25 Human genes 0.000 claims description 2
- 102100030617 Serine/threonine-protein kinase 26 Human genes 0.000 claims description 2
- 102100030618 Serine/threonine-protein kinase 31 Human genes 0.000 claims description 2
- 102100028032 Serine/threonine-protein kinase 32A Human genes 0.000 claims description 2
- 102100028030 Serine/threonine-protein kinase 32B Human genes 0.000 claims description 2
- 102100030515 Serine/threonine-protein kinase 33 Human genes 0.000 claims description 2
- 102100030620 Serine/threonine-protein kinase 35 Human genes 0.000 claims description 2
- 102100030513 Serine/threonine-protein kinase 36 Human genes 0.000 claims description 2
- 102100030514 Serine/threonine-protein kinase 38 Human genes 0.000 claims description 2
- 102100027898 Serine/threonine-protein kinase 38-like Human genes 0.000 claims description 2
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 claims description 2
- 102100037627 Serine/threonine-protein kinase 40 Human genes 0.000 claims description 2
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 claims description 2
- 102100028623 Serine/threonine-protein kinase BRSK1 Human genes 0.000 claims description 2
- 102100029891 Serine/threonine-protein kinase BRSK2 Human genes 0.000 claims description 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims description 2
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 claims description 2
- 102100037312 Serine/threonine-protein kinase D2 Human genes 0.000 claims description 2
- 102100037311 Serine/threonine-protein kinase D3 Human genes 0.000 claims description 2
- 102100039758 Serine/threonine-protein kinase DCLK1 Human genes 0.000 claims description 2
- 102100039775 Serine/threonine-protein kinase DCLK2 Human genes 0.000 claims description 2
- 102100039774 Serine/threonine-protein kinase DCLK3 Human genes 0.000 claims description 2
- 102100028474 Serine/threonine-protein kinase H1 Human genes 0.000 claims description 2
- 102100028475 Serine/threonine-protein kinase H2 Human genes 0.000 claims description 2
- 102100024031 Serine/threonine-protein kinase LATS1 Human genes 0.000 claims description 2
- 102100024043 Serine/threonine-protein kinase LATS2 Human genes 0.000 claims description 2
- 102100040293 Serine/threonine-protein kinase LMTK1 Human genes 0.000 claims description 2
- 102100040292 Serine/threonine-protein kinase LMTK2 Human genes 0.000 claims description 2
- 102100040291 Serine/threonine-protein kinase LMTK3 Human genes 0.000 claims description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims description 2
- 102100025352 Serine/threonine-protein kinase MRCK alpha Human genes 0.000 claims description 2
- 102100025347 Serine/threonine-protein kinase MRCK beta Human genes 0.000 claims description 2
- 102100025345 Serine/threonine-protein kinase MRCK gamma Human genes 0.000 claims description 2
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 claims description 2
- 102100037345 Serine/threonine-protein kinase NIM1 Human genes 0.000 claims description 2
- 102100028751 Serine/threonine-protein kinase Nek1 Human genes 0.000 claims description 2
- 102100028774 Serine/threonine-protein kinase Nek10 Human genes 0.000 claims description 2
- 102100028775 Serine/threonine-protein kinase Nek11 Human genes 0.000 claims description 2
- 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 claims description 2
- 102100037706 Serine/threonine-protein kinase Nek3 Human genes 0.000 claims description 2
- 102100037705 Serine/threonine-protein kinase Nek4 Human genes 0.000 claims description 2
- 102100037702 Serine/threonine-protein kinase Nek5 Human genes 0.000 claims description 2
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 claims description 2
- 102100031400 Serine/threonine-protein kinase Nek7 Human genes 0.000 claims description 2
- 102100037143 Serine/threonine-protein kinase OSR1 Human genes 0.000 claims description 2
- 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 claims description 2
- 102100027911 Serine/threonine-protein kinase PAK 3 Human genes 0.000 claims description 2
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 claims description 2
- 102100027941 Serine/threonine-protein kinase PAK 5 Human genes 0.000 claims description 2
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 claims description 2
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 claims description 2
- 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 claims description 2
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 claims description 2
- 102100028868 Serine/threonine-protein kinase PRP4 homolog Human genes 0.000 claims description 2
- 102100022261 Serine/threonine-protein kinase RIO1 Human genes 0.000 claims description 2
- 102100022090 Serine/threonine-protein kinase RIO2 Human genes 0.000 claims description 2
- 102100032771 Serine/threonine-protein kinase SIK1 Human genes 0.000 claims description 2
- 102100034377 Serine/threonine-protein kinase SIK2 Human genes 0.000 claims description 2
- 102100029938 Serine/threonine-protein kinase SMG1 Human genes 0.000 claims description 2
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 claims description 2
- 101710106079 Serine/threonine-protein kinase TAO1 Proteins 0.000 claims description 2
- 102100028954 Serine/threonine-protein kinase TAO3 Human genes 0.000 claims description 2
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 claims description 2
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 claims description 2
- 102100039987 Serine/threonine-protein kinase ULK2 Human genes 0.000 claims description 2
- 102100039985 Serine/threonine-protein kinase ULK3 Human genes 0.000 claims description 2
- 102100038455 Serine/threonine-protein kinase ULK4 Human genes 0.000 claims description 2
- 102100028235 Serine/threonine-protein kinase VRK1 Human genes 0.000 claims description 2
- 102100028234 Serine/threonine-protein kinase VRK2 Human genes 0.000 claims description 2
- 102100029064 Serine/threonine-protein kinase WNK1 Human genes 0.000 claims description 2
- 102100029063 Serine/threonine-protein kinase WNK2 Human genes 0.000 claims description 2
- 102100038115 Serine/threonine-protein kinase WNK3 Human genes 0.000 claims description 2
- 102100038101 Serine/threonine-protein kinase WNK4 Human genes 0.000 claims description 2
- 102100039278 Serine/threonine-protein kinase greatwall Human genes 0.000 claims description 2
- 102100029332 Serine/threonine-protein kinase haspin Human genes 0.000 claims description 2
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 claims description 2
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 claims description 2
- 102100036119 Serine/threonine-protein kinase pim-3 Human genes 0.000 claims description 2
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 claims description 2
- 102100032015 Serine/threonine-protein kinase tousled-like 1 Human genes 0.000 claims description 2
- 102100032014 Serine/threonine-protein kinase tousled-like 2 Human genes 0.000 claims description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 102100027659 Striated muscle preferentially expressed protein kinase Human genes 0.000 claims description 2
- 102100024750 TBC domain-containing protein kinase-like protein Human genes 0.000 claims description 2
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 claims description 2
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 claims description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 2
- 101150080074 TP53 gene Proteins 0.000 claims description 2
- 102100037671 TRAF2 and NCK-interacting protein kinase Human genes 0.000 claims description 2
- 102000003608 TRPM6 Human genes 0.000 claims description 2
- 102000003611 TRPM7 Human genes 0.000 claims description 2
- 102100023277 Tau-tubulin kinase 1 Human genes 0.000 claims description 2
- 102100023276 Tau-tubulin kinase 2 Human genes 0.000 claims description 2
- 102100029350 Testis-specific serine/threonine-protein kinase 1 Human genes 0.000 claims description 2
- 102100029355 Testis-specific serine/threonine-protein kinase 2 Human genes 0.000 claims description 2
- 102100030168 Testis-specific serine/threonine-protein kinase 3 Human genes 0.000 claims description 2
- 102100030167 Testis-specific serine/threonine-protein kinase 4 Human genes 0.000 claims description 2
- 102100030141 Testis-specific serine/threonine-protein kinase 6 Human genes 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 102100035222 Transcription initiation factor TFIID subunit 1 Human genes 0.000 claims description 2
- 102100035238 Transcription initiation factor TFIID subunit 1-like Human genes 0.000 claims description 2
- 102100022011 Transcription intermediary factor 1-alpha Human genes 0.000 claims description 2
- 102100022012 Transcription intermediary factor 1-beta Human genes 0.000 claims description 2
- 101710177718 Transcription intermediary factor 1-beta Proteins 0.000 claims description 2
- 102100032762 Transformation/transcription domain-associated protein Human genes 0.000 claims description 2
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 2
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 2
- 102100026387 Tribbles homolog 1 Human genes 0.000 claims description 2
- 102100026394 Tribbles homolog 2 Human genes 0.000 claims description 2
- 102100026390 Tribbles homolog 3 Human genes 0.000 claims description 2
- 102100036223 Twinfilin-1 Human genes 0.000 claims description 2
- 102100031721 Twinfilin-2 Human genes 0.000 claims description 2
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims description 2
- 102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 claims description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 claims description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 2
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 claims description 2
- 102100037781 Tyrosine-protein kinase STYK1 Human genes 0.000 claims description 2
- 102100029654 Tyrosine-protein kinase Srms Human genes 0.000 claims description 2
- 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 claims description 2
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 claims description 2
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 claims description 2
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims description 2
- 102100025993 Uncharacterized aarF domain-containing protein kinase 2 Human genes 0.000 claims description 2
- 102100025996 Uncharacterized aarF domain-containing protein kinase 5 Human genes 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 102100023037 Wee1-like protein kinase Human genes 0.000 claims description 2
- 102100037607 [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Human genes 0.000 claims description 2
- 102100024150 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Human genes 0.000 claims description 2
- 102100034824 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial Human genes 0.000 claims description 2
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 claims description 2
- 108060000200 adenylate cyclase Proteins 0.000 claims description 2
- 102000030621 adenylate cyclase Human genes 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 201000001531 bladder carcinoma Diseases 0.000 claims description 2
- 210000000133 brain stem Anatomy 0.000 claims description 2
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 claims description 2
- 102100029402 cAMP-dependent protein kinase catalytic subunit PRKX Human genes 0.000 claims description 2
- 102100033065 cAMP-dependent protein kinase catalytic subunit beta Human genes 0.000 claims description 2
- 102100033064 cAMP-dependent protein kinase catalytic subunit gamma Human genes 0.000 claims description 2
- 102100022421 cGMP-dependent protein kinase 2 Human genes 0.000 claims description 2
- 230000004745 cervical carcinogenesis Effects 0.000 claims description 2
- 208000024207 chronic leukemia Diseases 0.000 claims description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 201000010989 colorectal carcinoma Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 201000003914 endometrial carcinoma Diseases 0.000 claims description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 2
- 108010022946 erythrogenic toxin Proteins 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000001156 gastric mucosa Anatomy 0.000 claims description 2
- 108010054372 insulin receptor-related receptor Proteins 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 244000000010 microbial pathogen Species 0.000 claims description 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 2
- 210000000653 nervous system Anatomy 0.000 claims description 2
- 201000002575 ocular melanoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 2
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 108010062154 protein kinase C gamma Proteins 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 210000003079 salivary gland Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000008732 thymoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 108010071511 transcriptional intermediary factor 1 Proteins 0.000 claims description 2
- 108010064892 trkC Receptor Proteins 0.000 claims description 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 claims 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 claims 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 1
- 230000001018 virulence Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 76
- 108020004414 DNA Proteins 0.000 description 64
- 230000004044 response Effects 0.000 description 47
- 230000028993 immune response Effects 0.000 description 46
- 108091028043 Nucleic acid sequence Proteins 0.000 description 43
- 230000006698 induction Effects 0.000 description 40
- 230000009885 systemic effect Effects 0.000 description 36
- 239000002671 adjuvant Substances 0.000 description 29
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 29
- 230000004927 fusion Effects 0.000 description 29
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 26
- 230000000694 effects Effects 0.000 description 26
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 25
- 239000012634 fragment Substances 0.000 description 24
- 229940023064 escherichia coli Drugs 0.000 description 23
- 238000011160 research Methods 0.000 description 22
- 230000003248 secreting effect Effects 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 230000001900 immune effect Effects 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 16
- 210000000822 natural killer cell Anatomy 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 230000005867 T cell response Effects 0.000 description 15
- 230000036039 immunity Effects 0.000 description 14
- 210000005007 innate immune system Anatomy 0.000 description 14
- 230000005875 antibody response Effects 0.000 description 13
- 239000012528 membrane Substances 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 238000006062 fragmentation reaction Methods 0.000 description 11
- 101150024289 hly gene Proteins 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 238000004581 coalescence Methods 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 10
- 210000004988 splenocyte Anatomy 0.000 description 10
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 8
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 210000000170 cell membrane Anatomy 0.000 description 8
- 101150087320 ctxB gene Proteins 0.000 description 8
- 229940115931 listeria monocytogenes Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 description 7
- 238000013467 fragmentation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 7
- 238000002649 immunization Methods 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241001167018 Aroa Species 0.000 description 6
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 6
- 108700020796 Oncogene Proteins 0.000 description 6
- 201000005702 Pertussis Diseases 0.000 description 6
- 210000000612 antigen-presenting cell Anatomy 0.000 description 6
- 101150037081 aroA gene Proteins 0.000 description 6
- 229960001212 bacterial vaccine Drugs 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 210000000805 cytoplasm Anatomy 0.000 description 6
- 238000001784 detoxification Methods 0.000 description 6
- 238000004520 electroporation Methods 0.000 description 6
- 238000001976 enzyme digestion Methods 0.000 description 6
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000000899 immune system response Effects 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 239000002435 venom Substances 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000010367 cloning Methods 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 230000003308 immunostimulating effect Effects 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 231100000611 venom Toxicity 0.000 description 5
- 210000001048 venom Anatomy 0.000 description 5
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 4
- 206010008631 Cholera Diseases 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000000246 agarose gel electrophoresis Methods 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000016379 mucosal immune response Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 3
- 241000193468 Clostridium perfringens Species 0.000 description 3
- 241000193449 Clostridium tetani Species 0.000 description 3
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 239000000020 Nitrocellulose Substances 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 230000029662 T-helper 1 type immune response Effects 0.000 description 3
- 210000000447 Th1 cell Anatomy 0.000 description 3
- 108010073429 Type V Secretion Systems Proteins 0.000 description 3
- 206010047400 Vibrio infections Diseases 0.000 description 3
- 241001148129 Yersinia ruckeri Species 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 229940065181 bacillus anthracis Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037011 constitutive activity Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 208000028104 epidemic louse-borne typhus Diseases 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000581 natural killer T-cell Anatomy 0.000 description 3
- 229920001220 nitrocellulos Polymers 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
- 206010001513 AIDS related complex Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241000588832 Bordetella pertussis Species 0.000 description 2
- 208000003508 Botulism Diseases 0.000 description 2
- 206010051226 Campylobacter infection Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 241000588923 Citrobacter Species 0.000 description 2
- 108010073254 Colicins Proteins 0.000 description 2
- 241000186227 Corynebacterium diphtheriae Species 0.000 description 2
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 208000001204 Hashimoto Disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 2
- 241000222722 Leishmania <genus> Species 0.000 description 2
- 241000222732 Leishmania major Species 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 206010024641 Listeriosis Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 2
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 2
- 206010065764 Mucosal infection Diseases 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 102000012515 Protein kinase domains Human genes 0.000 description 2
- 108050002122 Protein kinase domains Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010039207 Rocky Mountain Spotted Fever Diseases 0.000 description 2
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 206010044684 Trismus Diseases 0.000 description 2
- 208000034784 Tularaemia Diseases 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000002096 anti-tetanic effect Effects 0.000 description 2
- 230000001147 anti-toxic effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 201000004927 campylobacteriosis Diseases 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 210000000991 chicken egg Anatomy 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 206010013023 diphtheria Diseases 0.000 description 2
- 235000014103 egg white Nutrition 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 210000003495 flagella Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 239000000568 immunological adjuvant Substances 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940072205 lactobacillus plantarum Drugs 0.000 description 2
- 238000004020 luminiscence type Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 229940022007 naked DNA vaccine Drugs 0.000 description 2
- 230000001254 nonsecretory effect Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 231100000617 superantigen Toxicity 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 101150059846 trpS gene Proteins 0.000 description 2
- 101150004782 trpS2 gene Proteins 0.000 description 2
- 230000029069 type 2 immune response Effects 0.000 description 2
- 206010061393 typhus Diseases 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YLDPIHLIWYLZID-UHFFFAOYSA-N 3-hydroxy-2,2-dimethyl-3'-[2-(2-methylpropanoyl)-4-oxoquinazolin-3-yl]spiro[3ah-imidazo[1,2-a]indole-4,5'-oxolane]-1,2'-dione Chemical compound C12N(O)C(C)(C)C(=O)N2C2=CC=CC=C2C1(OC1=O)CC1N1C(=O)C2=CC=CC=C2N=C1C(=O)C(C)C YLDPIHLIWYLZID-UHFFFAOYSA-N 0.000 description 1
- 101150008021 80 gene Proteins 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 244000030795 Annona lutescens Species 0.000 description 1
- 235000005288 Annona lutescens Nutrition 0.000 description 1
- 241000256844 Apis mellifera Species 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 101100096476 Bacillus subtilis (strain 168) splB gene Proteins 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 101100478849 Bifidobacterium adolescentis (strain ATCC 15703 / DSM 20083 / NCTC 11814 / E194a) sucP gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100378273 Brachyspira hyodysenteriae acpP gene Proteins 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000003732 Cat-scratch disease Diseases 0.000 description 1
- 241000010804 Caulobacter vibrioides Species 0.000 description 1
- 206010008617 Cholecystitis chronic Diseases 0.000 description 1
- 241000186581 Clostridium novyi Species 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000009802 Colorado tick fever Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010061573 Dermatophagoides pteronyssinus antigen p 5 Proteins 0.000 description 1
- 102100020743 Dipeptidase 1 Human genes 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 101100421425 Drosophila melanogaster Sply gene Proteins 0.000 description 1
- 206010073508 Drug reaction with eosinophilia and systemic symptoms Diseases 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010014979 Epidemic typhus Diseases 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 101150111889 F4 gene Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 206010017914 Gastroenteritis salmonella Diseases 0.000 description 1
- 201000003641 Glanders Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000020061 Hand, Foot and Mouth Disease Diseases 0.000 description 1
- 208000025713 Hand-foot-and-mouth disease Diseases 0.000 description 1
- 101710147195 Hemolysin A Proteins 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 101700012268 Holin Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 241000270878 Hyla Species 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 206010023927 Lassa fever Diseases 0.000 description 1
- 208000034800 Leukoencephalopathies Diseases 0.000 description 1
- 101100098690 Listeria monocytogenes serovar 1/2a (strain ATCC BAA-679 / EGD-e) hly gene Proteins 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000000932 Marburg Virus Disease Diseases 0.000 description 1
- 201000011013 Marburg hemorrhagic fever Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027260 Meningitis viral Diseases 0.000 description 1
- 102100030335 Midkine Human genes 0.000 description 1
- 108010092801 Midkine Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 241000231286 Neottia Species 0.000 description 1
- 101150063378 OMP gene Proteins 0.000 description 1
- 108010075205 OVA-8 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000193465 Paeniclostridium sordellii Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000009362 Pneumococcal Pneumonia Diseases 0.000 description 1
- 206010035728 Pneumonia pneumococcal Diseases 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 108010013381 Porins Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 101000762949 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Exotoxin A Proteins 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102000018673 SEC Translocation Channels Human genes 0.000 description 1
- 108010091732 SEC Translocation Channels Proteins 0.000 description 1
- 101150099060 SGPL1 gene Proteins 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 101100406813 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) pagC gene Proteins 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 206010040550 Shigella infections Diseases 0.000 description 1
- 201000010001 Silicosis Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 101100113494 Vibrio cholerae serotype O1 (strain ATCC 39315 / El Tor Inaba N16961) ctxB gene Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000003302 anti-idiotype Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000002223 anti-pathogen Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001484 arginines Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- SRBFZHDQGSBBOR-KLVWXMOXSA-N beta-L-arabinopyranose Chemical compound O[C@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-KLVWXMOXSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- ZWPRYVATYZPCDP-UHFFFAOYSA-M bis(dibutylamino)methylidene-dibutylazanium;fluoride Chemical compound [F-].CCCCN(CCCC)C(N(CCCC)CCCC)=[N+](CCCC)CCCC ZWPRYVATYZPCDP-UHFFFAOYSA-M 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 229940030156 cell vaccine Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229960005004 cholera vaccine Drugs 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229940038704 clostridium perfringens Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000001036 exonucleolytic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940046528 grass pollen Drugs 0.000 description 1
- 101150070420 gyrA gene Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 101150021605 hlyA gene Proteins 0.000 description 1
- 101150079947 hlyB gene Proteins 0.000 description 1
- 101150104052 hlyD gene Proteins 0.000 description 1
- 229930186900 holotoxin Natural products 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940126578 oral vaccine Drugs 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 101150028857 phoP gene Proteins 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 206010035653 pneumoconiosis Diseases 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 102000007739 porin activity proteins Human genes 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical class [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 102220012991 rs111033344 Human genes 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 208000022218 streptococcal pneumonia Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 101150089436 tcdB gene Proteins 0.000 description 1
- 229960002766 tetanus vaccines Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 230000032895 transmembrane transport Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 201000010044 viral meningitis Diseases 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
Abstract
本发明涉及作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物,其包含下列组分:(I)编码至少一个野生型或突变的蛋白的至少一个完整或部分抗原的至少一个核苷酸序列;和(II)编码至少一个蛋白毒素和/或至少一个蛋白毒素亚基的至少一个核苷酸序列;和(III)a)编码至少一个转运系统的至少一个核苷酸序列,所述的转运系统使得能够在微生物的外表面上表达组分(I)和组分(II)的表达产物和/或使得能够分泌组分(I)和组分(II)的表达产物;和/或编码使得能够分泌组分(I)和组分(II)的表达产物的至少一个信号序列的至少一个核苷酸序列;和/或(III)b)任选地,编码用于裂解哺乳动物细胞的胞质溶胶中的微生物且用于细胞内释放包含在裂解的微生物中的质粒或表达载体的至少一个蛋白的至少一个核苷酸序列;和(IV)用于表达组分(I)至(III)的一个或多个的至少一个活化序列的至少一个核苷酸序列,其中所述的活化序列能够在微生物中活化和/或是组织细胞特异性的,肿瘤细胞特异性的,巨噬细胞特异性的,树突特异性的,淋巴细胞特异性的,功能特异性的或非细胞特异性的;其中组分(I)至(IV)的任何一个能够以一倍或几倍存在并且可以是相同的或不同的。还公开了其制备方法,相应的质粒或表达载体以及该微生物用作药物的用途。
Description
技术领域
本发明涉及作为编码抗原和蛋白毒素的异种核苷酸序列的载体的微生物,其制备方法及相应的质粒或表达载体。这些微生物可以用作药物,特别是用作用于治疗各种肿瘤的肿瘤疫苗。
现有技术
癌症的免疫治疗代表肿瘤治疗的一种有希望的选择。使用不同方法的大量临床试验专注于其在患者中的功效。原则上,区别在于被动免疫治疗和主动免疫治疗。
主动免疫治疗旨在诱导疫苗相关的肿瘤特异性免疫应答。目前,临床上使用几种不同的方法探查后者。例如,所谓的全细胞疫苗,其原料为直接获自患者(自体)的或源自适当的细胞系(异源)的肿瘤细胞。通常,这些细胞进行灭活,特别处理并且(再)应用于患者。
相反,抗原特异性疫苗包含一种(或多种)肿瘤特异性抗原,抗原的部分或特异性抗原编码DNA以及所谓的抗独特型疫苗。通常,这些疫苗不是单独地,而是与适当的载体组合在一起注射。因此,一方面使用不同的传统佐剂,但也与生物学免疫刺激剂例如细胞因子组合。
为了免疫刺激的目的,使用这样的方法,其包含与免疫刺激剂(例如破伤风毒素)联合的抗原。此外,存在将抗原与树突细胞组合使用的尝试。并且最后,存在几种使用具有病毒或细菌载体的重组活疫苗的尝试。
细菌毒素(例如破伤风毒素,志贺菌毒素,致死毒素或霍乱毒素)的融合蛋白,作为佐剂和抗原一起用作疫苗,尤其是在相当一段时间抗感染的疫苗(Freytag和Clements,1999)。另外,还使用通常与靶细胞特异性分子(例如肿瘤细胞的细胞表面分子)融合的天然毒素以破坏靶细胞。
这里,通常包含酶单元和蛋白结合结构域的与天然毒素的融合蛋白在用作佐剂方面表现出它们的最佳效果(Freytag和Clements,1999)。借助这些疫苗,在粘膜免疫后和特别是在口服免疫后获得令人满意的免疫应答。使用这些融合蛋白的问题是天然毒素是高毒的并且因此不能用于人体中(Holmgren等,2005)。
因此,一连串的研究关注于毒素的脱毒(detoxification)同时保持佐剂功效。然而,在大多数情况下,佐剂功效与酶活性一致,而酶活性是形成毒性作用的原因(Lycke等,1992),因此不能以直接的方式进行脱毒,即使对于某些毒素而言,不丧失其酶促、佐剂活性似乎是可能的(Hormozi等,1999;Lycke等,1992)。
在霍乱毒素(CT)的情况下进行了脱毒的一些尝试(Agren等,1999;Byun等,2001;Eriksson等,2004;Kweon等,2002;Sanchez等,2002),对于其,作为粘膜佐剂的用途仍然奏效(Freytag和Clements)。因此,首先,抗体应答(主要是粘膜IgA)的有效诱导(其受到增加的毒素相关的MHC II类限制性T细胞支持)对于由蛋白-抗原和融合的或共施用(co-applied)的毒素组成的疫苗的粘膜佐剂来说是主要的先决条件(Freytag和Clements)。
就霍乱毒素来说,特别地测试其B亚基(CtxB)作为佐剂,因为它负责与GM-1受体结合并且当单独时,不表现毒性作用(Holmgren等)。与CtxB的蛋白融合的特征在于主要诱导所谓的Th2免疫应答。这些是T细胞应答,其主要的特征在于细胞因子,例如IL-4或IL-6,并且其主要导致抗体的诱导,但是其一点也不或最大程度地不限制启动细胞免疫应答,特别是细胞毒性T细胞(CTL)的细胞免疫应答(Holmgren等)。
另外,作为粘膜佐剂的CtxB诱导蛋白-抗原全身性耐受。全身性耐受形容抗原特异性淋巴细胞(特别是T细胞或B细胞)的耗尽或灭活。因此,这类方法不适用于全身性免疫应答的诱导(Holmgren等)。
和粘膜施用对比,腹膜内或皮下施用毒素-抗原融合蛋白能诱导全身性且低细胞毒性的应答。其已经用于模型系统中的肿瘤疫苗接种(参考例如(Becerra等人,2003))。然而,此类应答还可用经纯化的抗原本身获得并且主要依赖于所用的佐剂。除了模型中测量的CTL应答相当低的事实以外,没有证据表明保护也依赖于这些功效。而且,抗原不口服施用,而只通过抗原的直接注射(s.c.,i.d.,i.m.,i.p.)来施用。
与脱毒毒素融合的抗原蛋白如果作为口服肿瘤疫苗施用通常是无效的。主要原因是,如果真的存在,仅全身性免疫应答的低诱导或在CtxB的情况下,全身性耐受的诱导以及粘膜限制性(restricted)抗体和Th2型免疫应答的诱导。
例如McSorley等人表明使用CtxB-抗原融合蛋白的鼻免疫(对肿瘤疫苗而言,其代表诱导全身性应答的优选方法)优选耐受并且因此灭活Th1细胞,而Th2细胞不受影响(McSorley等人,1998)。Th2应答特征在于主要产生IL-4或IL-6的T辅助细胞。这些细胞因子特别负责起始B细胞产生抗体,在大多数常规的疫苗的情况下,这提供了保护。相反,Th1T细胞通常分泌IL-2和IFN-γ,因此细胞因子,其在细胞免疫应答中起作用。取决于免疫策略的目标,是发起抗体为主的Th2免疫应答(所谓的Th2免疫偏离)还是发起细胞为主的Th1应答(所谓的Th1免疫偏离)是至关重要的。
相比之下,用产生IFN-γ的T辅助细胞全身性诱导Th1为主的细胞免疫应答和诱导细胞毒性T细胞(CTL)对肿瘤免疫治疗来说是必不可少的。
现有技术表明毒素能用作佐剂。尤其是霍乱毒素(CT)表现出很强的佐剂作用。然而,该毒素一脱毒这个作用就显著地削弱。关于它的亚基CtxB,口服施用甚至诱导全身性耐受。这个问题能够通过经鼻施用部分地消除。然而,如果采用经鼻施用,则产生其他问题,特别地,例如与脑中的GM-1受体的表达有关的CtxB亚基相关的问题(vanGinkel等人,2000),其表现为增加的特别严重的副作用的风险(Mutsch等人,2004)。
为了克服这些问题,可以产生共表达毒素和(异源)抗原的重组的活疫苗。就感染疫苗(即抗特异性病原体例如结核病原体并且意欲诱导抗该病原体的免疫的疫苗)而言,这一选择已经被采用。
在开发此类感染疫苗的过程中,已经通过使用几种重组细菌菌株产生与适当的(异源)抗原融合的重组毒素,所述菌株作为活的或灭活的疫苗口服施用。在大多数情况下,产生的细菌只表达重组毒素。因此,这些方法主要目的在于抗毒素自身的单独免疫(抗体应答的诱导)从而抗表达毒素的菌株(病原体)的单独免疫。这类疫苗不适于用作肿瘤治疗中的潜在的肿瘤疫苗并且不令人惊讶地,相应的试验未提及任何此类可能的应用(Reveneau等人,2002)(Vertiev等人,2001)(Freytag和Clements,1999;Jackson等人,1996)。
关于此类感染疫苗,在抗体应答诱导期间,毒素不作为佐剂起作用,而是诱导粘膜抗体免疫应答。这些感染疫苗试验不包括全身性免疫应答或只有非常弱的全身性免疫应答。和肿瘤疫苗形成对比,此类疫苗不诱导细胞免疫应答,尤其是细胞毒性T细胞的细胞免疫应答。表达毒素的细菌病原体通常表现出细胞外活性模式并因此不促进CTL的活化,即通过此类感染疫苗赋予的保护是不依赖于CTL的。
下列细菌菌株已用于提及的感染疫苗试验:重组乳酸杆菌(Lactobacilli)(Reveneau等,2002),利斯特氏菌(Listeria)(Vertiev等,2001),炭疽芽孢杆菌(Bacillus anthracis)(Mendelson等,2005;Mesnage等,1999),志贺氏菌(Shigellae)(Anderson等,2000;Tzschaschel等,1996b),大肠杆菌(E.coli)(Walker等,1992),弧菌(Vibrio)(Butterton等,1995;Chen等,1998;Thungapathra等,1999)和沙门氏菌(Salmonella)(Jackson等,1996)。
另外,尝试通过表面呈递(Konieczny等,2000)或分泌毒素作为异源抗原(沙门氏菌,志贺氏菌:(Garmory等,2003;Orr等,1999;Su等,1992;Tzschaschel等,1996a;Tzschaschel等,1996b),耶尔森氏菌(Yersinia):(Sory和Cornelis,1990),弧菌(Ryan等,1997a),大肠杆菌(Zhu等,2006))增强粘膜免疫应答。然而,在这些另外的实例中,毒素自身代表免疫应答针对的抗原。
因此,应当注意毒素既不作为佐剂起作用,所描述的研究也不意欲表达与另外的分离的(异源)抗原一起作为融合蛋白的毒素。此外,与CT或CtxB的融合蛋白既不用这些系统产生也没有被暗示。
因而,上面引用的文献中提及的融合蛋白是肽分泌信号(例如HlyA)和毒素蛋白的融合蛋白,而非由毒素和(异源)抗原组成的融合蛋白。
这些研究的主要目的仅仅是为了获得最优化的粘膜免疫应答(Tzschaschel等,1996a)。没有进行全身性免疫应答的诱导。如果进行了测量,则全身性免疫应答的分析仅限于抗体(特别是全身性IgA),因为在这些种类的模型中保护主要由抗体介导(比较,例如[31])。未描述全身性细胞免疫应答的诱导,特别是细胞毒性T细胞应答的诱导。主要使用与分泌信号的融合以分别增加毒素的可溶性并增强它们的稳定性,因为强的,仅仅细胞质的表达通常导致不溶性聚集体的产生(Gentschev等,2002a)。
在这方面,一些作者观察到与分泌信号的融合蛋白引起快速的细胞质降解(Tzschaschel等,1996a),然而其他人观察到稳定性(Orr等,1999)。因此,现有技术在这点上相互矛盾。到目前为止,关于分泌性毒素(毒素+分泌信号)的之前的实验首先旨在增加稳定性,其显然未在所有实例中实现。
在可变的表达强度和质粒稳定性方面确实发现了一个原因。Tzschaschel等人描述,所用的质粒系统是高度不稳定的并且首先,不经筛选,其仅在少数细菌中发现。作者用经由微转座子的染色体整合作为可能的解决方案(Tzschaschel等,1996a;Tzschaschel等,1996b)。
然而,此类系统具有几个缺点。一方面整合位点是不确定的,其能够导致宿主菌的不期望的表型改变(例如侧翼基因的增加的/减少的表达)。另一方面,使用单基因拷贝的期望的表达水平低,其对免疫原性具有负面影响。最后,染色体转座子整合相对不稳定,因为它导致在重复元件两侧非常频繁地自发切除。
如上所述,现有技术在分泌性异源毒素的稳定性方面相互矛盾。
Garmory等人甚至认为异源抗原的分泌对于抗原性不具有任何特别的益处(Garmory等,2002;Roland等,2005)。在其他的实例中,确实观察到静脉施用后对分泌性毒素的全身性抗体应答增加,然而在口服施用后没有观察到这一结果。完全相反地,口服施用还被间接质疑(Roland等,2005)。
最后,对产生破伤风毒素的革兰氏阳性菌(植物乳杆菌(Lactobacillus plantarum))的研究表明与分泌毒素的细菌,表达结合于其细胞膜的毒素的细菌或在细胞质包含毒素的细菌相比,在全身性抗体应答的诱导方面没有显著的差别(Reveneau等,2002)。
全身性细胞免疫应答,特别是细胞毒性T细胞应答,和所产生的保护未被研究或描述。
因此,上面引用的基于毒素的感染疫苗的现有技术不能表明用作佐剂的毒素的分泌对于全身性(细胞)免疫应答的诱导是否具有优势。完全相反地,上面引用的研究指出了稳定性问题并且指出分泌性异源毒素的缺乏的优势。由分泌信号,毒素和异源抗原组成的融合蛋白完全没有被描述或提示。
上文给出的现有技术描述了异源表达毒素并且能够用作感染疫苗的细菌载体。在引用的实例中,主要对毒素的表达或稳定性和它们的可溶性进行修饰,例如插入强表达启动子或将毒素与分泌信号融合。
其他作者还研究了活疫苗中毒素与异源抗原的基因融合。在这些实例中,毒素主要用作佐剂。在一些例子中(例如(Brossier等,2000))异源抗原作为佐剂起作用而毒素作为真正的抗原起作用。
然而,应当指出,在提及的实例中,毒素-抗原基因融合构建体的表达完全在细胞质或周质发生。毒素-抗原构建体既不与另外的分泌信号(其可以导致它的完全分泌)融合,也不直接分泌。
在这些毒素-抗原基因融合构建体构建期间,使用重组大肠杆菌(Clemens等,2004),炭疽芽孢杆菌(Brossier等,2000),志贺氏菌(Koprowski等,2000;Ranallo等,2005;Zheng等,2005)和弧菌菌株(Silva等,2003)。对于沙门氏菌(概述于(Garmory等,2002)),CT变体与抗原的融合(Hajishengallis等,1996;Huang等,2000)或其他毒素与抗原的融合(Barry等,1996;Cardenas和Clements,1993;Chabalgoity等,1997;Chabalgoity等,1996;Chabalgoity等,2000;Chabalgoity等,1995;Chacon等,1996;Jagusztyn-Krynicka等,1993;Khan等,1994a;Khan等,1994b;Lee等,2000;Pogonka等,2003;Schodel等,1990;Smerdou等,1996;Ward等,1999;Wu等,2000)也已经被描述。
这些实例大多数主要关注于粘膜(抗体)免疫应答的诱导并且对于全身性免疫应答的诱导来说,只选择皮下而非口服施用[36]。
将沙门氏菌用作支持菌株(supporter strain)的一些工作仅限于菌株的特征描述(Gomez-Duarte等,1995;Jagusztyn-Krynicka等,1993),其他工作仅分析粘膜和/或全身性抗体应答和/或保护(Barry等,1996;Cardenas和Clements,1993;Dunstan等,2003;Hajishengallis等,1996;Harokopakis等,1997;Khan等,1994a;Khan等,1994b;Pogonka等,2003;Smerdou等,1996;Somner等,1999)。在其中附带使用抗原和破伤风毒素之间的融合并且其专门用作感染疫苗的所有这些实例中,全身性细胞免疫应答,特别是细胞毒性T细胞应答还未被研究。
因此,从免疫学观点,关于作为肿瘤疫苗的潜在的应用的结论不能够从这些研究得到,因为它们关注于抗体介导的效应作为感染疫苗。
包括所研究的免疫应答的同种型分析的研究似乎更相关。事实上,在这些实例中不直接测量细胞免疫应答,但是抗体应答的同种型谱允许得到免疫应答的Th1/Th2免疫偏离的结论。抗体同种型如IgG1与Th2应答相关并且同种型如IgG2a与Th1应答相关。如已经指出的,Th1应答为细胞为主的免疫应答,然而Th2应答主要代表体液抗体驱动(driven)的应答。同样,这些研究既未描述肿瘤疫苗,也未暗示任何作为抗肿瘤剂的应用。
基于作为载体的表达破伤风-毒素抗原融合蛋白的沙门氏菌的一个感染疫苗的研究已经在狗中实现。在狗中诱导的低抗体应答表明Th1免疫偏离,因此,在抗体谱方面,该应答与细胞型免疫应答更相关(Chabalgoity等人,2000)。然而,狗的免疫学几乎没有被研究过,因此,不清楚狗抗体谱能够在什么程度上提供关于Th1免疫偏离的信息。
然而,在小鼠中通过相同的组进行的,使用相当的(comparable)构建体的研究,表明抗体谱对于IgG1具有与对于IgG2a相同的水平,这表明混合的Th1/Th2应答。
有趣的是,如由于之前的免疫而在大多数人中所发现的,抗破伤风毒素的现有的免疫导致另一个相对强的IgG1的诱导,然而几乎不诱导IgG2a。这清楚地指示明确的Th2免疫偏离(Chabalgoity等,1995)。由于这个原因,基于破伤风毒素的活疫苗作为肿瘤疫苗用于人十分有害。因为能够预期其在表现出破伤风毒素特异性应答的大多数患者中诱导强的Th2抗体为主的应答。
只有很少的研究还分析细胞免疫应答并且比较具有和不具有毒素融合的基因构建体。在一个实例中,例如,与和不与破伤风毒素的抗原的融合已经在沙门氏菌中进行比较(Lee等人)。其中,破伤风毒素抗原融合构建体主要增加总的抗体水平,然而Th1/Th2谱难以改变。甚至代表性Th1细胞因子例如IFN-γ和IL-2的抗原特异性CD4+T细胞分泌,分别只表现出很微小的区别。经相同的组在较早的研究中,细胞IFN-γ水平也已经被测量。然而,没有与不具有破伤风毒素的构建体进行比较(Chabalgoity等人)。用不同的革兰氏阴性菌载体,如志贺氏菌(Koprowski等人,;Ranallo等人,;Zheng等人)或弧菌(Campos等人;Ryan等人)的其他研究也未分别分析同种型和细胞免疫应答。
总之,能够确定的是,提及的研究明确关注于抗体驱动的体液免疫应答的诱导。其中,确实使用了基因毒素抗原构建体,但是这些不具有分泌信号也不直接分泌。然而,绝对没有分析全身性细胞免疫应答,特别是细胞毒性T细胞应答。而且,此类细胞毒性T细胞应答不能从体液抗体应答推断并且如果由Th1/Th2组成抗体应答,此类细胞毒性T细胞应答不能进行检测。
然而,正是这些细胞毒性T细胞免疫应答对于在肿瘤疫苗治疗中的应用是至关重要的。
因此,就毒素-抗原融合物(其仅限于粘膜感染疫苗)而言,现有技术没有提供任何关于任何此类构建体可以用作肿瘤疫苗的表述。
如已经指出的,基因融合构建体的表达可无需分泌系统的帮助进行。通常,毒素和毒素抗原构建体分别定位于细胞质及周质,即在两个膜之间。为了诱导有效的细胞免疫应答,毒素必须可自由接近抗原呈递细胞(APC)。通常,天然毒素产生于革兰氏阴性菌的周质中。这对于仅粘膜免疫应答是足够的,因为周质毒素能够从结肠中的周质逃脱从而也是可接近的(Hunt和Hardy,1991)。然而,如果载体靶向结肠外例如派尔斑(Peyer’s Patches)或淋巴器官如淋巴结或脾的抗原呈递细胞,则这不计算在内。
原则上,两种因素对于肿瘤疫苗的功效至关重要:Th1型细胞免疫应答的诱导和先天免疫系统的组分的参与,例如NK细胞,NKT细胞和γ-δT细胞,其在肿瘤治疗的功效中起重要作用(Dunn等人,2004)。
先天免疫系统的这些组分的重要性在于多个水平。适当活化的NK和γ-δT细胞能够局部地产生大量IFN-γ。还由特定Th1极化T细胞产生的这种干扰素具有多种功能,与肿瘤治疗有关。它的核心功能之一是抑制血管生成,其切断了肿瘤的氧和营养的供给并且事实上饿死肿瘤。此外,NK细胞具有受体,所述受体识别MHC I类分子。如果这些分子在细胞上呈递,NK细胞被抑制。
对于其诱导特异性细胞毒性T细胞的疫苗,肿瘤细胞能够被这些CTL杀死。如果肿瘤细胞失去了表达MHC I类分子的能力(这种情况在肿瘤中非常频繁地发生),则特异性细胞毒性T细胞无效。因此,在这种情况下,NK细胞的抑制终止,并且它们能够直接清除肿瘤细胞。
因而,如果肿瘤疫苗有效诱导两种组分,其是理想的。存在关于融合的毒素佐剂的Th1-Th2免疫偏离的相互矛盾的数据。如之前讨论的,以单独的形式使用的毒素抗原融合构建体明显诱导强Th2极化免疫应答。一些作者还描述活载体的低Th2免疫偏离;其他作者观察到了轻微的Th1免疫偏离。
然而,这些数据仍基于非分泌性构建体。借助此类感染疫苗的先天免疫的诱导从未被比较或被关注(contemplate)。
如已经指出的,主要原因为现有的疫苗是粘膜感染疫苗,而非肿瘤疫苗。因此,Th1免疫应答、CTL免疫应答和先天免疫系统的应答的诱导未被关注。相比之下,对于肿瘤疫苗,这些免疫应答的诱导是必不可少的。
有趣的是,在细胞生物学中,天然毒素通常用作信号途径的抑制剂。其中已表明天然百日咳毒素,而非霍乱毒素,能够抑制NK细胞的特定的凋亡方式(Ramirez等人,1994)。不同的调查研究已能够表明霍乱毒素,而非它的B亚基,阻断特异性NK细胞功能(Poggi等人,1996)。使用天然百日咳毒素以抑制淋巴细胞的趋化作用(Spangrude等人,1985)。即使这些研究不涉及肿瘤疫苗接种,本领域技术人员也可以推断毒素作为肿瘤疫苗的应用是有害的,因为对于肿瘤治疗至关重要的先天免疫系统的应答被抑制而不是被诱导。
其他研究已能够表明毒素如天然百日咳毒素(而非灭活的百日咳毒素)有效诱导先天免疫系统的组分。对于抗肿瘤的免疫治疗,这意味着如果有可能,可以使用天然毒素。然而,由于毒性原因,此类施用是不可行的。进一步,此类诱导不可避免地导致Th2定向的二次免疫应答,其反过来对肿瘤治疗是有害的(Boyd等人,2005)。因此,关于先天免疫应答的诱导,现有技术未描述也未关注肿瘤疫苗接种。完全相反,文献的关键分析还对肿瘤治疗中毒素的应用产生不利的影响。
然而,毒素或它们的亚基与其他刺激剂,例如具有低甲基化CpG基序的免疫刺激DNA寡核苷酸(CpG ODN)(Holmgren等人,2005)或脂多糖(LPS)的协同效应的分析是引人关注的。在LPS的情况下,主要地,单核细胞的诱导似乎主要通过毒素的B亚基增加,然而其被作为整体的毒素(全毒素)抑制(Hajishengallis等,2004)。然而,这些研究只依赖于纯化的毒素抗原融合构建体的使用,对其加入物质如LPS或CpG作为佐剂。而且,该分析只在巨噬细胞上进行,其诱导适应性免疫应答,但是不直接攻击肿瘤。因此,这些研究对先天免疫系统的组分(特别是能够直接攻击肿瘤的NK细胞)的诱导没有意义。
然而,其他研究表明NK细胞能够被毒素如铜绿假单胞菌(Pseudomonas aeruginosa)外毒素A活化并且趋化吸引(Muhlen等,2004)。依赖于实验系统,还能诱导Th1应答,尽管主要出现NK细胞和Th1应答的抑制(Michalkiewicz等,1999)。然而,这些实验主要旨在分析外毒素A的肝毒性并且不涉及肿瘤疫苗接种。有趣的是,该作用高度依赖于剂量,并且只要轻微地改变剂量就能逆转该作用。然而,作者未能揭示在体内有效地发生哪种应答。结果,该数据没有提供如果毒素乃至脱毒的毒素用作佐剂,可以产生哪种作用的预测。
总而言之,免疫应答强烈依赖于所使用的特定系统。在大多数实例中,粘膜抗感染疫苗旨在在粘膜处局部操纵(manipulation)免疫系统,以诱导有效的粘膜免疫应答(Lycke,2005)。然而,这些研究不包括肿瘤疫苗的开发。另外,这些研究缺乏关于全身性细胞免疫应答,特别是细胞毒性T细胞的应答的诱导的信息,其对于肿瘤疫苗接种是基本的。
已经表明,异源抗原的分泌赋予对全身性免疫应答的优势(Hess等,1996)。然而,所述的分泌性抗原不是分泌性毒素-抗原构建体;没有使用毒素或其亚基。因此转基因肿瘤模型中可获得的免疫应答也是高度有限的(Gentschev等,2005)。当然,可以在这一实例中诱导弱的抗体和细胞毒性T细胞应答,其部分避免肿瘤进展。然而,不仅免疫应答自身,保护自身也是有限的。同样,这些肿瘤疫苗接种研究缺少与非分泌性构建体的比较。此外,没有在肿瘤疫苗接种的背景中进行比较研究(Hess等,1996)并且比较研究和进一步的研究相反,所述的进一步的研究未见到任何关于分泌的优点(Garmory等,2002;Roland等,2005)。
总之并且如前所述,现有技术在分泌方面是高度相互矛盾的,并且,总而言之,对分泌性毒素-抗原构建体在肿瘤治疗中的潜在优势没有给出任何线索。完全相反,现有文献的关键分析对此类应用意见非常不一致。
细菌毒素(Todar,2002):在化学水平,存在两类细菌毒素,脂多糖,其与革兰氏阴性菌的细胞壁结合,以及蛋白,其从细菌细胞释放并且可以在远离细菌生长位置的组织位置起作用。细胞结合脂多糖(LPS)毒素被称为内毒素并且细胞外可扩散的毒素被称为外毒素。
外毒素通常是由指数生长期间的活的细菌分泌的可溶蛋白,但是在一些实例中,它们通过细菌细胞的裂解释放。毒素的产生通常对产生与毒素相关的疾病的特定细菌种类是特异性的(例如只有破伤风梭菌(Clostridium tetani)产生破伤风毒素;只有白喉棒杆菌(Corynebacterium diphtheriae)产生白喉毒素)。革兰氏阳性菌和革兰氏阴性菌都产生可溶蛋白毒素。
通常,存在三类蛋白(外-)毒素:(i)I型毒素(超抗原),其与宿主细胞表面结合并且调节免疫应答但不转位入细胞,(ii)II型毒素(成孔毒素),其在宿主细胞膜上起作用并且使得宿主细胞渗漏并死亡,和(iii)III型毒素(A-B毒素),其经由一个特异性受体与宿主细胞结合,转位入细胞,在细胞中变成有活性的修饰蛋白或宿主细胞的其他组分。
如上面指出的,III型毒素(对于宿主细胞在细胞内起作用),由两个组分组成:一个组分(亚基A)负责毒素的酶活性;另一个组分(亚基B)参与与宿主细胞膜上的特异性受体的结合和酶的跨膜转运。直至其从天然(A+B)毒素释放,酶组分才具有活性。分离的A亚基具有酶活性但是缺乏结合和进入细胞的能力。分离的B亚基可以与靶细胞结合(并且甚至阻断天然毒素的结合),但是它们是无毒的。
存在可以合成和装配(arranged)毒素亚基的多种方法:A+B表示毒素作为在靶细胞表面相互作用的两个分离的蛋白亚基进行合成和分泌;A-B或A-5B或AB5表示A亚基和B亚基分别合成,但是在分泌和与它们的靶结合期间通过非共价键结合;5B或B5表示蛋白的结合结构域由5个相同亚基组成。AB或A/B表示作为单一多肽合成的毒素,分为A和B结构域,其可以通过蛋白水解切割进行分离。AB或A/B的实例为白喉毒素,外毒素A,肉毒杆菌毒素和破伤风毒素。A-5B或AB5毒素的实例为霍乱毒素和志贺菌毒素,而炭疽毒素LF和炭疽毒素EF为A-B毒素的实例。
其他相关的现有技术文献包括下列:
Michl等描述了细菌和细菌毒素作为用于实体瘤的治疗剂的用途。公开了毒素-抗原融合构建体及此类构建体的细菌靶向。研究了白喉毒素(DT),假单胞菌外毒素A(PE)和产气荚膜梭菌(Clostridiumperfringens)肠毒素(CPE)的用途。然而,作者既没有提及霍乱毒素的用途,也没有展示或提出细菌递送的毒素-抗原融合构建体的明显的分泌(Michl和Gress,2004)。
Lahiri给出了关于不同细菌毒素的综述并且讨论了它们的多种形式的应用。尽管作者提到了毒素-抗原融合蛋白,他完全没有提到霍乱毒素和分泌性毒素-抗原融合构建体的细菌靶向(Lahiri,2000)。
Lavelle等人公开了作为免疫调节药物的感染剂的分子。作者还提及霍乱毒素-抗原融合蛋白,但是此类构建体仅作为蛋白直接应用而没有借助遗传修饰的活疫苗进行应用(Lavelle等,2004)。
WO 01/74383关注嵌合抗原-肠毒素粘膜免疫原并且还提及霍乱毒素亚基A2和B的应用。然而,此类嵌合免疫原总是同时包含A2和B亚基并且意欲在粘膜免疫而非肿瘤治疗中使用。
WO 02/077249描述了用于将异源蛋白递送到特异性突变靶细胞的非致命性小肠结肠炎耶尔森氏菌(Yersinia enterocolitica)突变体菌株。还提及了霍乱毒素亚基A1的应用但是该专利文献完全没有提及分泌并且只涉及了感染和感染状态的治疗。
WO 2004/018630公开了编码双链真核表达盒的重组双链RNA噬菌体。尽管提及霍乱毒素亚基A,但该文献没有进一步的相关性。
Holmgren等人给出了关于粘膜免疫和佐剂领域的简短的综述。其中他们讨论了霍乱毒素作为粘膜佐剂的功效但是没有公开关于遗传表达系统或活疫苗的信息并且也完全没有提及肿瘤治疗(Holmgren等人,2003)。
Holmgren和Czerkinsky也给出了关于粘膜免疫和疫苗的综述。然而,这篇文章仅限于抗感染药并且没有讨论或提出在肿瘤治疗领域中明显的可能的应用(Holmgren和Czerkinsky,2005)。
Freytag和Clements的另一篇评论公开了用于抗感染免疫治疗的粘膜佐剂。尽管霍乱毒素作为粘膜佐剂被提及,但作者完全没有提及分泌性毒素抗原构建体和作为施用的可能范围的肿瘤治疗(Freytag和Clements,2005)。
Shaw和Starnbach描述了经修饰的细菌毒素用于递送疫苗抗原的应用。然而,该文章没有提及霍乱毒素并且由于疫苗接种的原因,进一步地限于毒素-抗原融合蛋白的直接使用(Shaw和Starnbach,2003)。
WO 03/072789关注于作为编码用于治疗肿瘤的细胞抗原的核苷酸序列的载体的微生物。尽管专利文献提及分泌和在肿瘤治疗领域中的应用,但其完全没有提及细菌毒素和融合蛋白。
Gentschev,Dietrich和Goebel以及Gentschev等人描述了细菌靶向和它在肿瘤疫苗开发中的应用。然而,这两篇文献均没有提及细菌毒素和融合蛋白在肿瘤治疗中的应用(Gentschev等人,2002a;Gentschev等人,2002b)。
WO 98/23763公开了将大肠杆菌溶血素B和D亚基与包括与hylA融合的异源抗原的融合多肽一起表达的霍乱弧菌细胞。进一步描述了表达霍乱毒素亚基B及分泌信号序列,异源抗原和霍乱毒素A2亚基的融合多肽的弧菌霍乱疫苗菌株。最后,公开了包括与艰难梭菌(C.difficile)毒素A或毒素B亚基的抗原部分融合的霍乱毒素B亚基的融合多肽。然而,该专利申请没有提及蛋白毒素加上异源非蛋白毒素抗原的融合蛋白在肿瘤治疗中的应用。
Dietrich和合作者讨论了两种疫苗递送工具——溶血素A和利斯特菌溶胞素--其能够用于细胞介导的免疫。然而,没有提及蛋白毒素-异源抗原融合蛋白或共表达(Dietrich等人,2003)。
Gentschev等人描述了大肠杆菌的α-溶血素分泌系统在伤寒沙门氏菌(Salmonella typhi)Ty21a疫苗菌株中用于抗原递送的应用。然而,作者没有提及细菌毒素和融合蛋白在肿瘤治疗中的应用(Gentschev等人,2004)。
WO 02/47727关注于包含蛋白毒素的B亚基的治疗剂。该文献只公开了CtxB和EtxB与病毒抗原的融合蛋白。没有提及细菌疫苗或细菌疫苗递送。
Cheng-hua S和合作者描述了霍乱毒素B亚基和HBV PreS2表位的基因融合及在直接免疫研究中该融合蛋白的抗原性。然而,没有提及细菌疫苗或细菌疫苗递送(Cheng-hua等人,1995)。
Sanchez等人公开,当与DNA疫苗皮内共同施用时霍乱毒素B亚基基因增强粘膜免疫球蛋白A,Th1型和CD8+细胞毒性应答(Sanchez等人,2004)。然而,在该方法中,作者用DNA作为载体,其单独用作Th1促进佐剂。另外,蛋白由宿主细胞产生而非直接地或经由细菌载体进行递送从而蛋白对于真核细胞来说是可以直接获得的。
WO 01/29233关注于嵌合免疫原性组合物和编码它们的核酸。然而,没有提及细菌疫苗或细菌疫苗递送。
WO 2007/044406涉及通过使用基于具有III型分泌信号的SopE的细菌抗原递送系统刺激免疫应答的方法。然而,该专利申请没有提及细菌毒素和融合蛋白在肿瘤治疗中的应用。
总之,从现有技术能够得到这样的结论,由于它们的强毒性,天然毒素不能在人体中使用。进一步地,因为先天免疫系统的应答,特别是NK细胞的应答被抑制,所以它们在肿瘤治疗中的使用将是有害的。然而,该免疫应答对于成功的肿瘤治疗来说是重要组成,因为肿瘤细胞经常失去其表达MHC I类分子的能力从而对CTL识别和攻击有抗性。
在另一方面,单独的或与(异源)抗原蛋白融合的脱毒毒素亚基的应用导致强烈的削弱的佐剂功效和/或甚至诱导免疫系统及粘膜限制性抗体和Th2型免疫应答的全身性耐受。
此外,(异源)抗原-毒素融合蛋白的分泌(其只在抗感染疫苗(即靶向抗原乃至毒素自身)期间被描述)据认为不仅在细胞质表达方面没有表现出优势,而且通常更不适用。
总之,既未给出肿瘤治疗方法也没有描述或获得用产生IFN-γ的T辅助细胞的Th1为主的细胞免疫应答的全身性诱导,CTL的诱导或先天免疫系统的激活,而对于肿瘤治疗来说,这些全部是必不可少的。
发明详述
本发明目的在于提供新的肿瘤疫苗,通过其可诱导强烈的全身性细胞免疫系统应答,并且能够获得有效的肿瘤治疗。
本发明的目的在一个方面令人惊讶地通过提供作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物解决,所述微生物包含下列组分:
(I)编码至少一个野生型或突变的蛋白的至少一个完整或部分抗原的至少一个核苷酸序列;和
(II)编码至少一个蛋白毒素和/或至少一个蛋白毒素亚基的至少一个核苷酸序列;和
(III)a)编码至少一个转运系统的至少一个核苷酸序列,所述的转运系统使得能够在微生物的外表面表达组分(I)和组分(II)的表达产物和/或使得能够分泌组分(I)和组分(II)的表达产物;和/或编码使得能够分泌组分(I)和组分(II)表达产物的至少一个信号序列的至少一个核苷酸序列;和/或
b)任选地,编码用于裂解哺乳动物细胞的胞质溶胶中的微生物且用于细胞内释放包含在裂解的微生物中的质粒或表达载体的至少一个蛋白的至少一个核苷酸序列;和
(IV)用于表达组分(I)至(III)的一个或多个的至少一个活化序列的至少一个核苷酸序列,其中所述的活化序列能够在微生物中活化和/或是组织细胞特异性的,肿瘤细胞特异性的,巨噬细胞特异性的,树突特异性的,淋巴细胞特异性的,功能特异性的或非细胞特异性的;
其中组分(I)至(IV)的任何一个能够以一倍或几倍存在并且如果组分(I)至(IV)的组分以几倍存在,其相互独立地可以是相同的或不同的。
在优选的实施方案中,提供包含上述组分(I)至(IV)的微生物,其中组分(I)和组分(II)是不同的,即组分(I)不编码编码至少一个蛋白毒素和/或至少一个蛋白毒素亚基的至少一个核苷酸序列。
在本发明中与组分(IV)相关的术语“组织细胞特异性”指在靶组织细胞中特异性活化的活化序列,例如在前列腺组织中的激素依赖性启动子。
在本发明中与组分(IV)相关的术语“肿瘤细胞特异性”指在肿瘤细胞中特异性活化的活化序列,例如通过肿瘤特异性癌基因的作用而活化的启动子元件。
在本发明中与组分(IV)相关的术语“巨噬细胞特异性”指在巨噬细胞中特异性活化的活化序列,例如编码巨噬细胞特异性基因,例如编码F4/80的基因的启动子元件。
在本发明中与组分(IV)相关的术语“树突特异性”指在树突细胞中特异性活化的活化序列,例如控制B7.1表达的启动子元件。术语“树突特异性”和“树突细胞特异性”是等价的,即他们具有相同的意义并且都涉及树突细胞。
在本发明中与组分(IV)相关的术语“淋巴细胞特异性”指在淋巴细胞谱系的细胞中特异性活化的元件,如在T细胞中调节CD3分子表达的启动子元件或在成熟B细胞中调节CD20表达的启动子元件。
在本发明中与组分(IV)相关的术语“功能特异性”指在细胞背景(context)中例如缺失p53表达的肿瘤细胞中特异性活化的活化序列,或依赖于背景,例如细胞定位或氧分压在细菌内活化的活化序列。
在本发明中与组分(IV)相关的术语“非细胞特异性”指具有广泛活性的活化序列,例如组成型活性细菌启动子。
在本发明中术语“核苷酸序列”指dsDNA,ssDNA,dsRNA,ssRNA或dsDNA/RNA杂交物。优选dsDNA。
在本发明中术语“抗原”指与抗体反应的分子,即其能够产生抗体。一些抗原不通过自身引起抗体产生;只有那些能够诱导抗体产生的抗原被称为免疫原。为了本发明的目的,意欲包括所有种类的已知抗原。通过数据库和/或实验筛选找到关于潜在抗原的必要的信息而没有额外负担在本领域技术人员的知识范围内。抗原的实例包括细胞抗原,组织细胞特异性抗原(例如从其衍生肿瘤的组织细胞),细胞蛋白抗原,病毒抗原,病毒蛋白抗原等。优选蛋白抗原。进一步优选异源抗原或外源抗原,即对于本发明的各自的微生物不是内源的抗原或天然地不由本发明的各自的微生物表达,但是通过标准分子生物学方法导入微生物的抗原。
在本发明中术语“完整抗原”指根据上述定义与抗体反应的完整分子。完整抗原的实例例如全长蛋白,其也是优选的。
在本发明中术语“部分抗原”指根据上述定义与抗体反应的分子的特定部分。例如,部分抗原可以是例如蛋白基序,例如蛋白质内的氨基酸环,蛋白激酶结构域,表位等。优选蛋白激酶结构域和表位,后者是被抗体识别的抗原特异性位点(也称为抗原决定簇)。
在本发明中与“蛋白”相关的术语“野生型”和“突变的”分别指由它们的“天然的”主要氨基酸序列(由各自的核苷酸序列编码)组成的蛋白和与野生型序列相比在它们的氨基酸序列(由各自的核苷酸序列编码)中具有一个或多个突变的蛋白。优选野生型和/或突变的蛋白得自肿瘤细胞。对于部分抗原而言,进一步优选具有突变的序列,即优选包含一个或多个突变的表位,例如B-Raf V600E表位。
本发明意义上的微生物为细菌,革兰氏阳性菌,革兰氏阴性菌和真核细胞,后者包含单细胞寄生虫,酵母,肿瘤细胞和细胞系细胞,例如酿酒酵母(Sacharomyces cerevisiae),利什曼原虫属的种(Leishmania spp.),得自患者的自体肿瘤细胞和肿瘤细胞系。此类微生物通常用作用于转移对微生物来说是外源的(异源的或异种的)核苷酸序列的载体。优选地,使用其毒性减弱的细菌,例如携带缺失或灭活的aroA,aro,asd,gal,pur,cya,crp,phoP/Q,omp基因的细菌或其为温度敏感型突变体或抗生素依赖性突变体的细菌(Cardenas和Clements,1992)。进一步优选的包含上述组分(I)至(IV)的微生物为革兰氏阴性的,减毒的,兼性细胞内细菌,其作为载体能够克服(overcome)肠粘膜(例如沙门氏菌属的种或志贺氏菌属的种)。
在优选的实施方案中,提供包含上述组分(I)至(IV)的微生物,其中微生物选自“细菌,革兰氏阳性菌,革兰氏阴性菌,真核细胞”并且优选选自“埃希氏菌属的种(Escherichia spp.),大肠杆菌,沙门氏菌属的种(Salmonella spp.),伤寒沙门氏菌,鼠伤寒沙门氏菌(Salmonella typhimurium),耶尔森氏菌属的种(Yersinia spp.),小肠结肠炎耶尔森氏菌,弧菌属的种(Vibrio spp.),霍乱弧菌(Vibrio cholerae),利斯特氏菌属的种(Listeria spp.),单核细胞增生利斯特氏菌(Listeria monocytogenes),志贺氏菌属的种(Shigella spp.),弗氏志贺氏菌(Shigella flexneri)”,其中优选微生物的毒性被减弱。进一步优选,将霍乱弧菌排除在上述定义的微生物以外。
与任意微生物相关的术语“属的种”为了本发明的目的意欲包含给定属的所有成员,包括种,亚种和其他。例如术语“沙门氏菌属的种”意欲包含沙门氏菌属的所有成员,例如伤寒沙门氏菌和鼠伤寒沙门氏菌。
在另一个优选的实施方案中,提供根据上述定义的微生物,其中根据组分(I)的至少一个野生型或突变蛋白的至少一个完整或部分抗原选自下列野生型蛋白和它们的已知的突变体:“受体;受体的胞外,跨膜或胞内部分;黏着分子;黏着分子的胞外,跨膜或胞内部分;信号转导蛋白;细胞周期蛋白;转录因子;分化蛋白;胚胎蛋白(embryonicprotein);病毒蛋白;过敏原;微生物病原体蛋白;真核病原体蛋白;癌-睾丸(cancer testis)抗原蛋白;肿瘤抗原蛋白;和/或组织细胞特异性蛋白”,其中组织细胞选自“甲状腺,乳腺,唾液腺,淋巴结,乳腺,胃粘膜,肾,卵巢,前列腺,宫颈,膀胱浆膜和痣”。
就突变蛋白而言,突变可以是致癌的并且可以导致其原有的细胞功能的丧失或增强。
此类抗原在细胞中控制细胞生长和细胞分裂并且呈递于正常细胞的细胞膜,例如通过MHC I类分子。在肿瘤细胞中,这些抗原经常被过表达或特异性突变。因而,此类突变可以对癌基因抑制物具有功能限制或导致原癌基因活化为癌基因并且可以单独或通常与过表达一起参与肿瘤生长。此类细胞抗原呈递于肿瘤细胞膜上从而代表肿瘤细胞上的抗原,而不导致影响患者的肿瘤疾病的免疫反应。Rapp(US5,156,841)已经描述了癌蛋白(即癌基因的表达产物)作为用于肿瘤疫苗的免疫原的应用。
根据本发明的抗原和其(致癌性)突变的实例为i)受体,例如Her-2/neu,雄激素受体,雌激素受体,乳铁蛋白受体,肝素结合生长因子(midkine)受体,EGF受体,ERBB2,ERBB4,TRAIL受体,FAS,TNFα受体,TGF-β受体;ii)信号转导蛋白,例如c-Raf(Raf-1),A-Raf,B-Raf,B-Raf V599E,B-Raf V600E,B-Raf KD,B-Raf V600E激酶结构域,B-Raf V600E KD,B-Raf V600E激酶结构域KD,B-Raf激酶结构域,B-Raf激酶结构域KD,Ras,Bcl-2,Bcl-X,Bcl-W,Bfl-1,Brag-1,Mcl-1,A1,Bax,BAD,Bak,Bcl-Xs,Bid,Bik,Hrk,Bcr/abl,Myb,C-Met,IAP1,IAO2,XIAP,ML-IAP LIVIN,存活素(survivin),APAF-1;iii)细胞周期控制蛋白,例如细胞周期蛋白D(1-3),细胞周期蛋白E,细胞周期蛋白A,细胞周期蛋白B,细胞周期蛋白H,Cdk-1,Cdk-2,Cdk-4,Cdk-6,Cdk-7,Cdc25C,p16,p15,p21,p27,p18,pRb,p107,p130,E2F(1-5),GAAD45,MDM2,PCNA,ARF,PTEN,APC,BRCA,p53和同源物;iv)转录因子,例如C-Myc,NFkB,c-Jun,ATF-2,Spl;v)胚胎蛋白,例如癌胚抗原,甲胎蛋白,MAGE,MAGE-1,MAGE-3,NY-ESO-1,PSCA;vi)分化抗原,例如MART,Gp100,酪氨酸酶,GRP,TCF-4,碱性髓磷脂,α-乳清蛋白,GFAP,前列腺特异性抗原(PSA),纤维酸性蛋白,酪氨酸酶,EGR-1,MUC1;vii)病毒抗原,例如下列病毒的抗原:HIV,HPV,HCV,HPV,EBV,CMV,HSV,流感病毒,A型流感病毒,A型流感病毒(H5N1)和(H3N2),B型流感病毒,C型流感病毒;血凝素,血凝素H1,血凝素H5,血凝素H7,血凝素HA1(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12C(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),neuramidase,微生物抗原:p60,LLO,脲酶等。真核病原体抗原:CSP(疟疾),calflagin(锥虫属),CPB(硕大利什曼原虫(Leishmaniamajor))等。
在另一个优选的实施方案中,提供根据上述定义的微生物,其中根据组分(I)的至少一个野生型或突变蛋白的至少一个完整或部分抗原选自下列野生型蛋白和其已知突变体:“Her-2/neu,雄激素受体,雌激素受体,肝素结合生长因子受体,EGF受体,ERBB2,ERBB4,TRAIL受体,FAS,TNFα受体,TGF-β受体,乳铁蛋白受体,碱性髓磷脂,α-乳清蛋白,GFAP,纤维酸性蛋白,酪氨酸酶,EGR-1,MUC1,c-Raf(Raf-1),A-Raf,B-Raf,B-Raf V599E,B-Raf V600E,B-RafKD,B-Raf V600E激酶结构域,B-Raf V600E KD,B-Raf V600E激酶结构域KD,B-Raf激酶结构域,B-Raf激酶结构域KD,N-Ras,K-Ras,H-Ras,Bcl-2,Bcl-X,Bcl-W,Bfl-1,Brag-1,Mcl-1,A1,Bax,BAD,Bak,Bcl-Xs,Bid,Bik,Hrk,Bcr/abl,Myb,C-Met,IAP1,IAO2,XIAP,ML-IAP LIVIN,存活素,APAF-1,细胞周期蛋白D(1-3),细胞周期蛋白E,细胞周期蛋白A,细胞周期蛋白B,细胞周期蛋白H,Cdk-1,Cdk-2,Cdk-4,Cdk-6,Cdk-7,Cdc25C,p16,p15,p21,p27,p18,pRb,p107,p130,E2F(1-5),GAAD45,MDM2,PCNA,ARF,PTEN,APC,BRCA,Akt,PI3K,mTOR,p53和同源物,C-Myc,NFkB,c-Jun,ATF-2,Sp1,前列腺特异性抗原(PSA),癌胚抗原,甲胎蛋白,PAP;PSMA;STEAP;MAGE,MAGE-1,MAGE-3,NY-ESO-1,PSCA,MART,Gp100,酪氨酸酶,GRP,TCF-4,病毒HIV,HPV,HCV,HPV,EBV,CMV,HSV,流感病毒,A型流感病毒,A型流感病毒(H5N1)和(H3N2),B型流感病毒,C型流感病毒的病毒抗原;血凝素,血凝素H1,血凝素H5,血凝素H7,血凝素HA1(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12C(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),neuramidase,p60,LLO,脲酶,CSP,calflagin和/或CPB”。
在另一个优选的实施方案中,提供根据上述定义的微生物,其中根据组分(I)的至少一个野生型或突变蛋白的至少一个完整或部分抗原选自由下列野生型蛋白和它们的已知的突变体组成的激酶(括号中是登录号):
AAK1(NM 014911),AATK(NM 004920),ABL1(NM005157),ABL2(NM 005158),ACK1(NM 005781),ACVR1(NM 001105),ACVR1B(NM 020328),ACVR2(NM 001616),ACVR2B(NM 001106),ACVRL1(NM 000020),ADCK1(NM 020421),ADCK2(NM 052853),ADCK4(NM 024876),ADCK5(NM174922),ADRBK1(NM 001619),ADRBK2(NM 005160),AKT1(NM 005163),AKT2(NM 001626),AKT3(NM 005465),ALK(NM 004304),ALK7(NM 145259),ALS2CR2(NM 018571),ALS2CR7(NM 139158),AMHR2(NM 020547),ANKK1(NM 178510),ANKRD3(NM 020639),APEG1(NM 005876),ARAF(NM 001654),ARK5(NM014840),ATM(NM 000051),ATR(NM 001184),AURKA(NM 003600),AURKB(NM004217),AURKC(NM 003160),AXL(NM 001699),BCKDK(NM 005881),BCR(NM004327),BIKE(NM 017593),BLK(NM 001715),BMPR1A(NM 004329),BMPR1B(NM 001203),BMPR2(NM 001204),BMX(NM 001721),BRAF(NM 004333),BRD2(NM 005104),BRD3(NM 007371),BRD4(NM 014299),BRDT(NM 001726),BRSK1(NM 032430),BRSK2(NM 003957),BTK(NM 000061),BUB1(NM 004336),BUB1B(NM 001211),CABC1(NM 020247),CAMK1(NM 003656),CaMK1b(NM 198452),CAMK1D(NM 020397),CAMK1G(NM 020439),CAMK2A(NM 015981),CAMK2B(NM 001220),CAMK2D(NM 001221),CAMK2G(NM 001222),CAMK4(NM 001744),CAMKK1(NM 032294),CAMKK2(NM 006549),CASK(NM 003688),CCRK(NM012119),CDC2(NM 001786),CDC2L1(NM 001787),CDC2L5(NM 003718),CDC42BPA(NM 014826),CDC42BPB(NM 006035),CDC7L1(NM 003503),CDK10(NM 003674),CDK11(NM 015076),CDK2(NM 001798),CDK3(NM 001258),CDK4(NM 000075),CDK5(NM 004935),CDK6(NM 001259),CDK7(NM 001799),CDK8(NM 001260),CDK9(NM 001261),CDKL1(NM 004196),CDKL2(NM 003948),CDKL3(NM 016508),CDKL4(NM 001009565),CDKL5(NM 003159),CHEK1(NM001274),CHUK(NM 001278),CIT(NM 007174),CLK1(NM 004071),CLK2(NM003993),CLK3(NM 003992),CLK4(NM 020666),CRK7(NM 016507),CSF1R(NM005211),CSK(NM 004383),CSNK1A1(NM 001892),CSNK1D(NM 001893),CSNK1E(NM 001894),CSNK1G1(NM 022048),CSNK1G2(NM 001319),CSNK1G3(NM 004384),CSNK2A1(NM 001895),CSNK2A2(NM 001896),DAPK1(NM 004938),DAPK2(NM 014326),DAPK3(NM 001348),DCAMKL1(NM 004734),DCAMKL2(NM152619),DCAMKL3(XM 047355),DDR1(NM 013993),DDR2(NM 006182),DMPK(NM 004409),DMPK2(NM 017525.1),DYRK1A(NM 001396),DYRK1B(NM006484),DYRK2(NM 006482),DYRK3(NM 003582),DYRK4(NM 003845),EEF2K(NM 013302),EGFR(NM 005228),EIF2AK3(NM 004836),EIF2AK4(NM_001013703),EPHA1(NM 005232),EPHA10(NM 001004338),EPHA2(NM004431),EPHA3(NM 005233),EPHA4(NM 004438),EPHA5(NM 004439),EPHA6(XM 114973),EPHA7(NM 004440),EPHA8(NM 020526),EPHB1(NM 004441),EPHB2(NM 017449),EPHB3(NM 004443),EPHB4(NM 004444),EPHB6(NM004445),ERBB2(NM 004448),ERBB3(NM 001982),ERBB4(NM 005235),ERK8(NM 139021),ERN1(NM 001433),ERN2(NM 033266),FASTK(NM 025096),FER(NM 005246),FES(NM 002005),FGFR1(NM 000604),FGFR2(NM 022970),FGFR3(NM 000142),FGFR4(NM 022963),FGR(NM 005248),FLJ23074(NM 025052),FLJ23119(NM 024652),FLJ23356(NM 032237),FLT1(NM 002019),FLT3(NM004119),FLT4(NM 002020),FRAP1(NM 004958),FRK(NM 002031),FYN(NM002037),GAK(NM 005255),GPRK5(NM 005308),GPRK6(NM 002082),GPRK7(NM 139209),GRK4(NM 005307),GSG2(NM 031965),GSK3A(NM 019884),GSK3B(NM 002093),GUCY2C(NM 004963),GUCY2D(NM 000180),GUCY2F(NM001522),H11(NM 014365),HAK(NM 052947),HCK(NM 002110),HIPK1(NM152696),HIPK2(NM 022740),HIPK3(NM 005734),HIPK4(NM 144685),HRI(NM014413),HUNK(NM 014586),ICK(NM 016513),IGF1R(NM 000875),IKBKB(NM001556),IKBKE(NM 014002),ILK(NM 004517),INSR(NM 000208),INSRR(NM014215),IRAK1(NM 001569),IRAK2(NM 001570),IRAK3(NM 007199),IRAK4(NM016123),ITK(NM 005546),JAK1(NM 002227),JAK2(NM 004972),JAK3(NM000215),KDR(NM 002253),KIS(NM 144624),KIT(NM 000222),KSR(XM 290793),KSR2(NM 173598),LAK(NM 025144),LATS1(NM 004690),LATS2(NM 014572),LCK(NM 005356),LIMK1(NM 016735),LIMK2(NM 005569),LMR3(XM 055866),LMTK2(NM 014916),LOC149420(NM 152835),LOC51086(NM 015978),LRRK2(XM 058513),LTK(NM 002344),LYN(NM 002350),MAK(NM 005906),MAP2K1(NM 002755),MAP2K2(NM 030662),MAP2K3(NM 002756),MAP2K4(NM 003010),MAP2K5(NM 002757),MAP2K6(NM 002758),MAP2K7(NM 005043),MAP3K1(XM042066),MAP3K10(NM 002446),MAP3K11(NM 002419),MAP3K12(NM 006301),MAP3K13(NM 004721),MAP3K14(NM 003954),MAP3K2(NM 006609),MAP3K3(NM 002401),MAP3K4(NM 005922),MAP3K5(NM 005923),MAP3K6(NM 004672),MAP3K7(NM 003188),MAP3K8(NM 005204),MAP3K9(NM 033141),MAP4K1(NM007181),MAP4K2(NM 004579),MAP4K3(NM 003618),MAP4K4(NM 145686),MAP4K5(NM 006575),MAPK1(NM 002745),MAPK10(NM 002753),MAPK11(NM002751),MAPK12(NM 002969),MAPK13(NM 002754),MAPK14(NM 001315),MAPK3(NM 002746),MAPK4(NM 002747),MAPK6(NM 002748),MAPK7(NM002749),MAPK8(NM 002750),MAPK9(NM 002752),MAPKAPK2(NM 032960),MAPKAPK3(NM 004635),MAPKAPK5(NM 003668),MARK(NM 018650),MARK2(NM 017490),MARK3(NM 002376),MARK4(NM 031417),MAST1(NM 014975),MAST205(NM 015112),MAST3(XM 038150),MAST4(XM 291141),MASTL(NM032844),MATK(NM 139355),MELK(NM 014791),MERTK(NM 006343),MET(NM000245),MGC33182(NM 145203),MGC42105(NM 153361),MGC43306(C9orf96),MGC8407(NM 024046),MIDORI(NM 020778),MINK(NM 015716),MKNK1(NM003684),MKNK2(NM 017572),MLCK(NM 182493),MLK4(NM 032435),MLKL(NM152649),MOS(NM 005372),MST1R(NM 002447),MST4(NM 016542),MUSK(NM005592),MYLK(NM 053025),MYLK2(NM 033118),MYO3A(NM 017433),MYO3B(NM 138995),NEK1(NM 012224),NEK10(NM 152534),NEK11(NM 024800),NEK2(NM 002497),NEK3(NM 002498),NEK4(NM 003157),NEK5(MGC75495),NEK6(NM 014397),NEK7(NM 133494),NEK8(NM 178170),NEK9(NM 033116),NLK(NM016231),NPR1(NM 000906),NPR2(NM 003995),NRBP(NM 013392),NRBP2(NM178564),NRK(NM 198465),NTRK1(NM 002529),NTRK2(NM 006180),NTRK3(NM002530),OBSCN(NM 052843),OSR1(NM 005109),PACE-1(NM 020423),PAK1(NM 002576),PAK2(NM 002577),PAK3(NM 002578),PAK4(NM 005884),PAK6(NM 020168),PAK7(NM 020341),PASK(NM 015148),PCTK1(NM 006201),PCTK2(NM 002595),PCTK3(NM 212503),PDGFRA(NM 006206),PDGFRB(NM 002609),PDK1(NM 002610),PDK2(NM 002611),PDK3(NM 005391),PDK4(NM 002612),PDPK1(NM 002613),PFTK1(NM 012395),PHKG1(NM 006213),PHKG2(NM000294),PIK3R4(NM 014602),PIM1(NM 002648),PIM2(NM 006875),PIM3(NM001001852),PINK1(NM 032409),PKE(NM 173575),PKMYT1(NM 004203),pknbeta(NM 013355),PLK(NM 005030),PLK3(NM 004073),PRKAA1(NM 006251),PRKAA2(NM 006252),PRKACA(NM 002730),PRKACB(NM 002731),PRKACG(NM 002732),PRKCA(NM 002737),PRKCB1(NM 002738),PRKCD(NM 006254),PRKCE(NM 005400),PRKCG(NM 002739),PRKCH(NM 006255),PRKCI(NM002740),PRKCL1(NM 002741),PRKCL2(NM 006256),PRKCM(NM 002742),PRKCN(NM 005813),PRKCQ(NM 006257),PRKCZ(NM 002744),PRKD2(NM016457),PRKDC(NM 006904),PRKG1(NM 006258),PRKG2(NM 006259),PRKR(NM 002759),PRKWNK1(NM 018979),PRKWNK2(NM 006648),PRKWNK3(NM020922),PRKWNK4(NM 032387),PRKX(NM 005044),PRKY(NM 002760),PRPF4B(NM 003913),PSKH1(NM 006742),PSKH2(NM 033126),PTK2(NM005607),PTK2B(NM 004103),PTK6(NM 005975),PTK7(NM 002821),PTK9(NM002822),PTK9L(NM 007284),PXK(NM 017771),QSK(NM 025164),RAD53(NM007194),RAF1(NM 002880),RAGE(NM 014226),RET(NM 020975),RHOK(NM002929),RIOK1(NM 031480),RIOK2(NM 018343),RIPK1(NM 003804),RIPK2(NM003821),RIPK3(NM 006871),RIPK5(NM 015375),RNASEL(NM 021133),ROCK1(NM 005406),ROCK2(NM 004850),ROR1(NM 005012),ROR2(NM 004560),ROS1(NM 002944),RPS6KA1(NM 002953),RPS6KA2(NM 021135),RPS6KA3(NM004586),RPS6KA4(NM 003942),RPS6KA5(NM 004755),RPS6KA6(NM 014496),RPS6KB1(NM 003161),RPS6KB2(NM 003952),RPS6KC1(NM 012424),RPS6KL1(NM 031464),RYK(NM 002958),SBK(XM 370948),SCYL1(NM 020680),SCYL2(NM 017988),SGK(NM 005627),SgK069(SU SgK069),SgK085(XM 373109),SgK110(SU SgK110),SGK2(NM 016276),SgK223(XM 291277),SgK269(XM370878),SgK424(CGP SgK424),SgK493(SU_SgK493),SgK494(NM 144610),SgK495(NM 032017),SGKL(NM 013257),SK681(NM 001001671),SLK(NM014720),SMG1(NM 015092),SNARK(NM 030952),SNF1LK(NM 173354),SNF1LK2(NM 015191),SNK(NM 006622),SNRK(NM 017719),SRC(NM 005417),SRMS(NM 080823),SRPK1(NM 003137),SRPK2(NM 003138),SSTK(NM032037),STK10(NM 005990),STK11(NM 000455),STK16(NM 003691),STK17A(NM 004760),STK17B(NM 004226),STK18(NM 014264),STK19(NM 032454),STK22B(NM 053006),STK22C(NM 052841),STK22D(NM 032028),STK23(NM014370),STK24(NM 003576),STK25(NM 006374),STK3(NM 006281),STK31(NM031414),STK32B(NM 018401),STK33(NM 030906),STK35(NM 080836),STK36(NM 015690),STK38(NM 007271),STK38L(NM 015000),STK39(NM 013233),STK4(NM 006282),STLK5(NM 001003787),STYK1(NM 018423),SUDD(NM003831),SYK(NM 003177),TAF1(NM 138923),TAF1L(NM 153809),TAO1(NM004783),TAOK1(NM 020791),TAOK3(NM 016281),TBCK(NM 033115),TBK1(NM013254),TEC(NM 003215),TEK(NM 000459),TESK1(NM 006285),TESK2(NM007170),TEX14(NM 031272),TGFBR1(NM 004612),TGFBR2(NM 003242),TIE(NM 005424),TIF1(NM 003852),TLK1(NM 012290),TLK2(NM 006852),TNIK(NM015028),TNK1(NM 003985),TOPK(NM 018492),TP53RK(NM 033550),TRAD(NM007064),TRIB1(NM 025195),TRIB2(NM 021643),TRIB3(NM 021158),TRIM28(NM 005762),TRIM33(NM 015906),TRIO(NM 007118),TRPM6(NM 017662),TRPM7(NM 017672),TRRAP(NM 003496),TSSK4(NM 174944),TTBK1(NM032538),TTBK2(NM 173500),TTK(NM 003318),TTN(NM 003319),TXK(NM003328),TYK2(NM 003331),TYRO3(NM 006293),ULK1(NM 003565),ULK2(NM014683),ULK3(NM 015518),ULK4(NM 017886),VRK1(NM 003384),VRK2(NM006296),VRK3(NM 016440),WEE1(NM 003390),Wee1B(NM 173677),YANK1(NM145001),YES1(NM 005433),ZAK(NM 016653),和/或ZAP70(NM 001079)。
在本发明中术语“过敏原”指如本文所定义的完整或部分抗原,其引起过敏和/或变态反应。实例为Der p 5(螨),Bet v 1(桦树花粉),Phl p 1(草花粉(grass pollen)),Asp f I/a(曲霉),PLA2(蜜蜂),Hev b(胶乳)(Schmid-Grendelmeier和Crameri,2001)。
微生物和真核病原体的抗原和癌-睾丸抗原附于上述列表中。
在本发明中,根据组分(I I)的蛋白毒素和/或它们的亚基优选细菌蛋白毒素,更优选外毒素。细菌外毒素的实例为I型毒素(超抗原),II型毒素(成孔毒素)和(iii)III型毒素(A-B毒素)。
在优选的实施方案中,提供根据上述定义的微生物,其中组分(II)选自“细菌毒素,肠毒素,外毒素,I型毒素,II型毒素,III型毒素,IV型毒素,V型毒素,RTX毒素,AB毒素,A-B毒素,A/B毒素,A+B毒素,A-5B毒素和/或AB5毒素”。
在进一步优选的实施方案中,提供根据上述定义的微生物,其中组分(II)选自“腺苷酸环化酶毒素,炭疽毒素,炭疽毒素(EF),炭疽毒素(LF),肉毒杆菌毒素,霍乱毒素(CT,Ctx),霍乱毒素B亚基(CTB,CtxB),白喉毒素(DT,Dtx),大肠杆菌LT毒素,大肠杆菌热不稳定肠毒素(LT),大肠杆菌热不稳定肠毒素B亚基(LTB),大肠杆菌ST毒素,大肠杆菌热稳定肠毒素(ST),红斑毒素,表皮剥脱毒素(Exfoliatin toxin),外毒素A,产气荚膜菌肠毒素(Perfringens enteratoxin),百日咳毒素(PT,Ptx),志贺菌毒素(ST,Stx),志贺菌毒素B亚基(STB,StxB),志贺样毒素,葡萄球菌肠毒素,破伤风毒素(TT),中毒性休克综合征毒素(TSST-1),Vero细胞毒素(VT),艰难梭菌(Clostridium difficile)的毒素A(TA)和毒素B(TB),索氏梭菌(Clostridium sordellii)的致死毒素(LT)和出血毒素(HT),诺氏梭菌(Clostridium novyi)的α毒素(AT)”。
然而,如果霍乱毒素或其亚基CtxB用作根据本发明的组分(II)的毒素,优选不用霍乱弧菌作为细菌载体(微生物)。
在优选的实施方案中,提供根据上述定义的微生物,其中组分(I)和组分(II)连接在一起使得能够表达和/或分泌由两个组分编码的融合蛋白。更优选,融合蛋白选自“CtxB-PSA,CtxB-B-Raf V600E KD(激酶失活型(kinase dead)),CtxB-B-Raf V600E激酶结构域,CtxB-B-Raf V600E激酶结构域KD(激酶失活型),CtxB-B-Raf,CtxB-B-Raf KD(激酶失活型),CtxB B-Raf激酶结构域KD(激酶失活型),CtxB-HA1(流感病毒的血凝素亚基1),CtxB-HA12C”。
分泌是从细胞分离,精心制作和释放化学物的过程,或分泌的化学物质或物质的量。分泌不是真核细胞独有的;其还存在于细菌和古细菌(archaea)中。ATP结合盒(ABC)型转运蛋白是三种生物界所共有的。Sec系统是另一种保守的分泌系统,其与在酵母中由Sec61易位子复合物组成的真核内质网中的易位子及细菌中的Sec Y-E-G复合物同源。革兰氏阴性菌具有两层膜,因此使得分泌在拓扑学上更复杂。因此,在革兰氏阴性菌中存在至少五种专门的分泌系统:
(1)I型分泌系统:其与上述的ATP结合盒转运蛋白相同。
(2)II型分泌系统:其依赖于用于使蛋白跨过内膜的Sec系统和另一个用于跨过外膜的特殊系统。细菌菌毛利用修饰的sec系统,但是不同于I型系统。
(3)III型分泌系统(T3SS):其与细菌鞭毛基体同源。其像是分子注射器,通过其细菌(例如志贺氏菌或耶尔森氏菌)能够将蛋白注入真核细胞中。胞质溶胶中的低Ca2+浓度打开调节T3SS的门控。植物病原体中的Hrp系统通过相似的机制将发夹结构注入植物中。
(4)IV型分泌系统:其与细菌(和古细菌鞭毛)的接合装置(conjugation machinery)同源。其能够转运DNA和蛋白。其在根癌土壤杆菌(Agrobacterium tumefaciens)中被发现,所述菌使用这一系统将Ti质粒和蛋白导入宿主中,宿主形成冠瘿(根瘤)。幽门螺杆菌(Helicobactor pylori)使用IV型分泌系统将Cag A注入胃上皮细胞。百日咳博德特氏菌(Bordetella pertussis)(百日咳的致病剂)部分通过IV型系统分泌百日咳毒素。
(5)V型分泌系统,也称为自主转运蛋白系统:该系统使用sec系统跨过内膜。使用这一途径的蛋白具有在其C末端形成β桶并且插入到外膜中以将肽的剩下的部分转运出去的能力。最后,β桶可以被切除并留在外膜中。一些人认为自主转运蛋白的这些残余部分产生与β桶相似的孔蛋白(porin)。
细菌及线粒体和叶绿体还使用多种其他的特殊转运系统,例如双精氨酸转运(twin-arginine translocation)(Tat)途径,与Sec依赖性输出相比,其转运完全折叠的蛋白跨膜。该系统的名称来自靶向这一系统所需的信号序列中的两个连续的精氨酸的需要。革兰氏阴性菌的分泌包括通过合适的分泌系统,如例如Hly I型或III型分泌系统或AIDA自主转运蛋白,克服内膜和外膜。在革兰氏阳性菌中,分泌系统必须克服内膜和细胞壁,在大多数菌株中,其可以通过与合适的分泌信号融合来实现。
组分(III)a)为编码至少一个转运系统的至少一个核苷酸序列,所述的转运系统使得能够在微生物的外表面上表达组分(I)和组分(II)的表达产物和/或使得能够分泌组分(I)和组分(II)的表达产物。各个组分可以供选择地被分泌或在微生物细胞膜上表达,即是膜结合的。此类转运系统为例如i)I型分泌系统,II型分泌系统,III型分泌系统,IV型分泌系统,V型分泌系统,ii)大肠杆菌的溶血素转运系统(信号)(在hly-特异性启动子控制下的包含HlyA,HlyB和HlyD的核苷酸序列);使用下列转运信号:对于分泌-在HlyB和HlyD蛋白存在的情况下,C末端HlyA转运信号;对于膜结合表达-在HlyB蛋白存在的情况下,C末端HlyA转运信号,iii)大肠杆菌的溶血素转运系统(信号)(在非hly特异性细菌启动子控制下的包含HlyA,HlyB和HlyD的核苷酸序列),iv)新月柄杆菌(Caulobactercrescentus)的S-层蛋白(RsaA)的转运信号;使用下列转运信号:对于分泌和膜结合表达-C末端RsaA转运信号,v)大肠杆菌TolC蛋白的转运信号;使用下列转运信号:对于膜结合表达-TolC的N末端转运信号(大肠杆菌膜整合蛋白TolC是大肠杆菌的外膜的多功能成孔蛋白,其除了用于接受大肠杆菌素E1(Morona等人,1983)和分泌大肠杆菌素V(Fath等人,1991)外还用做U3噬菌体的受体(Austin等人,1990);该蛋白不仅在大肠杆菌中发现,还在多数革兰氏阴性菌中发现(Wiener,2000);在外膜中的定位和广泛存在使TolC成为呈递异源抗原以例如引起免疫反应的理想的候选物。
革兰氏阳性菌不具有外膜。在这些情况中分泌较简单并且通常不需要专用的分泌装置用于转运通过细胞膜和细胞壁。在革兰氏阳性菌的情况下,将分泌信号与异源蛋白N末端融合对分泌来说通常是必要的并且是充分的。已描述用于其的这些信号序列的蛋白主要包含所有的分泌性细菌蛋白。利斯特菌属的实例为源自利斯特菌溶胞素,p60或ActA的分泌信号。通常,相似的方法用于真核细胞,其中在保留信号不存在的情况下,使蛋白靶向内质网的信号序列(例如广泛存在的分泌信号Vtgss)对分泌是必要的并且是充分的。
任选的组分(III)b)为编码至少一个蛋白的至少一个核苷酸序列,所述蛋白用于裂解哺乳动物细胞的胞质溶胶中的微生物和细胞内释放质粒或表达载体,所述质粒或表达载体包含在裂解的微生物中。此类裂解性蛋白(细胞内溶素)例如为在利斯特菌启动子控制下的利斯特菌属特异性裂解蛋白,例如PLY551(Loessner等人,1995)和/或利斯特菌属特异性穿孔素(holin)。本发明优选的实施方案为不同的组分(III)b)的组合,例如裂解蛋白和穿孔素的组合。
组分(III)a)和/或组分(III)b)可以相互独立地具有组成型活性。
在优选的实施方案中,提供根据上述定义的微生物,其中组分(III)a)选自“I型分泌系统,II型分泌系统,III型分泌系统,IV型分泌系统,V型分泌系统,大肠杆菌溶血素转运系统(信号)(在hly特异性启动子控制下的包含HlyA,HlyB和HlyD的核苷酸序列),大肠杆菌溶血素转运系统(信号)(在非hly特异性细菌启动子的控制下的包含HlyA,HlyB和HlyD的核苷酸序列),新月柄杆菌的S层(Rsa A)蛋白的转运信号,大肠杆菌的TolC蛋白的转运信号,分泌信号Vtgss和/或源自利斯特菌溶胞素,p60和/或ActA的分泌信号”并且其中组分(III)b)选自“细胞内溶素,革兰氏阳性菌的裂解性蛋白,单核细胞增生利斯特菌的裂解性蛋白,单核细胞增生利斯特菌的PLY551和/或单核细胞增生利斯特菌的穿孔素”。
在进一步优选的实施方案中,相同的组分(III)a)使得能够在微生物的外表面上表达组分(I)和组分(II)的表达产物和/或使得能够分泌组分(I)和组分(II)的表达产物。即在这一优选的实施方案中,组分(III)a)为编码仅一个转运系统的至少一个核苷酸序列,所述的转运系统使得能够在微生物的外表面上共表达组分(I)和组分(II)的表达产物和/或使得能够共分泌组分(I)和组分(II)的表达产物,其中此类优选的组分(III)a)为编码大肠杆菌溶血素转运系统(信号)(在hly特异性启动子的控制下的包含HlyA,HlyB和HlyD的核苷酸序列)或大肠杆菌的溶血素转运系统(信号)(在非hly特异性细菌启动子控制下的包含HlyA,HlyB和HlyD的核苷酸序列)的至少一个核苷酸序列。
在另一个优选的实施方案中,提供根据上述定义的微生物,其中根据组分(III)a),分泌组分(I)和组分(II)的表达产物。更优选地,组分(I)和组分(II)连接在一起,一起表达并且作为由两个组分编码的融合蛋白分泌。更优选地,该融合蛋白选自“CtxB-PSA,CtxB-B-Raf V600E KD(激酶失活型),CtxB-B-Raf V600E激酶结构域,CtxB-B-Raf V600E激酶结构域KD(激酶失活型),CtxB-B-Raf,CtxB-B-Raf KD(激酶失活型),CtxB B-Raf激酶结构域KD(激酶失活型),CtxB-HA1(流感病毒的血凝素的亚基1),CtxB-HA12C”。
在本发明中,术语“分泌”指通过合适的分泌系统,例如上述系统,将蛋白抗原,蛋白毒素和/或毒素-抗原融合蛋白分泌通过革兰氏阴性菌的两层膜或通过革兰氏阳性菌的内膜和细胞壁到附近环境中。
如所已知的,使用分泌系统,例如源自大肠杆菌的溶血素I型分泌系统,分泌产物通常在所有细胞部分中被发现:在细胞质中,膜结合的,在自体-膜小泡(auto-membrane vesicle)中定位的和完整分泌到附近环境中的(Balsalobre等人,2006),在本发明中分泌不必是完全的。然而,期望和优选完全的或几乎完全的分泌(即大量的完整分泌的分泌产物)。
组分(IV)指用于组分(I)至(III)的一个或多个的表达的至少一个活化序列的至少一个核苷酸序列,其中所述的活化序列能够在微生物中被活化和/或其为组织细胞特异性的,肿瘤细胞特异性的,巨噬细胞特异性的,树突特异性的,淋巴细胞特异性的,功能特异性的或非细胞特异性的。
如果表达为在微生物的外表面上膜结合的,则活化序列优选经选择以便其能够在微生物中活化。此类活化序列例如:i)组成型活性启动子区域,例如具有大肠杆菌的β-内酰胺酶的或tetA基因的“核糖体结合位点”(RBS)的启动子区域(Busby和Ebright,1994),大肠杆菌hly基因座的内源启动子;ii)能够被诱导的启动子,优选在细胞中接受后变成有活性的启动子。单核细胞增生利斯特菌的actA启动子(Dietrich等人,1998)或鼠伤寒沙门氏菌的pagC启动子(Bumann,2001)属于这些启动子。
如果在微生物裂解后质粒从微生物释放到哺乳动物细胞的胞质溶胶中,则活化序列不是细胞特异性的,而是组织细胞特异性的,细胞周期特异性的或功能特异性的。优选地,选择此类活化序列,其特别地在巨噬细胞,树突细胞和淋巴细胞中被活化。
在进一步优选的实施方案中,提供根据上述定义的微生物,其中
组分(I)选自B-Raf V600E,B-Raf V600E激酶结构域,B-RafV600E KD(激酶失活型),B-Raf V600E激酶结构域KD(激酶失活型),B-Raf KD(激酶失活型),B-Raf激酶结构域,B-Raf激酶结构域KD(激酶失活型),前列腺特异性抗原(PSA),血凝素HA1(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12C(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1)”;
组分(II)选自“霍乱毒素B亚基(CTB,CtxB),大肠杆菌热不稳定肠毒素B亚基(LTB),破伤风毒素(TT)”;
组分(III)a)选自“和Hly分泌系统的组分一起的大肠杆菌HlyA溶血素转运信号(在hly特异性启动子的控制下的包含HlyA,HlyB和HlyD的核苷酸序列)”;
组分(IV)选自“大肠杆菌hly基因座的内源启动子”;
其中组分(I)和组分(II)连接在一起以使得能够表达由两个组分编码的融合蛋白并且其中该融合蛋白被分泌。
根据组分(I)至(IV)及优选的实施方案的上述举例说明的微生物在下文中称为本发明的微生物。
本发明的微生物有利地适合于在肿瘤治疗中使用,在肿瘤靶向中作为活疫苗。即借助用作遗传信息的载体的本发明的微生物,异源抗原和蛋白毒素一起转运到肿瘤位点,以融合蛋白形式表达并且在原位分泌。
本发明的微生物令人惊讶地并且有利地通过被转运、编码和表达的毒素-抗原融合蛋白的有效的和较高的表达和分泌来表征,即不出现细胞质和/或周质集体。
此外,与口服施用的蛋白疫苗相比(其诱导免疫系统的全身性耐受),通过本发明的微生物的施用,令人惊讶地引起强的全身性细胞免疫系统应答。
更显著地,除了诱导Th1型全身性细胞免疫系统应答,本发明的微生物还诱导MHC I类限制性CD8+细胞毒性T细胞(CTL)的活化并且强烈地增强该CTL免疫应答。
进一步地,除了强的细胞全身性Th1和CTL免疫系统应答的诱导和/或增强,令人惊讶地,先天免疫系统,例如NK细胞,NKT细胞和/或λ-δT细胞也通过本发明的微生物以协同方式被活化。
如果霍乱毒素用作毒素组分,则本发明的微生物具有这样的优势,即在人体中通常不存在抗该毒素的预先存在的免疫性(与例如破伤风毒素相反,由于在儿童期间接种抗破伤风疫苗)。因此,优选使用霍乱毒素和/或其亚基,特别是CtxB。
本发明的微生物特别适合于在基于活疫苗的靶向肿瘤(免疫)治疗中口服施用。从而,能够实现提高的患者依从性。
然而,本发明的微生物不仅限于在肿瘤治疗中使用。主要地,本发明的微生物还适用于所有这些疾病的治疗和/或预防,所述的疾病需要这样的治疗,其中全身性细胞Th1免疫系统应答的诱导是必须的。此类感染性疾病的实例包括但不限于HIV,流感病毒,HCV和其他病毒性疾病,结核分枝杆菌(Mycobacterium tuberculosis),单核细胞增生利斯特菌和其他细菌性疾病。
本发明的微生物优选适用于疾病如流行性感冒的治疗,其需要通过粘膜免疫系统应答和全身性细胞免疫应答的组合的最佳的保护。另外,它们可用于过敏性疾病中Th1样免疫性的特异性诱导,所述过敏性疾病例如过敏性鼻炎。在此类情况下,抗原可以是与蛋白毒素组分融合的过敏原并且各个疫苗的作用原理是免疫应答从抗过敏反应(疾病)中的过敏原的Th2为主的免疫应答向Th1免疫应答的转变。
施用的优选方式为口服施用。在优选的实施方案中,根据本发明的沙门氏菌菌株在合适的介质中发酵,通过离心收获和清洗并且随后用合适的物质配制和稳定并进行冻干。将冻干的物质装入包含数目优选在109至1010个细菌之间的活细胞的胃抗性胶囊。胶囊用液体口服摄取。
可选地,上述冻干的细菌和包含能够中和胃酸的缓冲剂的囊剂(sachet)一起分布(药物试剂盒)。在优选的实施方案中,该缓冲剂为碳酸盐缓冲剂。紧在使用前,用水制备该缓冲剂并摄取,然后立即用水混合摄取冻干的细菌。
另一个可选方案使用冷冻的细菌。在这种情况下,清洗后,细菌经由稳定剂(优选蔗糖(succhrose)或甘油)稳定,然后冷冻并在-80℃保存,优选以109至1010个细菌每剂量的浓度。该制剂优选在上述药物试剂盒中与碳酸盐缓冲剂结合使用。
在优选的实施方案中,提供包含至少一种本发明的微生物(优选至少一种本发明的冻干微生物)和药学上可接受的载体(优选胶囊)的药物组合物。
根据本发明的组分(I)至(IV)通过本领域技术人员公知的方法导入本发明的微生物。如果微生物指细菌,则将组分插入质粒或表达载体中,并且将该质粒或表达载体转移到细菌中。适用于制备本发明的质粒,表达载体和微生物的分子生物学克隆和转化技术是本领域技术人员公知的并且为常规的实验操作。
本发明的另一个主题为包含本发明的微生物的药物制剂的施用。施用为局部的或全身性的,例如口服,经口,经直肠,表皮内,皮下组织内,肌肉组织内,体腔内,器官内,肿瘤内或血液循环内施用。
此类药物制剂为例如在药剂师熟悉的,适用于注射的溶液中的本发明的微生物的悬浮液。
本发明的特别的主题为用于治疗和/或预防疾病的根据本发明的药物的经口或直肠施用。施用可以是一次或数次。在每次施用时,施用大约10至1011个本发明的微生物。如果施用这一数目的本发明的微生物不能引起足够的免疫反应,则必须增加待注射的数目。
施用本发明的微生物后,呈递组分(I)的细胞,例如肿瘤细胞,或肿瘤源自其的组织细胞的耐受被破坏,并且触发抗肿瘤和/或它的组织细胞的强的全身性免疫应答。依靠组分(I)的选择,该细胞免疫反应只抗肿瘤或还抗包含肿瘤细胞的组织细胞(肿瘤细胞源自于其)。
在另一方面,本发明的目的已经通过提供包含含有上述遗传组分(I)至(IV)的至少一种本发明的微生物或至少一种本文所定义的药物组合物的药物而解决。
在优选的实施方案中,本发明的微生物能够用于制备用于治疗和/或预防生理学和/或病理生理学病况的药物,所述的病况选自“不受控制的细胞分裂,恶性肿瘤,良性肿瘤,实体瘤,肉瘤,癌,过度增殖性疾病,类癌,尤文肉瘤(Ewing sarcoma),卡波西肉瘤(Kaposisarcoma),脑肿瘤,源自脑和/或神经系统和/或脑脊膜的肿瘤,神经胶质瘤,神经母细胞瘤,胃癌,肾癌,肾细胞癌,前列腺癌(prostate cancer),前列腺癌变(prostate carcinomas),结缔组织肿瘤,软组织肉瘤,胰腺肿瘤,肝肿瘤,头部肿瘤,颈部肿瘤,食管癌,甲状腺癌,骨肉瘤,视网膜母细胞瘤,胸腺瘤,睾丸癌,肺癌,支气管癌,乳腺癌,乳癌,肠癌,结直肠肿瘤,结肠癌,直肠癌,妇科肿瘤,卵巢肿瘤(ovaryt umors)/卵巢的肿瘤(ovariantumors),子宫癌,宫颈癌(cervical cancer),宫颈癌变(cervixcarcinomas),子宫体癌,子宫体癌变(corpus carcinomas),子宫内膜癌(endometrial carcinomas),尿膀胱癌(urinary bladdercancer),膀胱癌(bladder cancer),皮肤癌,基底细胞瘤,肌脊瘤(spinaliomas),黑色素瘤,眼内黑色素瘤,白血病,慢性白血病,急性白血病,淋巴瘤,感染,病毒性或细菌性感染,流行性感冒,慢性炎症,器官排斥和/或自身免疫性疾病”。
细菌感染包括但不限于炭疽,细菌性脑膜炎,肉毒中毒(botulism),布鲁氏菌病,弯曲菌病(campylobacteriosis),猫抓病,霍乱,白喉,流行性斑疹伤寒,脓疱病,军团病,麻风(汉森氏病),钩端螺旋体病(leptospirosis),利斯特氏菌病(listeriosis),莱姆病(lyme disease),类鼻疽,MRSA感染,诺卡氏菌病,百日咳(pertussis,whooping cough),鼠疫,肺炎球菌性肺炎,鹦鹉热,Q热,洛矶山斑点热(Rocky Mountain SpottedFever)(RMSF),沙门氏菌病,猩红热,志贺氏菌病,梅毒,破伤风,沙眼,肺结核,土拉菌病(tularemia),伤寒,斑疹伤寒,泌尿道感染,细菌引起的心脏病。
病毒感染包括但不限于AIDS,AIDS相关复合症(ARC),禽痘(水痘),感冒,巨细胞病毒感染,科罗拉多蜱热,登革热,埃博拉出血热,手足口病,肝炎,单纯疱疹,带状疱疹,HPV,流行性感冒(flu),拉沙热,麻疹,马尔堡出血热,传染性单核细胞增多症,腮腺炎,脊髓灰质炎,进行性多灶性脑白质病,狂犬病,风疹,SARS,天花(痘疮),病毒性脑炎,病毒性肠胃炎,病毒性脑膜炎,病毒性肺炎,西尼罗病(West Nile disease),黄热病。
慢性炎症或慢性炎性疾病包括但不限于,慢性胆囊炎,支气管扩张,类风湿性关节炎,桥本甲状腺炎,炎性肠病(溃疡性结肠炎和克罗恩氏病),硅肺病和其他尘肺病。
自身免疫性疾病包括但不限于,全身性综合征,例如SLE,干燥综合征,硬皮病,类风湿性关节炎和多发性肌炎以及局部综合征,例如IDDM,桥本甲状腺炎,爱迪生氏病(Addison′s disease),寻常性天疱疹,银屑病,特应性皮炎,过敏综合征,哮喘,自身免疫性溶血性贫血,多发性硬化。
用于治疗和/或预防本文所描述和定义的生理学和/或病理生理学病况的根据所有本文描述的实施方案的包含本文所定义的至少一种微生物或本文所定义的至少一种药物组合物的相应的药物也包含在本发明中。
在另一个方面,本发明的目的通过提供包含本文所述的组分(I)至(IV)的质粒或表达载体而解决。优选是携带至少一个包含本文所述的组分(I)至(IV)的质粒或表达载体的本发明的微生物。
在另一方面,本发明的目的通过提供用于制备本发明的微生物的方法而解决,其中制备如本文所述的质粒或表达载体,并且用该质粒或表达载体转化微生物。
在另一方面,本发明的目的通过提供包含至少一种本发明的微生物或如上所述的药物组合物或如上所述的药物以及药学上可接受的缓冲剂(优选碳酸盐缓冲剂)的药物试剂盒而解决。
附图简介
图1描述了大肠杆菌溶血素A(hlyA)分泌信号的核苷酸序列(5’→3’)。下划线为NsiI位点。
图2描述了大肠杆菌溶血素I型转运系统的大肠杆菌溶血素B(hlyB)的核苷酸序列(5’→3’)。
图3描述了大肠杆菌溶血素I型转运系统的大肠杆菌溶血素D(hlyD)的核苷酸序列(5’→3’)。
图4描述了不具有信号肽的人前列腺特异性抗原(PSA)的核苷酸序列(5’→3’),登录号M26663(智人(Homo sapiens)前列腺特异性抗原mRNA,完整cds),区域100-807(相应的肽:AA26-261)。
图5描述了不具有信号肽的霍乱毒素B亚基(CtxB)的核苷酸序列(5’→3’),其包含登录号K01170(霍乱肠毒素A2亚基(γ)的霍乱弧菌toxA和toxB基因)的区域204-494。
图6描述了人B-raf蛋白(BRAF)的B-Raf激酶结构域(B-Raf KD)的核苷酸序列(5’→3’),登录号M95712(智人B-raf蛋白(BRAF)mRNA,完整cds),包含V600E突变的不具有区域1448-1477的区域1403-2359(相应的肽:不具有AA463-472的AA448-766)。
图7描述了人HLA B27限制性B-Raf V600E表位的核苷酸序列(5’→3’)。
图8描述了CtxB-PSA-HlyA的基因融合构建体的核苷酸序列(5’→3’)。
图9描述了Ctx-B-Raf V600E-HlyA的基因融合构建体的核苷酸序列(5’→3’)。
图10描述了CtxB-B-Raf V600E激酶结构域KD-HlyA的基因融合构建体的核苷酸序列(5’→3’)。
图11描述了pMKhly-PSA-CtxB的不同细菌物种的重组体中PSA-CtxB融合蛋白的功能性表达和分泌。
图12描述了作为对在用不同活疫苗载体免疫的小鼠中的CD8+T细胞和先天免疫系统(NK细胞)应答的测量的IFN-γ分泌脾细胞。
图13描述了对用不同活疫苗载体的免疫应答的肿瘤体积的减小。
图14描述了作为对小鼠中的CD8+T细胞和先天免疫系统(NK细胞)应答的测量的IFN-γ分泌脾细胞,所述小鼠用具有不同免疫学佐剂与CtxB-OVA融合构建体的不同活疫苗免疫。
图15描述了在兽医疫苗菌株中鸡流感病毒血凝素H1-CtxB融合蛋白的有效表达和功能性分泌,所述的融合蛋白具有H5N1血凝素(HA1+HA2,描述为HA12)的全长序列,不具有跨膜区域(HA12c)。活的减毒的肠沙门氏菌鼠伤寒血清型(Salmonella enterica serovarTyphimurium)vacT(gyrA D87G)和活的减毒的肠沙门氏菌肠炎血清型(Salmonella enterica serovar Enteritidis)vacE,(Sm24/Rif12/Ssq菌株),都得自LOHMANN ANIMAL HEALTH GMBH & COKG。
图16描述了编码CtxB-HA12c-HlyA融合蛋白的核苷酸序列。
图17描述了利用电穿孔到伤寒沙门氏菌Ty21a菌株和其他细菌菌株中的载体pMBKDC的融合蛋白的表达和分泌:
A)道A1-A3:使用用于检测的抗B-Raf抗体的根据TPStMoBKDC的上清液分析。道A1:伤寒沙门氏菌Ty21a pMoBKDC,A2:伤寒沙门氏菌Ty21a,A3:鼠伤寒沙门氏菌aroA。
用上面的箭头标记融合蛋白BRaf-V600E KD-CtxB并且其具有预期的约48kDa的分子量。蛋白分子量标准:Invitrogen Bench-MarkPre-Stained protein ladder,#10748-010。
B)和A中等价的分析,使用新制备的抗HlyA抗体作为检测抗体。道1,2:StMoPC构建体,道3:伤寒沙门氏菌Ty21a MoBKDC;道4:大肠杆菌MoBKDC,道5:伤寒沙门氏菌Ty21a,道6:鼠伤寒沙门氏菌aroA。蛋白分子量标准:Invitrogen BenchMark Pre-Stainedprotein ladder,#10748-010,Lot.1315592。
图18描述了空载体pMKhly1的全核苷酸序列(5’→3’)。
所有引用的参考文献和专利的内容通过引用以其全文并入本文。通过下列实施例更详细的说明本发明,但是本发明不限于此。
实施例
实施例1:在不同细菌载体菌株中PSA-CtxB融合蛋白的构建,表达和分泌
为了证明大肠杆菌I型溶血素分泌系统分泌肿瘤抗原的融合蛋白的可行性和功效,在此,前列腺特异性抗原(PSA),和作为佐剂的蛋白毒素组分,在此为CtxB,PSA-CtxB融合蛋白如本文所述进行构建。测试在不同革兰氏阴性菌菌株中的表达和分泌,所述的革兰氏阴性菌菌株潜在地用作肿瘤治疗中的活疫苗菌株。分子生物学克隆基于质粒/表达载体pMOhly1,其之前已经被描述过(Gentschev等人,2005;Gentschev等人,1996,WO 03/072789)。
1A卡那霉素抗性pMOhly1表达载体衍生物的构建
如在(Datsenko和Wanner,2000)中描述的,进行pMOhly1氨苄青霉素抗性盒的替换。
简单而言,有义引物P1(5′-GAGTATTCAACATTTCCGTGTCGCCCTTATTC CCTTTTTTGGTGTAGGCTGGAGCTGCTTC-3′)和反义引物P2(5′-GCGATCTGTC TATTTCGTTCATCCATAGTTGCCTGACTCCCCATATGAATATCCTCCTTA-3′)和作为模板的质粒pKD4用于PCR以产生携带卡那霉素抗性基因(KanR)的片段,所述基因侧翼于与氨苄青霉素抗性基因同源的区域(加下划线的)。
在转化PCR片段前,包含pKD46质粒和靶质粒pMOhly1的大肠杆菌菌株BW25114在37℃下在添加有0.2%L-(+)-阿拉伯糖的LB培养基(Difco)中培养3-4小时。
转化后,将细菌细胞铺到包含25μg/mL卡那霉素的LB琼脂平板上并在37℃下过夜温育。
第二天,挑选KanR克隆并在包含50μg/mL卡那霉素的LB培养基中另外温育48小时以除去所有赋予氨苄青霉素抗性的质粒。
最后,选择具有KanR和氨苄青霉素敏感表型的克隆。通过PCR和测序证实KanR盒对ApR基因的取代。所得的质粒称为pMKhly1。
1B pMKhly-PSA质粒的克隆
有义引物PSA-Nsi1(5′-GATTGGTGATGCATCCCTCAT-3′;下划线为NsiI限制性位点)和反义引物PSA-Nsi2(5′-GGTGCTCATGCATTGGCCACG-3′)用于通过PCR扩增编码PSA的DNA片段。在Thermal Cycler 60(Biometra,Germany)中进行PCR,以94℃1分钟,54℃1分钟,72℃2分钟循环30次。
用NsiI限制性酶消化后,将携带psa基因的DNA片段插入输出载体pMKhly1的单一NsiI位点中。从大肠杆菌DH5α(Invitrogene,Germany)分离所得的质粒pMKhly-PSA,并通过限制性酶切进行分析并测序。
1C pMKhly-PSA/CtxB质粒的克隆
有义引物Ptac-SalI(5′-AAAAAAGTCGACGGCTGTGCAGGTCGTAAATCACTGC-3′)和反义引物Ptac-NotI(5′-AAAAAAGCGGCCGCGAAATTGTTATCCGCTCACAATTCC-3′)用于通过PCR扩增来自pGEX-6p-1-质粒(Amersham Bioscience,Germany)的编码Ptac启动子的201bp的DNA片段。在T3 thermocycler(Biometra,Germany)中进行PCR:以95℃30秒,55℃30秒,72℃90秒循环30次。有义引物Rbs-NotI-正向(5′-AAAAAAGCGGCCGCTAAGGATGAATTATGATTAAATTAAAATTTGG-3′)和反义引物ctb-SalI-反向(5′-TTTATAGTCGACTTAATTTGCCATACTAATTGCGGCAATCGC-3′)用于通过PCR扩增编码核糖体结合位点的413bp DNA片段和来自霍乱弧菌El tor的CtxB全编码序列。在T3Thermocycler(Biometra,Germany)中进行PCR:步骤1:以95℃30秒,50℃30秒和72℃2分钟循环30次。用Qiaquick PCRPurification Kit(Qiagen,Germany)纯化和用NotI限制性酶消化两个片段后,将两个片段连接,获得594bp Ptac-ctxB片段。纯化所得的片段并且用SalI限制性酶消化后,将Ptac-ctxB片段插入到输出载体pMKhly-PSA的单一SalI位点中。从大肠杆菌DH5α(Invitrogene,Germany)分离所得的质粒pMKhly-PSA/CtxB,分析并测序。
1D PSA-CtxB-HlyA融合构建体的克隆
正义引物5′ctxB NsiI(5′-GCATATGCACATGCATCACCTCAAAATATTACTGAT-3′)和反义引物3′ctxB SrfI NsiI(5′-GGCTTTTTTATATCTTATGCAT ATTGCGGCAATCGC-3′)(粗体为SrfI位点)用于通过PCR扩增代表来自霍乱弧菌El tor的ctxB基因的~300bp DNA片段。用QIAquick PCR Purification Kit(Qiagen,Germany)纯化和用NsiI限制性酶消化后,将携带全长ctxB基因而不具有N末端信号序列的DNA片段插入到输出载体pMKhly1的单一NsiI位点中。从大肠杆菌DH5α(Life Technologies)分离所得的质粒pMKhly-CtxB,分析并测序。通过PCR用引物5-PSA-Blunt(5′-GTGGGAGGCTGGGAGTGC-3′)和3-PSA-Blunt(5′-GGGGTTGGCCACGATGGT-3′)从质粒pCDNA3PSA扩增人psa基因。在Thermal Cycler 60(Biometra,Germany)中进行PCR,以94℃1分钟,56℃1分钟,72℃2分钟循环30次。然后将0.7kbDNA产物克隆到pMKhly-CtxB的SrfI位点中。通过限制性酶切分析和测序验证所得的质粒pMKhly-CtxB-PSA。
1E融合蛋白在不同细菌种中的表达和分泌
使用标准电穿孔法,将质粒pMKhly-CtxB-PSA转化到不同的电转感受态细菌菌株中。挑选单个卡那霉素抗性克隆并且在BHI培养基中培养(Beckton Dickinson,USA:牛脑,浸出物200g,6.0g/L;牛心,浸出物250g,9.8g/L;蛋白胨10.0g/L;氯化钠溶液5.0g/L;葡萄糖2.0g/L;磷酸氢二钠2.5g/L)至1×109个细胞每ml的密度。培养后,将20ml培养物在Heraeus离心机中在4℃以4000rpm(3000g)离心30分钟。将18ml上清液转移到新鲜试管中。然后,加入1.8ml TCA(三氯乙酸,Applichem,Germany),混合液体并在冰上温育至少1小时。温育后,将悬浮液在Heraeus离心机中在4℃以4000rpm(3000g)离心30分钟。移去上清液并用1ml丙酮p.a.(Applichem,Germany)清洗沉淀。沉淀物在Heraeus离心机中在4℃以4000rpm(3000g)离心10分钟。沉淀进行风干并且用具有或不具有β-巯基乙醇(Laemmli,1970)的150μl 5x Laemmli缓冲液(70mM Tris-HCl,pH 6.8,40%(v/v)甘油,3%(v/v)十二烷基硫酸钠,5%(v/v)2-巯基乙醇和0.05%(w/v)溴酚蓝)进行处理。在SDS PAGE中的各道使用20μl溶液。分离的蛋白经电泳转移到(Western印迹)Hybond ECL硝化纤维素膜(Amer-sham-Pharmacia,Little Chalfont,UK)并且用包含1%BSA的PBS(0.20g/l氯化钾,0.20g/l磷酸二氢钾,8.00g/l氯化钠,1.15g/l无水磷酸氢二钠)封闭过夜。用PBS-Tween 0.05%清洗膜,用多克隆兔抗PSA抗体(1∶750,DAKO,Denmark),CtxB抗体(1∶1000,Zytomed,Berlin,Germany)或HlyAs抗体(Gentschev等,1996))温育,然后用HRP偶联的抗兔IgG(1/2,000;Dianova,Hamburg,Germany)温育1小时。用增强的化学发光试剂盒(GE Healthcare LifeScience,Germany)对Western印迹显影。
图11描述了在不同的细菌菌株中PSA-CtxB融合蛋白的功能性表达和分泌,所述细菌菌株包括大肠杆菌的种(Escherichia coli spp.),都柏林沙门氏菌(Salmonella dublin),柠檬酸杆菌属的种(Citrobacter spp),伤寒沙门氏菌Ty21a,鼠伤寒沙门氏菌的种,欧文氏菌属的种(Erwinia spp)和弗氏志贺氏菌的种。
表达和分泌PSA-CtxB融合蛋白的伤寒沙门氏菌Ty21a菌株保藏在德意志微生物保藏中心(German Collection of Microorganismsand Cell Cultures)(DSMZ),保藏号为DSM19244。
实施例2:用分泌肿瘤抗原和CtxB的融合蛋白或分泌单独的CtxB的沙门氏菌菌株免疫的小鼠中抗肿瘤细胞攻击的免疫应答和保护
通过以下实验,在动物肿瘤模型中证明肿瘤抗原和蛋白毒素的分泌性融合蛋白的较高的保护功效。对于这个模型,将表达和分泌CtxB-PSA融合蛋白的菌株鼠伤寒沙门氏菌aroA(SL7207)pMKhly-CtxB-PSA与其他对照菌株进行比较。
2A免疫方法
以3周的间隔免疫DBA/2小鼠三次。为了用细菌免疫,通过胃内施用50μl 7%NaHCO3来预处理动物以增加胃内pH。预处理后5-10分钟,胃内施用在体积为100μl的PBS中的5×108个活的卡那霉素不敏感的细菌。作为对照,如(Fensterle等人,2005)中所描述用编码PSA的裸质粒DNA(pcDNA-PSA)肌内免疫小鼠。
2B T细胞应答
最后一次免疫7天后,如之前所公开的(Fensterle等人,1999),通过使脾通过网眼然后裂解红细胞来制备经免疫的小鼠的脾细胞。根据(Fensterle等人,1999)中公开的方法,进行ELISPOT分析,以检测PSA特异性CD8+T细胞。
简单而言,用于PSA特异性CD8+T细胞的离体分析的96孔硝化纤维素板(Millititer HA;Millipore,Bedford,MA)用在pH 9.6的100μl碳酸盐缓冲液(Fensterle等,1999)中的5μg/ml抗小鼠IFN-γ单克隆抗体(mAb)R4(PharMingen)进行包被。在4℃温育过夜和用含1%BSA的PBS封闭后,将来自经免疫的小鼠的1×105个脾细胞加入每孔100μl RP10中(Fensterle等人,1999)。
对于CD8+T细胞应答的分析,使用表达PSA的P815细胞克隆PPSA24;简单来说,该克隆经由由质粒pCDNA3编码的CMV启动子表达全长PSA(Fensterle等人,2005)。在37℃,5%CO2,在30U/ml IL-2存在下温育20-22小时后,清洗平板并且用100μl生物素化的抗小鼠IFN-γmAb XMB1.2(0.25μg/ml,PharMingen)另外温育2小时。清洗平板并且在100μl 1/20,000稀释的碱性磷酸酶-偶联的链霉亲和素(PharMingen)的存在下,在37℃温育1小时。通过加入50μl溶于水中的即用的底物BCIP/NBT(Sigma,St.Louis,MO)显现斑点。在解剖显微镜下以3倍放大倍率对斑点计数。
肽特异性T细胞(CTL)的频率表达为每105个脾细胞的IFN-γ分泌细胞的数目。对于再刺激后T细胞应答的分析,用2×106个经辐射处理的表达PSA的P815细胞(Fensterle等,2005)在RP10培养基(Fensterle等,1999)中,在60U/ml重组IL-2存在下再刺激2.5×107个脾细胞5天。如上所述,用与4×105个饲养细胞(=来自首次用于实验的DBA/2小鼠的新鲜制备的脾细胞)混合的不同量的再刺激细胞(105,3×104,104或3×103每孔)和105个PPSA24细胞进行ELISPOT分析。
细胞免疫应答的诱导,尤其是CD8+细胞毒性T细胞的诱导对肿瘤治疗的功效具有重要的作用(Boon等人,2006;Rosenberg,2001)。因此,首先测试携带pMKhly-CtxB-PSA表达载体的重组细菌菌株鼠伤寒沙门氏菌(SL7207)诱导PSA特异性CD8+T细胞免疫应答的功效。
为了这一目的,如本文所描述,用重组SL7207/pMKhly-CtxB(n=10),SL7207/pMKhly-CtxB-PSA(n=10),SL7207/pMKhly-PSA(n=10),SL7207/pMKhly-PSA/CxtB(n=10),SL7207/pMKhly1(n=7)和作为阳性对照的裸pcDNA3-PSA(n=10)p.o.免疫10-14周龄的64只雌性DBA-2小鼠。
图12展示ELISPOT数据,其揭示经DNA免疫的小鼠表现出显著的CD8+T细胞应答。再刺激后,在用分泌与CtxB融合的PSA蛋白的沙门氏菌接种的动物中检测到显著的免疫应答,而在分泌单独的PSA或分别分泌PSA和CtxB的菌株中没有检测到显著的免疫应答。有趣的是,用分泌单独的CtxB毒素的沙门氏菌接种的动物在再刺激后也表现出显著的免疫应答。这些应答很可能是由于先天免疫系统的NK细胞或其他细胞引起,所述细胞非特异性识别靶细胞系。因此,从分泌单独的CtxB的数据可以推断观察到的针对分泌性CtxB-PSA融合蛋白的免疫应答(分泌IFN-γ的脾细胞)由CD8+T细胞应答和先天免疫系统(很可能是NK细胞)的显著应答组成。
2C抗肿瘤细胞攻击的保护
为了分析免疫的保护能力,按照上述程序免疫每组6-7只小鼠。第三次免疫两周后,通过将1×106个细胞s.c.注射到剃毛的腹部皮肤两侧内两次,用PPSA 24攻击小鼠(见上文)。在14天期间内监测小鼠的肿瘤外观,通过测量最大(a)和最小(b)的肿瘤直径来评估肿瘤体积。使用如下公式,按照旋转椭球计算肿瘤体积:
通过单因素ANOVA和Dunnett’s多重比较事后检验(Dunnett′smultiple comparison post-test)使用Graph Pad Prism软件分析结果的显著性。仅当ANOVA表现出显著性时,进行事后检验。
图13以平均值+/-SD表示结果。在第6,9,12和14天观察到显著的保护功效。如所预期的,所包括的作为对照的裸DNA疫苗接种完全保护小鼠避免肿瘤生长。然而,裸DNA疫苗接种在人体中至多表现出中等功效。关于细菌构建体,疫苗菌株SL7207/pMKhly-CtxB-PSA(表达和分泌CtxB-PSA融合蛋白)表现为最有效。其在肿瘤攻击后的第9,12和14天显著减小了肿瘤体积。引人注意的是,在第14天,就数值而言,菌株SL7207/pMKhly-CtxB对肿瘤生长的降低也与SL7207/pMKhly-CtxB-PSA相当。尽管不显著,但这一延迟效应与在ELISPOT试验中测量到的细胞应答非常一致。此外,SL7207/pMKhly-PSA菌株在第14天也实现了显著的保护,这表明该菌株也诱导低于检测阈的T细胞应答。相反,SL7207/pMKhly-PSA/CxtB菌株不诱导相关效应并且保持在与单独的SL7207/pMKhly1相同的范围。
实施例3:伤寒沙门氏菌Ty21a中癌基因-毒素融合蛋白的表达和分泌
与实施例1相似,使用另一个肿瘤抗原——在激酶结构域具有10个氨基酸缺失的癌基因B-Raf V600E的激酶结构域(BRaf V600E激酶结构域激酶失活型(KD),或简称BRaf*KD,更简单称为BKD)。该癌基因和作为佐剂的蛋白毒素组分,在此为CtxB,BKD-CtxB融合蛋白如本文所述进行构建。在人疫苗菌株伤寒沙门氏菌Ty21a中证明表达和分泌。分子克隆基于质粒/表达载体pMOhly1,其之前已被描述(Gentschev等人,2005;Gentschev等人,1996)并且克隆方法与本申请实施例1相似。所得的载体命名为pMBKDC。该融合蛋白的序列在图10中给出。
图17描述了使用电穿孔到伤寒沙门氏菌Ty21a菌株和其他细菌菌株中的载体pMBKDC的融合蛋白的表达和分泌。
表达和分泌BKD-CtxB融合蛋白的伤寒沙门氏菌Ty21a菌株保藏在德意志微生物保藏中心(German Collection of Microorganisms andCell Cultures)(DSMZ),保藏号为DSM 19245。
实施例4:OVA-CtxB融合构建体与不同的遗传编码的免疫学佐剂的比较
为了比较通过活疫苗分泌的毒素-抗原融合蛋白的免疫学功效,构建包含对免疫学研究来说广泛使用的抗原,鸡卵清蛋白(OVA)和CtxB的融合蛋白。
有义引物NsiI-OVA-正向5′-CAT GTA TGC ATT AGC CAT GGTATA CCT GG-3′和反义引物NsiI-OVA-反向5′-TTT TTT ATG CATAAG GG AAA CAC CAC ATC TGC C-3′用于通过PCR扩增代表ova基因(NM205152)的1033bp DNA片段。用QIAquick PCR PurificationKit(Qiagen,Germany)纯化并用NsiI限制性酶消化后,将携带不具有N末端信号序列的完整ova基因的DNA片段插入输出载体pMKhly1的单一NsiI位点中。从大肠杆菌DH5α(Life Technologies)分离所得的质粒pMKhly-Ova,分析并测序。
使用有义引物5′ctxB NsiI(5′-GCATATGCACATGCATCACCTCAAAATATTACTGAT-3′)和反义引物3′ctxB SrfI NsiI(5′-GGCTTTTTTATATCTTATGCAT ATTGCGGCAATCGC-3′)(粗体为SrfI位点)通过PCR扩增表示来自霍乱弧菌El tor的ctxB基因的~300bp DNA片段。用QIAquick PCR Purification Kit(Qiagen,Germany)纯化和用NsiI限制性酶消化后,将携带不具有N末端信号序列的完整ctxB基因的DNA片段插入输出载体pMKhly1的单一NsiI位点中。从大肠杆菌DH5α(Life Technologies)分离所得的质粒pMKhly-CtxB,分析并测序。用5-OVA-SfrI GCC ATC ATG TCA GCT CTA和3-OVA-SfrI AGG GGA AAC ACA TCT GCC引物通过PCR从pCI-OVA质粒扩增ova基因。在Thermal Cycler 60(Biometra,Germany)中进行PCR,以94℃1分钟,49℃1分钟和72℃2分30秒循环30次。然后将1.1-kb DNA产物克隆到pMKhly-CtxB的SrfI位点中。通过限制性酶切分析和测序检验所得的pMKhly-CtxB-OVA质粒。
将该融合蛋白引起Th1免疫应答的能力与和编码干扰素(IFN-γ),白介素(IL-12)和趋化因子(IP-10)的DNA递送质粒(编码在真核启动子控制下的蛋白)相结合的仅编码分泌性OVA的pMKhly载体的能力进行比较。
如上述的进行免疫程序和ELISPOT分析。简单来说,用不同菌株口服免疫C57BL/6小鼠三次。最终免疫后7天,取出脾细胞,再刺激5天并且在ELISPOT测定中进行分析。为了再刺激脾细胞,使用用SIINFEKL肽(字母表示氨基酸),卵清蛋白的H-2b限制性MHC-I表位脉冲的细胞。
图14展示与共递送IFN-γ或IP-10的构建体相比,包含鸡卵清蛋白(OVA)和CtxB的融合蛋白在诱导OVA特异性CD8+T细胞应答和潜在的先天免疫系统应答中的较高的功效。其表现出与具有共递送IL-12构建体的菌株相似的功效。
实施例5:病毒抗原的表达和分泌
通过在兽医疫苗菌株,鼠伤寒沙门氏菌VacT中表达与CtxB融合的鸡流感病毒H5N1的血凝素H1蛋白,证明本发明的微生物用于分泌和表达任意(非肿瘤的)抗原的适宜性。
在PCR中使用有义引物5`-HA-G:5′-ATC TGT CAA ATG GAG AAA-3′和反义引物3-HA12C:5`-TAC TCC ACT TAT TTC CTC TCT-3`扩增编码不具有C末端膜结构域的H5的DNA片段(H12C)。然后将PCR产物克隆到pMKhly-CtxB的SrfI位点中。通过限制性酶切分析和测序检验所得的pMKhly-CtxB-H12C质粒。鼠伤寒沙门氏菌VacT/pMKhly-CtxB-H12C菌株有效地表达和分泌杂合的H5蛋白,如通过用抗CtxB和HlyA的多克隆抗体的免疫印迹所示(图2)。在实验条件下,分泌的H5的量为2-3μg蛋白/ml上清液。
在BHI培养基中培养细菌达到1×109个细胞每毫升的密度。20ml培养物在Hereaus离心机中在4℃以4000rpm(3000g)离心30′。将18ml上清液转移入新鲜试管中。然后,加入1.8ml TCA(三氯乙酸,Applichem,Germany);混合液体并且在冰上温育至少1小时。温育后,悬浮液在Hereaus离心机中在4℃以4000rpm(3000g)离心30′。移去上清并且用1ml丙酮p.a.(Applichem,Germany)清洗沉淀;沉淀物在Hereaus离心机中在4℃以4000rpm(3000g)离心10′。风干沉淀并用150μl 5x Laemmli缓冲液进行处理。在SDS PAGE中各道使用20μl溶液。分离的蛋白电泳转移到Hybond ECL硝化纤维素膜(Amersham-Pharmacia,Little Chalfont,U.K.)并且用含1%BSA的PBS封闭过夜。在PBS-Tween 0.05%中清洗膜,用多克隆兔抗CtxB抗体(1∶1000,Zytomed,Berlin,Germany)或HlyAs抗体(Gentschev等人,1996)温育,然后用HRP-偶联的抗兔IgG(1/2,000;Dianova,Hamburg,Germany)温育1小时。用增强的化学发光试剂盒(GEHealthcare Life Science,Germany)进行Western印迹。
图15描述了在兽医疫苗菌株,鼠伤寒沙门氏菌VacT中HA12C-CtxB融合蛋白的有效表达和功能性分泌。
实施例6:经由III型分泌系统的毒素佐剂和肿瘤抗原的融合蛋白的表达和分泌
一些革兰氏阴性细菌具有III型分泌系统,所述分泌系统能够用于抗原分泌。通常,这些系统能够用于直接将异源抗原注射入细胞中。在该实施例中,用作分泌信号的耶尔森氏菌的毒素组分(YopE)与作为佐剂的热不稳定肠毒素B亚基(LT-B)片段和肿瘤抗原PSA基因融合。该构建体在合适的,优选减毒的耶尔森氏菌菌株中表达,其导致融合蛋白经由YopE信号序列由内源III型分泌装置分泌。
在该实施例中,将基因融合体YopE18-LT-B-PSA克隆到paCYC184质粒的EcoRI位点中,使用具有和cat基因相同的方向的构建体,产生由编码cat启动子的质粒表达的产物(http://www.fermentas.com/tecbinfo/nucleicacids/mappacyc184.htm)。为了增强表达,可以使用任何合适的启动子。
在下文中,示例了克隆方法。具有热不稳定肠毒素B亚基的大肠杆菌的染色体DNA或具有该序列(GenBank登录号AF242418)的载体用下列引物在PCR反应中进行扩增:
Eco-yope18-f(包含EcoRI位点+YopE18信号序列):
(5’区域黑色:EcoRI位点+3碱基5’,红色:编码用于YopE蛋白的III型分泌的分泌信号的序列(aa 1-18),GenBank登录号M92066;斜体区域:LT-B基因的同源区域(GB登录号AF242418),碱基4-28)。
磷酸化的反向引物LT-B-r:
5’GTTTTCCATACTGATTGCCGCAATTGAATTGG-3’
(GB AF242418的反向链372-341)。
同时,如在本申请中所描述的来自载体pMK CtxB-PSA的PSA序列用下列引物进行扩增:
磷酸化的正向引物psa-f:5’-GTGGGAGGCTGGGAGTGCGAG-3’
反向引物psa-eco-r:5’CCTGAATTCTTAGACGTGATACCTTGAAGCAC
(5’黑色:EcoRI位点+3碱基5’,蓝色:终止密码子,黑色:本申请PSA序列的3’区域)
然后用DNA连接酶在合适的条件下连接这两个片段。连接后,在第二次PCR反应中用上述的Eco-yope18-f和PSA-Eco-R引物扩增新的片段。
用合适的PCR纯化试剂盒纯化所得的片段以除去缓冲液和寡核苷酸,然后用EcoRI酶在合适的反应条件下进行消化。用琼脂糖凝胶电泳纯化所得的1040bp片段并连接到EcoRI消化的载体paCYC184中。对抗四环素,cm敏感的克隆测序后,选择具有以与cm基因相同的方向整合的正确的序列的克隆,并且用电穿孔法转化到合适的耶尔森氏菌菌株中。该疫苗菌株将经由它的内源的III型分泌系统分泌LT-B-PSA融合蛋白。
实施例7:在革兰氏阳性菌中毒素-抗原融合蛋白的表达和分泌
革兰氏阳性菌和阴性菌就分泌而言具有不同的先决条件。革兰氏阴性菌具有两层膜,因此对于完整分泌来说,除分泌信号以外,分泌装置也是必须的。在革兰氏阳性菌的情况下,分泌信号序列是充分的。
在该实施例中,描述了在利斯特菌中使用p60分泌信号的用于破伤风类毒素PSA融合蛋白的分泌的系统。
在第一步中,用NsiI消化载体pUC18(PS)actAOVATinlA(Loeffler等人,2006),然后用3’-5’核酸外切酶在适宜条件下进行处理。最后通过琼脂糖凝胶电泳纯化片段。
同时,从合适的来源,例如来自破伤风梭菌菌株的基因组DNA扩增破伤风类毒素片段C(GenBank登录号M12739),使用下列磷酸化引物:
tetc for:5’-TAAAAATCTGGATTGTTGGGTTG-3’,下划线的额外的碱基是为了确保正确的融合框。
tetc rev:5’-ATCATTTGTCCATCCTTCATCTG-3’.
从本申请中描述的质粒pMO BKDC扩增BRAF KD片段,使用下列磷酸化的引物:
br for:5’-GATTGGGAGATTCCTGATG-3’
br rev:5’-CCCGTGGACAGGAAACGCACC-3’.
用合适的PCR纯化试剂盒纯化两个片段,然后用DNA连接酶在合适的条件下进行连接。连接后,用合适的PCR纯化试剂盒再次纯化片段并且用tetc for和br rev引物进行扩增。扩增后,经琼脂糖凝胶电泳纯化所得的2280bp片段并将其连接到经纯化的pUC18(PS)actAOVATinlA的NsiI-3’-5’核酸外切酶片段中。连接并转化到大肠杆菌中后,选择携带符合读框片段的克隆。然后,用PstI和SacI切割质粒并且用凝胶电泳纯化2837bp片段并且将其连接到适宜的经PstI和SacI消化并经纯化的载体pSP118(Loeffler等人,2006)中。
将所得的载体,pSP118-act-TetC-BRaf*KD转化到携带trpS缺失的利斯特菌菌株,例如单核细胞增生利斯特菌ΔtrpsΔaroA/B(Loeffler等,2006)中。在该环境中,该质粒经由基于质粒的trpS(“平衡致死系统”)稳定并且编码导致菌株的细胞内裂解的噬菌体赖氨酸。act-TetC-BRaf*KD盒在actA启动子控制下主要在真核宿主细胞中表达,其具有一些细胞外渗漏(Loeffler等人,2006)。该盒的actA信号序列导致TetC-BRaf*KD融合蛋白的分泌。
实施例8:真核细胞分泌毒素-抗原融合蛋白
在本实施例中,构建真核细胞系(例如肿瘤细胞系),所述细胞系分泌CtxB-PSA融合蛋白。为了这一目的,使用通用性分泌信号(US6,733,997),其原则上允许相应的表达盒在不同来源(包括哺乳动物细胞,酵母和原核细胞)的细胞中分泌。
在第一步中,从质粒pMO BKDC(本申请)扩增CtxB-BRaf*KD融合物,使用下列引物:
CB-for:5’-atcGGATCCTCAAAATATTACTGATTTGTGTGC-3’(小写字母:间隔,下划线:BamHI位点,大写字母:CtxB 5’)
然后,用合适的PCR纯化试剂盒纯化PCR产物,然后用BamHI进行部分消化(片段包含内部BamHI位点)。经由琼脂糖凝胶电泳分离部分消化物的1231bp片段,然后将其连接到经BamHI消化并且经凝胶纯化的质粒pVtgEGFP(美国专利申请6733997)中。然后,选择携带符合读框的与Vtgss同向的插入物的克隆并且命名为pVtgCtxBRAf。该质粒可以经由电穿孔转化到真核细胞系中,其可以经由kan/neo选择盒进行选择。该细胞系可以建立用作异源癌疫苗的细胞系如癌细胞系或用作自体癌疫苗的得自患者的肿瘤细胞。
无论如何,由载体pVtgEGFP编码的与CtxB-BRaf*KD基因融合的分泌信号Vtgss将导致融合蛋白的分泌。
使用相似的方法,还能够在酵母中表达融合蛋白。作为实例,示范如US 6,733,997的图11中所描述的改进的克隆策略。在第一步中,通过EagI和Eco47III从上述的质粒pVtgCtxBRAf中切出包含Vtgss-CtxB-BRaf*KD融合物的盒并将其插入载体pBSPGK中(US6,733,997,图11)。然后,类似于US 6,733,997(图11)的描述,用SacI和HindIII消化所得的载体并且将包含PGK元件和Vtgss-CtxB-BRaf*KD融合物的片段整合到载体pYEX-S1的相应区域中。通过电穿孔能够将所得的质粒转化到酵母菌株(如酿酒酵母)中。该酵母将表达并分泌融合蛋白并且能够用于接种疫苗的目的。
缩写
ABC ATP结合盒
AIDA 参与扩散粘着的粘附素
APC 抗原呈递细胞
aroA aroA基因
AT α毒素
ATP 三磷酸腺苷
B-Raf KD B-Raf激酶结构域
BSA 牛血清白蛋白
Cag A 幽门螺杆菌的主要疾病相关的毒性蛋白
CPE 产气荚膜梭菌肠毒素
CpG 包含低甲基化的含有CpG基序的免疫刺激
DNA序列的DNA序列
CT/Ctx 霍乱毒素
CTB/CtxB 霍乱毒素B亚基
CTL 细胞毒性CD8+T细胞(T杀伤细胞)
CMV 巨细胞病毒
DNA 脱氧核糖核酸
ds 双链
DT/Dtx 白喉毒素
E.coli 大肠杆菌
EBV EB病毒
GM-1受体 单唾液酸神经节苷脂受体1
HA 血凝素
HCV 丙型肝炎病毒
HIV 人免疫缺陷病毒
Hly 溶血素
HPV 人乳头瘤病毒
HT 出血毒素
i.d. 皮内
i.m. 肌内
i.p. 腹膜内
IFN 干扰素
IgA 免疫球蛋白同种型A
IgG 免疫球蛋白同种型G
IL 白介素
KD 激酶失活型
LPS 脂多糖
LT 大肠杆菌热不稳定肠毒素
LT 致死毒素
LTB 大肠杆菌热不稳定肠毒素B亚基
mAb 单克隆抗体
MHC 主要组织相容性复合物
NK细胞 自然杀伤细胞
NKT细胞 自然杀伤T细胞
PAGE 聚丙烯酰胺凝胶电泳
PBS 磷酸盐缓冲液
PCR 聚合酶链式反应
PE 假单胞菌外毒素A
PSA 前列腺特异性抗原
PT/Ptx 百日咳毒素
RNA 核糖核酸
s.c. 皮下
SDS 十二烷基硫酸钠
Sec 通用分泌(Sec)途径
ss 单链
ST 大肠杆菌热稳定肠毒素
ST/Stx 志贺菌毒素
STB/StxB 志贺菌毒素B亚基
T3SS III型分泌系统
Tat 双精氨酸转运
TCA 三氯乙酸
Th1(细胞) 炎性CD4+T细胞
Th2(细胞) 辅助CD4+T细胞
TSST-1 中毒性休克综合征毒素
TT 破伤风毒素
VT Vero细胞毒素
参考文献
Agren,L.C.,Ekman,L.,Lowenadler,B.,Nedrud,J.G.,and Lycke,N.Y.(1999).Adju-vanticity of the cholera toxin A1-based gene fusion protein,CTA1-DD,is critically de-pendent on the ADP-ribosyltransferase and Ig-binding activity.J Immunol 162,2432-2440.
Anderson,R.J.,Pasetti,M.F.,Sztein,M.B.,Levine,M.M.,and Noriega,F.R.(2000).DeltaguaBA attenuated Shigella flexneri 2a strain CVD 1204 as a Shigella vaccine andas a live mucosal delivery system for fragment C of tetanus toxin.Vaccine 18,2193-2202.
Austin,E.A.,Graves,J.F.,Hite,L.A.,Parker,C.T.,and Schnaitman,C.A.(1990).Genetic analysis of lipopolysaccha ride core biosynthesis by Escherichia coli K-12:in-sertion mutagenesis of the rfa locus.J Bacte riol 172,5312-5325.
Balsalobre,C.,Silvan,J.M.,Berglund,S.,Mizunoe,Y.,Uhlin,B.E.,and Wai,S.N.(2006).Release of the type I secreted alpha-haemolysin via outer membrane vesiclesfrom Escherichia coli.Mol Microbiol 59,99-112.
Barry,E.M.,Gomez-Duarte,O.,Chatfield,S.,Rappuoli,R.,Pizza,M.,Losonsky,G.,Galen,J.,and Levine,M.M.(1996).Expression and immunogenicity of pertussis toxinS1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD908.Infect Immun 64,4172-4181.
Becerra,J.C.,Arthur,J.F.,Landucci,G.R.,Forthal,D.N.,and Theuer,C.P.(2003).CD8+T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbuminin C57BL/6 mice.Surgety 133,404-410.
Boon,T.,Coulie,P.G.,Van den Eynde,B.J.,and van der Bruggen,P.(2006).HumanT cell responses against melanoma.Annu Rev Immunol 24,175-208.
Boyd,A.P.,Ross,P.J.,Conroy,H.,Mahon,N.,Lavelle,E.C.,and Mills,K.H.(2005).
Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immuneresponses:distinct roles for acylation and enzymatic activity in immunomodulation andcell death.J Immunol 175,730-738.
Brossier,F.,Weber-Levy,M.,Mock,M.,and Sirard,J.C.(2000).Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacil-Ius anthracis.Infect Immun 68,5731-5734.
Bumann,D.(2D01).Regulated antigen expression in live recombinant Salmonella en-terica serovar Typhimurium strongly affects colonization capabilities and specificCD4(+)-T-cell responses.Infect Immun 69,7493-7500.
Busby,S.,and Ebright,R.H.(1994).Promoter structure,promoter recognition,andtranscription activation in prokaryotes.Cell 79,743-746.
Butterton,J.R.,Beattie,D.T.,Gardel,C.L.,Carroll,P.A.,Hyman,T.,Killeen,K.P.,Mekalanos,J.J.,and Calderwood,S.B.(1995).Heterologous antigen expression inVibrio cholerae vector strains.Infect Immun 63,2689-2696.
Byun,Y.,Ohmura,M.,Fujihashi,K.,Yamamoto,S.,McGhee,J.R.,Udaka,S.,Kiyono,H.,Takeda,Y.,Kohsaka,T.,and Yuki,Y.(2001).Nasal immunization with E.coli vero-toxin 1(VT1)-B subunit and a nontoxic mutant of cholera toxin elicits serum neutralizingantibodies.Vaccine 19,2061-2070.
Campos,J.,Martinez,E.,Marrero,K.,Silva,Y.,Rod riguez,B.L.,Suzarte,E.,Ledon,T.,and Fando,R.(2003).Novel type of specialized transduction for CTXphi or its sat-ellite phage RS1 mediated by filamentous phage VGJ phi in Vibrio cholerae.J Bacteriol185,7231-7240.
Cardenas,L.,and Clements,J.D.(1992).Oralimmunization using live attenuatedSalmonella spp.as carriers of foreign antigens.Clin Microbiol Rev 5,328-342.
Cardenas,L.,and Clements,J.D.(1993).Development of mucosal protection againstthe heat-stable enterotoxin(ST)of Escherichia coli by oral immunization with a geneticfusion delivered by a bacterial vector.Infect Immun 61,4629-4636.
Chabalgoity,J.A.,Harrison,J.A.,Esteves,A.,Demarco de Hormaeche,R.,Ehrlich,R.,Khan,C.M.,and Hormaeche,C.E.(1997).Expression and immunogenicity of anEchinococcus granulosus fatty acid-binding protein in live attenuated Salmonella vac-cine strains.Infect Immun 65,2402-2412.
Chabalgoity,J.A.,Khan,C.M.,Nash,A.A.,and Hormaeche,C.E.(1996).A Salmo-nella typhimurium htrA live vaccine expressing multiple copies of a peptide comprisingamino acids 8-23 of herpes simplex virus glycoprotein D as a genetic fusion to tetanustoxin fragment C protects mice from herpes simplex virus infection.Mol Microbiol 19,791-801.
Chabalgoity,J.A.,Moreno,M.,Carol,H.,Dougan,G.,and Hormaeche,C.E.(2000).Salmonella typhimurium as a basis for a live oral Echinococcus granulosus vaccine.Vaccine 19,460-469.
Chabalgoity,J.A.,Villareal-Ramos,B.,Khan,C.M.,Chatfield,S.N.,de Hormaeche,R.D.,and Hormaeche,C.E.(1995).Influence of preimmunization with tetanus toxoidon immune responses to tetanus toxin fragment C-guest antigen fusions in a Salmo-nella vaccine carrier.Infect Immun 63,2564-2569.
Chacon,M.R.,Londono,P.,Dougan,G.,and Selkirk,M.E.(1996).Heterologous ex-pression of the cuticular-glutath ione peroxidase of lymphatic filariae in an attenuatedvaccine strain of Salmonella typhimurium abrogates H-2 restriction of specific antibodyresponses.Parasite Immunol 18,307-316.
Chen,I.,Finn,T.M.,Yanqing,L.,Guoming,Q.,Rappuoli,R.,and Pizza,M.(1998).Arecombinant live attenuated strain of Vibrio cholerae induces immunity against tetanustoxin and Bordetella pertussis tracheal colonization factor.Infect Immun 66,1648-1653.
Cheng-hua,S.,Cheng,C.,Jing-sheng,Z.,Jiezhi.,L.,and Qing-jun,M.(1995).Genefusion of cholera toxin B subunit and HBV PreS2 epitope and the antigenicity of fusionprotein.Vaccine 13,933-937.
Clemens,J.,Savarino,S.,Abu-Elyazeed,R.,Safwat,M.,Rao,M.,Wierzba,T.,Sven-nerholm,A.M.,Holmgren,J.,Frenck,R.,Park,E.,and Naficy,A.(2004).Developmentof pathogenicity-driven definitions of outcomes for a field trial of a killed oral vaccineagainst enterotoxigenic Escherichia coli in Egypt:application of an evidence-basedmethod.J Infect Dis 189,2299-2307.
Datsenko,K.A.,and Wanner,B.L.(2000).One-step inactivation of chromosomalgenes in Escherichia coli K-12 using PCR products.Proc Natl Acad Sci USA 97,6640-6645.
Dietrich,G.,Bubert,A.,Gentschev,I.,Sokolovic,Z.,Simm,A.,Catic,A.,Kaufmann,S.H.,Hess,J.,Szalay,A.A.,and Goebel,W.(1998).Delivery of antigen-encoding plas-mid DNA into the cytosol of macrophages by attenuated suicide Listeria monocyto-genes.Nat Biotechnol 16,181-185.
Dietrich,G.,Viret,JF,and Gentschev,I.(2003).Haemolysin A and listeriolysin-twovaccine delivery tools for the induction of cell-mediated immunity.Int.J.Parasitol 33,495-505
Dunn,G.P.,Old,L.J.,and Schreiber,R.D.(2004).The immunobiology of cancer im-munosurveillance and immunoediting.Immunity 21,137-148.
Dunstan,S.J.,Simmons,C.P.,and Strugnell,R.A.(2003).In vitro and in vivo stabilityof recombinant plasmids in a vaccine strain of Salmonella enterica var.Typhimurium.FEMS Immunol Med Microbiol 37,111-119.
Eriksson,A.M.,Schon,K.M.,and Lycke,N.Y.(2004).The cholera toxin-derivedCTA1-DD vaccine adjuvant administered intranasally does not cause inflammation oraccumulate in the nervous tissues.J Immunol 173,3310-3319.
Fath,M.J.,Skvirsky,R.C.,and Kolter,R.(1991).Functional complementation be-tween bacterial MDR-like export systems:colicin V,alpha-hemolysin,and Erwinia pro-tease.J Bacteriol 173,7549-7556.
Fensterle,J.,Grode,L.,Hess,J.,and Kaufmann,S.H.E.(1999).Effective DNA vacci-nation against listeriosis by prime/boost inoculation with the gene gun.J Immunol 163,4510-4518.
Fensterle,J.,Schwartz,V.,Riedmiller,H.,and Rapp,U.R.(2005).Animal models forDNA vaccination against prostate cancer using PSA encoding plasmids.Onkologie 28(suppl 2),52.
Freytag,L.C.,and Clements,J.D.(1999).Bacterial toxins as mucosal adjuvants.CurrTop Microbiol Immunol 236,215-236.
Freytag,L.C.,and Clements,J.D.(2005).Mucosal adjuvants.Vaccine 23,1804-1813.
Garmory,H.S.,Brown,K.A.,and Titball,R.W.(2002).Salmonella vaccines for use inhumans:present and future perspectives.FEMS Microbiol Rev 26,339-353.
Garmory,H.S.,Titball,R.W.,Griffin,K.F.,Hahn,U.,Bohm,R.,and Beyer,W.(2003).Salmonella enterica serovar typhimurium expressing a chromosomally integrated copyof the Bacillus anthracis protective antigen gene protects mice against an anthraxspore challenge.Infect Immun 71,3831-3836.
Gentschev,I.,Dietrich,G.,and Goebel,W.(2002a).The E.coli alpha-hemolysin secre-tion system and its use in vaccine development.Trends Microbiol 10,39-45.
Gentschev,I.,Dietrich,G.,Spreng,S.,Pilgrim,S.,Stritzker,J.,Kolb-Maurer,A.,andGoebel,W.(2002b).Delivery of protein antigens and DNA by attenuated intracellularbacteria.Int J Med Microbiol 291,577-582.
Gentschev,I.,Fensterle,J.,Schmidt,A.,Potapenko,T.,Troppmair,J.,Goebel,W.,andRapp,U.R.(2005).Use of a recombinant Salmonella enterica serovar Typhimuriumstrain expressing C-Raf for protection against C-Raf induced lung adenoma in mice.BMC Cancer 5,15.
Gentschev,I.,Mollenkopf,H.,Sokolovic,Z.,Hess,J.,Kaufmann,S.H.,and Goebel,W.(1996).Development of antigen-delivery systems,based on the Escherichia colihemolysin secretion pathway.Gene 179,133-140.
Gentschev,I.,Dietrich,G.,Spreng,S.,Neuhaus,B.,Maier,E.,Benz,R.,Goebel,W.,Fensterle,J.,and Rapp,UR.(2004).Use of the alpha-hemolysin secretion system ofEscherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain.Int JMed Microbiol 294,363-371.
Gomez-Duarte,O.G.,Galen,J.,Chatfield,S.N.,Rappuoli,R.,Eidels,L.,and Levine,M.M.(1995).Expression of fragment C of tetanus toxin fused to a carboxyl-terminalfragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain.Vaccine 13,1596-1602.
Hajishengallis,G.,Harokopakis,E.,Hollingshead,S.K.,Russell,M.W.,and Michalek,S.M.(1996).Construction and oral immunogenicity of a Salmonella typhimurium strainexpressing a streptococcal adhesin linked to the A2/B subunits of cholera toxin.Vac-cine 14,1545-1548.
Hajishengallis,G.,Nawar,H.,Tapping,R.I.,Russell,M.W.,and Connell,T.D.(2004).The Type II heat-labile enterotoxins LT-IIa and LT-IIb and their respective B pentamersdifferentially induce and regulate cytokine production in human monocytic cells.InfectImmun 72,6351-6358.
Harokopakis,E.,Hajishengallis,G.,Greenway,T.E.,Russell,M.W.,and Michalek,S.M.(1997).Mucosal immunogenicity of a recombinant Salmonella typhimurium-clonedheterologous antigen in the absence or presence of coexpressed cholera toxin A2 andB subunits.Infect Immun 65,1445-1454.
Hess,J.,Gentschev,I.,Miko,D.,Welzel,M.,Ladel,C.,Goebel,W.,and Kaufmann,S.H.(1996).Superior efficacy of secreted over somatic antigen display in recombinantSalmonella vaccine induced protection against listeriosis.Proc Natl Acad Sci U S A 93,1458-1463.
Holmgren,J.,Adamsson,J.,Anjuere,F.,Clemens,J.,Czerkinsky,C.,Eriksson,K.,Flach,C.F.,George-Chandy,A.,Harandi,A.M.,Lebens,M.,et al.(2005).Mucosaladjuvants and anti-infection and anti-immunopathology vaccines based on choleratoxin,cholera toxin B subunit and CpG DNA.Immunol Lett 97,181-188.
Holmgren,J.,and Czerkinsky,C.(2005).Mucosal immunity and vaccines.Nat Med 11,S45-53.
Holmgren,J.,Czerkinsky,C.,Eriksson,K.,and Mharandi,A.(2003).Mucosal immuni-sation and adjuvants:a brief overview of recent advances and challenges.Vaccine 21Suppl 2,S89-95.
Hormozi,K.,Parton,R.,and Coote,J.(1999).Adjuvant and protective properties ofnative and recombinant Bordetella pertussis adenylate cyclase toxin preparations inmice.FEMS Immunol Med Microbiol 23,273-282.
Huang,Y.,Hajishengallis,G.,and Michalek,S.M.(2000).Construction and characteri-zation of a Salmonella enterica serovar typhimurium clone expressing a salivary adhe-sin of Streptococcus mutans under control of the anaerobically inducible nirB promoter.Infect Immun 68,1549-1556.
Hunt,P.D.,and Hardy,S.J.(1991).Heat-labile enterotoxin can be released from Es-cherichia coli cells by host intestinal factors.Infect Immun 59,168-171.
Jackson,R.J.,Marinaro,M.,VanCott,J.L.,Yamamoto,M.,Okahashi,N.,Fujihashi,K.,Kiyono,H.,Chatfield,S.N.,and McGhee,J.R.(1996).Mucosal immunity:regula-tion by helper T cells and a novel method for detection.J Biotechnol 44,209-216.
Jagusztyn-Krynicka,E.K.,Clark-Curtiss,J.E.,and Curtiss,R.,3rd(1993).Escherichiacoli heat-labile toxin subunit B fusions with Streptococcus sobrinus antigens expressedby Salmonella typhimurium oral vaccine strains:importance of the linker for antigenicityand biological activities of the hybrid proteins.Infect Immun 61,1004-1015.
Khan,C.M.,Villarreal-Ramos,B.,Pierce,R.J.,Demarco de Hormaeche,R.,McNeill,H.,Ali,T.,Chatfield,S.,Capron,A.,Dougan,G.,and Hormaeche,C.E.(1994a).Con-struction,expression,and immunogenicity of multiple tandem copies of the Schisto-soma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain ofSalmonella.J Immunol 153,5634-5642.
Khan,C.M.,Villarreal-Ramos,B.,Pierce,R.J.,Riveau,G.,Demarco de Hormaeche,R.,McNeill,H.,Ali,T.,Fairweather,N.,Chatfield,S.,Capron,A.,and et al.(1994b).Construction,expression,and immunogenicity of the Schistosoma mansoni P28 glu-tathione S-transferase as a genetic fusion to tetanus toxin fragment C in a live Aro at-tenuated vaccine strain of Salmonella.Proc Natl Acad Sci U S A 91,11261-11265.
Konieczny,M.P.,Suhr,M.,Noll,A.,Autenrieth,I.B.,and Alexander Schmidt,M.(2000).Cell surface presentation of recombinant(poly-)peptides including functional T-cell epitopes by the AIDA autotransporter system.FEMS Immunol Med Microbiol 27,321-332.
Koprowski,H.,2nd,Levine,M.M.,Anderson,R.J.,Losonsky,G.,Pizza,M.,and Barry,E.M.(2000).Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressingcolonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Es-cherichia coli.Infect Immun 68,4884-4892.
Kweon,M.N.,Yamamoto,M.,Watanabe,F.,Tamura,S.,Van Ginkel,F.W.,Miyauchi,A.,Takagi,H.,Takeda,Y.,Hamabata,T.,Fujihashi,K.,et al.(2002).A nontoxic chi-meric enterotoxin adjuvant induces protective immunity in both mucosal and systemiccompartments with reduced IgE antibodies.J Infect Dis 186,1261-1269.
Laemmli,U.K.(1970).Cleavage of structural proteins during the assembly of the headof bacteriophage T4.Nature 227,680-685.
Lahiri,S.S.(2000).Bacterial toxins--an overview.J Nat Toxins 9,381-408.
Lavelle,E.C.,McGuirk,P.,and Mills,K.H.(2004).Molecules of infectious agents asimmunomodulatory drugs.Curr Top Med Chem 4,499-508.
Lee,J.J.,Sinha,K.A.,Harrison,J.A.,de Hormaeche,R.D.,Riveau,G.,Pierce,R.J.,Capron,A.,Wilson,R.A.,and Khan,C.M.(2000).Tetanus toxin fragment C ex-pressed in live Salmonella vaccines enhances antibody responses to its fusion partnerSchistosoma haematobium glutathione S-transferase.Infect Immun 68,2503-2512.
Loeffler,D.I.,Schoen,C.U.,Goebel,W.,and Pilgrim,S.(2006).Comparison of differ-ent live vaccine strategies in vivo for delivery of protein antigen or antigen-encodingDNA and mRNA by virulence-attenuated Listeria monocytogenes.Infect Immun 74,3946-3957.
Loessner,M.J.,Wendlinger,G.,and Scherer,S.(1995).Heterogeneous endolysins inListeria monocytogenes bacteriophages:a new class of enzymes and evidence forconserved holin genes within the siphoviral lysis cassettes.Mol Microbiol 16,1231-1241.
Lycke,N.(2005).From toxin to adjuvant:basic mechanisms for the control of mucosalIgA immunity and tolerance.Immunol Lett 97,193-198.
Lycke,N.,Tsuji,T.,and Holmgren,J.(1992).The adjuvant effect of Vibrio choleraeand Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferaseactivity.Eur J Immunol 22,2277-2281.
McSorley,S.J.,Rask,C.,Pichot,R.,Julia,V.,Czerkinsky,C.,and Glaichenhaus,N.(1998).Selective tolerization of Th1-like cells after nasal administration of a choleratoxoid-LACK conjugate.Eur J Immunol 28,424-432.
Mendelson,I.,Gat,O.,Aloni-Grinstein,R.,Altboum,Z.,Inbar,I.,Kronman,C.,Bar-Haim,E.,Cohen,S.,Velan,B.,and Shafferman,A.(2005).Efficacious,nontoxigenicBacillus anthracis spore vaccines based on strains expressing mutant variants of lethaltoxin components.Vaccine 23,5688-5697.
Mesnage,S.,Weber-Levy,M.,Haustant,M.,Mock,M.,and Fouet,A.(1999).Cell sur-face-exposed tetanus toxin fragment C produced by recombinant Bacillus anthracisprotects against tetanus toxin.Infect Immun 67,4847-4850.
Michalkiewicz,J.,Stachowski,J.,Barth,C.,Patzer,J.,Dzierzanowska,D.,andMadalinski,K.(1999).Effect of Pseudomonas aeruginosa exotoxin A on IFN-gammasynthesis:expression of costimulatory molecules on monocytes and activity of NKcells.Immunol Lett 69,359-366.
Michl,P.,and Gress,T.M.(2004).Bacteria and bacterial toxins as therapeutic agentsfor solid tumors.Curr Cancer Drug Targets 4,689-702.
Morona,R.,Manning,P.A.,and Reeves,P.(1983).Identification and characterizationof the TolC protein,an outer membrane protein from Escherichia coli.J Bacteriol 153,693-699.
Muhlen,K.A.,Schumann,J.,Wittke,F.,Stenger,S.,Van Rooijen,N.,Van Kaer,L.,and Tiegs,G.(2004).NK cells,but not NKT cells,are involved in Pseudomonasaeruginosa exotoxin A-induced hepatotoxicity in mice.J Immunol 172,3034-3041.
Mutsch,M.,Zhou,W.,Rhodes,P.,Bopp,M.,Chen,R.T.,Linder,T.,Spyr,C.,andSteffen,R.(2004).Use of the inactivated intranasal influenza vaccine and the risk ofBell′s palsy in Switzerland.N Engl J Med 350,896-903.
Orr,N.,Galen,J.E.,and Levine,M.M.(1999).Expression and immunogenicity of amutant diphtheria toxin molecule,CRM(197),and its fragments in Salmonella typhivaccine strain CVD 908-htrA.Infect Immun 67,4290-4294.
Poggi,A.,Spada,F.,Costa,P.,Tomasello,E.,Revello,V.,Pella,N.,Zocchi,M.R.,and Moretta,L.(1996).Dissection of lymphocyte function-associated antigen 1-dependent adhesion and signal transduction in human natural killer cells shown by theuse of cholera or pertussis toxin.Eur J Immunol 26,967-975.
Pogonka,T.,Klotz,C.,Kovacs,F.,and Lucius,R.(2003).A single dose of recombinantSalmonella typhimurium induces specific humoral immune responses against heterolo-gous Eimeria tenella antigens in chicken.Int J Parasitol 33,81-88.
Ramirez,R.,Carracedo,J.,Zamzami,N.,Castedo,M.,and Kroemer,G.(1994).Per-tussis toxin inhibits activation-induced cell death of human thymocytes,pre-B leukemiacells and monocytes.J Exp Med 180,1147-1152.
Ranallo,R.T.,Fonseka,C.P.,Cassels,F.,Srinivasan,J.,and Venkatesan,M.M.(2005).Construction and characterization of bivalent Shigella flexneri 2a vaccinestrains SC608(pCFAI)and SC608(pCFAI/LTB)that express antigens from enterotoxi-genic Escherichia coli.Infect Immun 73,258-267.
Reveneau,N.,Geoffroy,M.C.,Locht,C.,Chagnaud,P.,and Mercenier,A.(2002).Comparison of the immune responses induced by local immunizations with recombi-nant Lactobacillus plantarum producing tetanus toxin fragment C in different cellularlocations.Vaccine 20,1769-1777.
Roland,K.L.,Tinge,S.A.,Killeen,K.P.,and Kochi,S.K.(2005).Recent advances inthe development of live,attenuated bacterial vectors.Curr Opin Mol Ther 7,62-72.
Rosenberg,S.A.(2001).Progress in human tumour immunology and immunotherapy.Nature 411,380-384.
Ryan,E.T.,Butterton,J.R.,Smith,R.N.,Carroll,P.A.,Crean,T.I.,and Calderwood,S.B.(1997a).Protective immunity against Clostridium difficile toxin A induced by oralimmunization with alive,attenuated Vibrio cholerae vector strain.Infect Immun 65,2941-2949.
Ryan,E.T.,Butterton,J.R.,Zhang,T.,Baker,M.A.,Stanley,S.L.,Jr.,and Calder-wood,S.B.(1997b).Oral immunization with attenuated vaccine strains of Vibrio chol-erae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica pro-tein fused to the cho lera toxin B subunit induces systemic and mucosal antiamebic andanti-V.cholerae antibody responses in mice.Infect Immun 65,3118-3125.
Sanchez,J.,Wallerstrom,G.,Fred riksson,M.,Angstrom,J.,and Holmgren,J.(2002).Detoxification of cholera toxin without removal of its immunoadjuvanticity by the addi-tion of(STa-related)peptides to the catalytic subunit.A potential new strategy to gen-erate immunostimulants for vaccination.J Biol Chem 277,33369-33377.
Sanchez,AE.,Aquino,G.,Ostoa-Saloma,P.,Laclette,JP.,and Rocha-Zavaleta,L.(2004).Cholera toxin B-subunit gene enhances mucosal Immunoglobulin A,Th1-typeand CD8+cytotoxic responses when co-administeredintradermally with a DNA vac-cine.Clinic Diagnost Laborat Immun 11,711-719.
Schmid-Grendelmeier,P.,and Crameri,R.(2001).Recombinant allergens for skin test-ing.Int Arch Allergy Immunol125,96-111.
Schodel,F.,Enders,G.,Jung,M.C.,and Will,H.(1990).Recognition of a hepatitis Bvirus nucleocapsid T-cell epitope expressed as a fusion protein with the subunit B ofEscherichia coli heat labile enterotoxin in attenuated salmonellae.Vaccine 8,569-572.
Shaw,C.A.,and Stambach,M.N.(2003).Using Modified Bacterial Toxins to DeliverVaccine Antigens.ASM News 69,384-389.
Silva,A.J.,Mohan,A.,and Benitez,J.A.(2003).Cholera vaccine candidate 638:in-tranasal immunogenicity and expression of a foreign antigen from the pulmonarypathogen Coccidioides immitis.Vaccine 21,4715-4721.
Smerdou,C.,Anton,I.M.,Plana,J.,Curtiss,R.,3rd,and Enjuanes,L.(1996).A con-tinuous epitope from transmissible gastroenteritis virus S protein fused to E.coliheat-labile toxin B subunit expressed by attenuated Salmonella induces serum and secre-tory immunity.Virus Res 41,1-9.
Somner,E.A.,Ogun,S.A.,Sinha,K.A.,Spencer Valero,L.M.,Lee,J.J.,Harrison,J.A.,Holder,A.A.,Hormaeche,C.E.,and Khan,C.M.(1999).Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuatedSalmonella vaccine strains.Microbiology 145(Pt 1),221-229.
Sory,M.P.,and Cornelis,G.R.(1990).Delivery of the cholera toxin B subunit by usinga recombinant Yersinia enterocolitica strain as a live oral carrier.Res Microbiol 141,921-929.
Spangrude,G.J.,Sacchi,F.,Hill,H.R.,Van Epps,D.E.,and Daynes,R.A.(1985).Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin.J Immunol 135,4135-4143.
Su,G.F.,Brahmbhatt,H.N.,de Lorenzo,V.,Wehland,J.,and Timmis,K.N.(1992).Extracellular export of Shiga toxin B-subunit/haemolysin A(C-terminus)fusion proteinexpressed in Salmonella typhimurium aroA-mutant and stimulation of B-subunit specificantibody responses in mice.Microb Pathog 13,465-476.
Thungapathra,M.,Sharma,C.,Gupta,N.,Ghosh,R.K.,Mukhopadhyay,A.,Koley,H.,Nair,G.B.,and Ghosh,A.(1999).Construction of a recombinant live oral vaccine froma non-toxigenic strain of Vibrio cholerae O1 serotype inaba biotype E1 Tor and as-sessment of its reactogenicity and immunogenicity in the rabbit model.Immunol Lett68,219-227.
Todar,K.(2002).Mechanism of bacterial pathogenicity:protein toxins.Todar′s OnlineTextbook of Bacteriology.:http://textbookofbacteriology.net/proteintoxins.html.
Tzschaschel,B.D.,Guzman,C.A.,Timmis,K.N.,and de Lorenzo,V.(1996a).AnEscherichia coli hemolysin transport system-based vector for the export of polypep-tides:export of Shiga-like toxin IleB subunit by Salmonella typhimurium aroA.Nat Bio-technol 14,765-769.
Tzschaschel,B.D.,Klee,S.R.,de Lorenzo,V.,Timmis,K.N.,and Guzman,C.A.(1996b).Towards a vaccine candidate against Shigella dysenteriae 1:expression ofthe Shiga toxin B-subunit in an attenuated Shigella flexneri aroD carrier strain.MicrobPathog 21,277-288.
van Ginkel,F.W.,Jackson,R.J.,Yuki,Y.,and McGhee,J.R.(2000).Cutting edge:the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues.JImmunol 165,4778-4782.
Vertiev,Y.V.,Zdanovsky,A.G.,Shevelev,A.B.,Borinskaya,S.A.,Gening,E.L.,Martin,T.,Ivanov,P.A.,and Yankovsky,N.K.(2001).Recombinant Listeria strainsproducing the nontoxic L-chain of botulinum neurotoxin A in a soluble form.Res Micro-biol 152,563-567.
Walker,M.J.,Rohde,M.,Timmis,K.N.,and Guzman,C.A.(1992).Specific lung mu-cosal and systemic immune responses after oral immunization of mice with Salmonellatyphimurium aroA,Salmonella typhi Ty21a,and invasive Escherichia coli expressingrecombinant pertussis toxin S1 subunit.Infect Immun 60,4260-4268.
Ward,S.J.,Douce,G.,Figueiredo,D.,Dougan,G.,and Wren,B.W.(1999).Immuno-genicity of a Salmonella typhimurium aroA aroD vaccine expressing a nontoxic domainof Clostridium difficile toxin A.Infect Immun 67,2145-2152.
Wiener,M.C.(2000).Bacterial export takes its Tol.Structure 8,R171-175.
Wu,S.,Beier,M.,Sztein,M.B.,Galen,J.,Pickett,T.,Holder,A.A.,Gomez-Duarte,O.G.,and Levine,M.M.(2000).Construction and immunogenicity in mice of attenuatedSalmonella typhi expressing Plasmodium falciparum merozoite surface protein 1(MSP-1)fused to tetanus toxin fragment C.J Biotechnol 83,125-135.
Zheng,J.P.,Zhang,Z.S.,Li,S.Q.,Liu,X.X.,Yuan,S.L.,Wang,P.,Zhan,D.W.,Wang,L.C.,and Huang,C.F.(2005).Construction of a novel Shigella live-vectorstrain co-expressing CS3 and LTB/STm of enterotoxigenic E.coli.World J Gastroen-terol11,3411-3418.
Zhu,C.,Ruiz-Perez,F.,Yang,Z.,Mao,Y.,Hackethal,V.L.,Greco,K.M.,Choy,W.,Davis,K.,Butterton,J.R.,and Boedeker,E.C.(2006).Delivery of heterologous proteinantigens via hemolysin or autotransporter systems by an attenuated ler mutant of rabbitenteropathogenic Escherichia coli.Vaccine 24,3821-3831.
序列表
<110>Zentaris GmbH
<120>作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物,其制备方法和用途
<130>PCT 06/02 Z
<140>PCT/EP2007/062237
<141>2007-11-13
<150>EP 06123974.5
<151>2006-11-13
<150>US 60/939,140
<151>2007-05-21
<150>US 60/865,484
<151>2006-11-13
<160>40
<170>PatentIn version 3.3
<210>1
<211>61
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>1
gagtattcaa catttccgtg tcgcccttat tccctttttt ggtgtaggct ggagctgctt 60
c 61
<210>2
<211>60
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>2
gcgatctgtc tatttcgttc atccatagtt gcctgactcc ccatatgaat atcctcctta 60
<210>3
<211>21
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>3
gattggtgat gcatccctca t 21
<210>4
<211>21
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>4
ggtgctcatg cattggccac g 21
<210>5
<211>37
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>5
aaaaaagtcg acggctgtgc aggtcgtaaa tcactgc 37
<210>6
<211>39
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>6
aaaaaagcgg ccgcgaaatt gttatccgct cacaattcc 39
<210>7
<211>46
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>7
aaaaaagcgg ccgctaagga tgaattatga ttaaattaaa atttgg 46
<210>8
<211>42
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>8
tttatagtcg acttaatttg ccatactaat tgcggcaatc gc 42
<210>9
<211>36
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>9
gcatatgcac atgcatcacc tcaaaatatt actgat 36
<210>10
<211>44
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>10
ggctttttta tatcttatgc atgcccgggc attgcggcaa tcgc 44
<210>11
<211>18
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>11
gtgggaggct gggagtgc 18
<210>12
<211>18
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>12
ggggttggcc acgatggt 18
<210>13
<211>29
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>13
catgtatgca ttagccatgg tatacctgg 29
<210>14
<211>33
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>14
ttttttatgc ataagggaaa caccacatct gcc 33
<210>15
<211>18
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>15
gccatcatgt cagctcta 18
<210>16
<211>18
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>16
aggggaaaca catctgcc 18
<210>17
<211>18
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>17
atctgtcaaa tggagaaa 18
<210>18
<211>21
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>18
tactccactt atttcctctc t 21
<210>19
<211>87
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>19
ctgaattcat gaaaatatca tcatttattt ctacatcact gcccctgccg gcatcagtgt 60
caaataaagt aaaatgttat gttttat 87
<210>20
<211>32
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>20
gttttccata ctgattgccg caattgaatt gg 32
<210>21
<211>21
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>21
gtgggaggct gggagtgcga g 21
<210>22
<211>32
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>22
cctgaattct tagacgtgat accttgaagc ac 32
<210>23
<211>23
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>23
taaaaatctg gattgttggg ttg 23
<210>24
<211>23
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>24
atcatttgtc catccttcat ctg 23
<210>25
<211>19
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>25
gattgggaga ttcctgatg 19
<210>26
<211>21
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>26
cccgtggaca ggaaacgcac c 21
<210>27
<211>33
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>27
atcggatcct caaaatatta ctgatttgtg tgc 33
<210>28
<211>36
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>28
tagggatcct tagtggacag gaaacgcacc atatcc 36
<210>29
<211>285
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>29
atgccaacaa taaccactgc acaaattaaa agcacactgc agtctgcaaa gcaatccgct 60
gcaaataaat tgcactcagc aggacaaagc acgaaagatg cattagccta tggaagtcag 120
ggtgatctta atccattaat taatgaaatc agcaaaatca tttcagctgc aggtagcttc 180
gatgttaaag aggaaagaac tgcagcttct ttattgcagt tgtccggtaa tgccagtgat 240
ttttcatatg gacggaactc aataaccctg accacatcag cataa 285
<210>30
<211>2124
<212>DNA
<213>人工序列
<220>
<223>人DNA序列
<400>30
atggattctt gtcataaaat tgattatggg ttatacgccc tggagatttt agcccaatac 60
cataacgtct ctgttaaccc ggaagaaatt aaacatagat ttgatacaga cgggacaggt 120
ctgggattaa cgtcatggtt gcttgctgcg aaatctttag aactaaaggt aaaacaggta 180
aaaaaaacaa ttgatcgatt aaactttatt tttctgcccg cattagtctg gagagaggat 240
ggacgtcatt ttattctgac taaaatcagc aaagaagtaa acagatatct tatttttgat 300
ttggagcagc gaaatccccg tgttctcgaa cagtctgagt ttgaggcgtt atatcagggg 360
catattattc ttattacttc ccgttcttct gttaccggga aactggcaaa atttgacttt 420
acctggttta ttcctgccat tataaaatac aggagaatat ttattgaaac ccttgttgta 480
tctgtttttt tacaattatt tgcattaata accccccttt tttttcaggt ggttatggac 540
aaagtattag tgcacagggg gttttcaacc cttaatgtta ttactgttgc cttatctgtt 600
gtagtggtgt ttgagattat actcagcggt ttaagaactt acatttttgc acatagtaca 660
agtcggattg atgttgagtt gggtgccaaa ctcttccggc atttactggc gctaccgatc 720
tcttattttg agagtcgtcg tgttggtgat actgttgcga gggtaagaga attagaccag 780
atccgtaatt ttctgacagg acaggcatta acatctgttt tggacttatt attttcactc 840
atattttttg cggtaatgtg gtattacagc ccaaagctta ctctggtgat cttattttcg 900
ctgccttgtt atgctgcatg gtctgttttt attagcccca ttttgcgacg tcgccttgat 960
gataagtttt cacggaatgc ggataatcaa tctttcctgg tggaatcagt aacggcgatt 1020
aacactataa aagctatggc agtctcacct cagatgacga acatatggga caaacaattg 1080
gcaggatatg ttgctgcagg ctttaaagtg acagtattag caaccattgg tcaacaagga 1140
atacagttaa tacaaaagac tgttatgatc atcaacctat ggttgggagc acacctggtt 1200
atttccgggg atttaagtat tggtcagtta attgctttta atatgcttgc tggtcagatt 1260
gttgcaccgg ttattcgcct tgcacaaatc tggcaggatt tccagcaggt tggtatatca 1320
gttacccgcc ttggtgatgt gcttaactct ccaactgaaa gttatcatgg gaaactgaca 1380
ttgccggaaa ttaatggtga tatcactttt cgtaatatcc ggtttcgcta taaacctgat 1440
tctccggtta ttttggacaa tatcaatctt agtattaagc agggggaggt tattggtatt 1500
gtcggacgtt ctggttcagg aaaaagcaca ttaactaaat taattcaacg tttttatatt 1560
cctgaaaatg gccaggtatt aattgatgga catgatcttg cgttggccga tcctaactgg 1620
ttacgtcgtc aggtgggggt tgtgttgcag gacaatgtgc tgcttaatcg cagtattatt 1680
gataatattt cactggctaa tcctggcatg tccgtcgaaa aagttattta tgcagcgaaa 1740
ttagcaggtg ctcatgattt tatttctgaa ttgcgtgagg ggtataacac cattgtcggg 1800
gaacaggggg caggattatc cggaggtcaa cgtcaacgca tcgcaattgc aagggcgctg 1860
gtgaacaacc ctaaaatact catttttgat gaagcaacca gtgctctgga ttatgagtcg 1920
gagcatgtca tcatgcgcaa tatgcacaaa atatgtaagg gcagaacggt tataatcatt 1980
gctcatcgtc tgtctacagt aaaaaatgca gaccgcatta ttgtcatgga aaaagggaaa 2040
attgttgaac agggtaaaca taaggagctg ctttctgaac cggaaagttt atacagttac 2100
ttatatcagt tacagtcaga ctaa 2124
<210>31
<211>1437
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>31
atgaaaacat ggttaatggg gttcagcgag ttcctgttgc gctataaact tgtctggagt 60
gaaacatgga aaatccggaa gcaattagat actccggtac gtgaaaagga cgaaaatgaa 120
ttcttacccg ctcatctgga attaattgaa acgccagtat ccagacggcc gcgtctggtt 180
gcttatttta ttatggggtt tctggttatt gcttttattt tatctgtttt aggccaagtg 240
gaaattgttg ccactgcaaa tgggaaatta acacacagtg ggcgtagtaa agaaattaaa 300
cctattgaaa actcaatagt taaagaaatt atcgtaaaag aaggagagtc agtccggaaa 360
ggggatgtgt tattaaagct tacagcactg ggagctgaag ctgatacgtt aaaaacacag 420
tcatcactgt tacaggccag gctggaacaa actcggtatc aaattctgag caggtcaatt 480
gaattaaata aactacctga actaaagctt cctgatgagc cttattttca gaatgtatct 540
gaagaggaag tactgcgttt aacttctttg ataaaagaac agttttccac atggcaaaat 600
cagaagtatc aaaaagaact gaatttggat aagaaaagag cagagcgatt aacagtactt 660
gcccgtataa accgttatga aaatttatca agggttgaaa aaagccgtct ggatgatttc 720
agtagtttat tgcataaaca ggcaattgca aaacatgctg tacttgagca ggagaataaa 780
tatgtcgaag cagtaaatga attacgagtt tataaatcac aactggagca aattgagagt 840
gagatattgt ctgcaaaaga agaatatcag cttgttacgc agctttttaa aaatgaaatt 900
ttagataagc taagacaaac cacagacaac attgggttat taactctgga attagcgaaa 960
aatgaagagc gtcaacaggc ttcagtaatc agggccccag tttcggtaaa agttcagcaa 1020
ctgaaggttc atactgaagg tggggttgtt acaacagcgg aaacactgat ggtcatcgtt 1080
ccggaagatg acacgctgga ggttactgct ctggtacaaa ataaagatat tggttttatt 1140
aacgtcgggc agaatgccat cattaaagtg gaggcatttc cttatacacg atatggttat 1200
ctggtgggta aggtgaaaaa tataaattta gatgcaatag aagaccagag actgggactt 1260
gtttttaatg ttattatttc tattgaagag aattgtttgt caaccggaaa taaaaacatt 1320
ccattaagct cgggtatggc agtcactgca gaaataaaga caggtatgcg aagtgtaatc 1380
agttatcttc ttagtccttt agaagagtca gtaacagaaa gtttacgtga gcgttaa 1437
<210>32
<211>708
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>32
gtgggaggct gggagtgcga gaagcattcc caaccctggc aggtgcttgt ggcctctcgt 60
ggcagggcag tctgcggcgg tgttctggtg cacccccagt gggtcctcac agctgcccac 120
tgcatcagga acaaaagcgt gatcttgctg ggtcggcaca gcctgtttca tcctgaagac 180
acaggccagg tatttcaggt cagccacagc ttcccacacc cgctctacga tatgagcctc 240
ctgaagaatc gattcctcag gccaggtgat gactccagcc acgacctcat gctgctccgc 300
ctgtcagagc ctgccgagct cacggatgct gtgaaggtca tggacctgcc cacccaggag 360
ccagcactgg ggaccacctg ctacgcctca ggctggggca gcattgaacc agaggagttc 420
ttgaccccaa agaaacttca gtgtgtggac ctccatgtta tttccaatga cgtgtgtgcg 480
caagttcacc ctcagaaggt gaccaagttc atgctgtgtg ctggacgctg gacagggggc 540
aaaagcacct gctcgggtga ttctgggggc ccacttgtct gtaatggtgt gcttcaaggt 600
atcacgtcat ggggcagtga accatgtgcc ctgcccgaaa ggccttccct gtacaccaag 660
gtggtgcatt accggaagtg gatcaaggac accatcgtgg ccaacccc 708
<210>33
<211>291
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>33
cctcaaaata ttactgattt gtgtgcagaa taccacaaca cacaaatata tacgctaaat 60
gataagatat tttcgtatac agaatctcta gctggaaaaa gagagatggc tatcattact 120
tttaagaatg gtgcaatttt tcaagtagaa gtaccaggta gtcaacatat agattcacaa 180
aaaaaagcga ttgaaaggat gaaggatacc ctgaggattg catatcttac tgaagctaaa 240
gtcgaaaagt tatgtgtatg gaataataaa acgcctcatg cgattgccgc a 291
<210>34
<211>927
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>34
gatgattggg agattcctga tgggcagatt acagtgggac aaagaaaggg aaagtggcat 60
ggtgatgtgg cagtgaaaat gttgaatgtg acagcaccta cacctcagca gttacaagcc 120
ttcaaaaatg aagtaggagt actcaggaaa acacgacatg tgaatatcct actcttcatg 180
ggctattcca caaagccaca actggctatt gttacccagt ggtgtgaggg ctccagcttg 240
tatcaccatc tccatatcat tgagaccaaa tttgagatga tcaaacttat agatattgca 300
cgacagactg cacagggcat ggattactta cacgccaagt caatcatcca cagagacctc 360
aagagtaata atatatttct tcatgaagac ctcacagtaa aaataggtga ttttggtcta 420
gctacagaga aatctcgatg gagtgggtcc catcagtttg aacagttgtc tggatccatt 480
ttgtggatgg caccagaagt catcagaatg caagataaaa atccatacag ctttcagtca 540
gatgtatatg catttgggat tgttctgtat gaattgatga ctggacagtt accttattca 600
aacatcaaca acagggacca gataattttt atggtgggac gaggatacct gtctccagat 660
ctcagtaagg tacggagtaa ctgtccaaaa gccatgaaga gattaatggc agagtgcctc 720
aaaaagaaaa gagatgagag accactcttt ccccaaattc tcgcctctat tgagctgctg 780
gcccgctcat tgccaaaaat tcaccgcagt gcatcagaac cctccttgaa tcgggctggt 840
ttccaaacag aggattttag tctatatgct tgtgcttctc caaaaacacc catccaggca 900
gggggatatg gtgcgtttcc tgtccac 927
<210>35
<211>92
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>35
cgattttggc ctggcgaccg aaaaagcggg cgattttggc ctggcgaccg aaaaagcggg 60
cgattttggc ctggcgaccg aaaaagcggg gc 92
<210>36
<211>1302
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>36
atgccaacaa taaccactgc acaaattaaa agcacactgc agtctgcaaa gcaatccgct 60
gcaaataaat tgcactcagc aggacaaagc acgaaagatg catcacctca aaatattact 120
gatttgtgtg cagaatacca caacacacaa atatatacgc taaatgataa gatattttcg 180
tatacagaat ctctagctgg aaaaagagag atggctatca ttacttttaa gaatggtgca 240
atttttcaag tagaagtacc aggtagtcaa catatagatt cacaaaaaaa agcgattgaa 300
aggatgaagg ataccctgag gattgcatat cttactgaag ctaaagtcga aaagttatgt 360
gtatggaata ataaaacgcc tcatgcgatt gccgcaatgc ccgtgggagg ctgggagtgc 420
gagaagcatt cccaaccctg gcaggtgctt gtggcctctc gtggcagggc agtctgcggc 480
ggtgttctgg tgcaccccca gtgggtcctc acagctgccc actgcatcag gaacaaaagc 540
gtgatcttgc tgggtcggca cagcctgttt catcctgaag acacaggcca ggtatttcag 600
gtcagccaca gcttcccaca cccgctctac gatatgagcc tcctgaagaa tcgattcctc 660
aggccaggtg atgactccag ccacgacctc atgctgctcc gcctgtcaga gcctgccgag 720
ctcacggatg ctgtgaaggt catggacctg cccacccagg agccagcact ggggaccacc 780
tgctacgcct caggctgggg cagcattgaa ccagaggagt tcttgacccc aaagaaactt 840
cagtgtgtgg acctccatgt tatttccaat gacgtgtgtg cgcaagttca ccctcagaag 900
gtgaccaagt tcatgctgtg tgctggacgc tggacagggg gcaaaagcac ctgctcgggt 960
gattctgggg gcccacttgt ctgtaatggt gtgcttcaag gtatcacgtc atggggcagt 1020
gaaccatgtg ccctgcccga aaggccttcc ctgtacacca aggtggtgca ttaccggaag 1080
tggatcaagg acaccatcgt ggccaacccc gggcatgcat tagcctatgg aagtcagggt 1140
gatcttaatc cattaattaa tgaaatcagc aaaatcattt cagctgcagg tagcttcgat 1200
gttaaagagg aaagaactgc agcttcttta ttgcagttgt ccggtaatgc cagtgatttt 1260
tcatatggac ggaactcaat aaccctgacc acatcagcat aa 1302
<210>37
<211>684
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>37
atgacaacaa taaccactgc acaaattaaa agcacactgc agtctgcaaa gcaatccgct 60
gcaaataaat tgcactcagc aggacaaagc acgaaagatg catcacctca aaatattact 120
gatttgtgtg cagaatacca caacacacaa atacatacgc taaatgataa gatattttcg 180
tatacagaat ctctagctgg aaaaagagag atggctatca ttacttttaa gaatggtgca 240
acttttcaag tagaagtacc aggtagtcaa catatagatt cacaaaaaaa agcgattgaa 300
aggatgaagg ataccctgag gattgcatat cttactgaag ctaaagtcga aaagttatgt 360
gtatggaata ataaaacgcc tcatgcgatt gccgcaatgc ccggcgattt tggcctggcg 420
accgaaaaag cgggcgattt tggcctggcg accgaaaaag cgggcgattt tggcctggcg 480
accgaaaaag cggggcatgc attagcctat ggaagtcagg gtgatcttaa tccattaatt 540
aatgaaatca gcaaaatcat ttcagctgca ggtagcttcg atgttaaaga ggaaagaact 600
gcagcttctt tattgcagtt gtccggtaat gccagtgatt tttcatatgg acggaactca 660
ataaccctga ccacatcagc ataa 684
<210>38
<211>1521
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>38
atgccaacaa taaccactgc acaaattaaa agcacactgc agtctgcaaa gcaatccgct 60
gcaaataaat tgcactcagc aggacaaagc acgaaagatg catcacctca aaatattact 120
gatttgtgtg cagaatacca caacacacaa atatatacgc taaatgataa gatattttcg 180
tatacagaat ctctagctgg aaaaagagag atggctatca ttacttttaa gaatggtgca 240
atttttcaag tagaagtacc aggtagtcaa catatagatt cacaaaaaaa agcgattgaa 300
aggatgaagg ataccctgag gattgcatat cttactgaag ctaaagtcga aaagttatgt 360
gtatggaata ataaaacgcc tcatgcgatt gccgcaatgc ccgatgattg ggagattcct 420
gatgggcaga ttacagtggg acaaagaaag ggaaagtggc atggtgatgt ggcagtgaaa 480
atgttgaatg tgacagcacc tacacctcag cagttacaag ccttcaaaaa tgaagtagga 540
gtactcagga aaacacgaca tgtgaatatc ctactcttca tgggctattc cacaaagcca 600
caactggcta ttgttaccca gtggtgtgag ggctccagct tgtatcacca tctccatatc 660
attgagacca aatttgagat gatcaaactt atagatattg cacgacagac tgcacagggc 720
atggattact tacacgccaa gtcaatcatc cacagagacc tcaagagtaa taatatattt 780
cttcatgaag acctcacagt aaaaataggt gattttggtc tagctacaga gaaatctcga 840
tggagtgggt cccatcagtt tgaacagttg tctggatcca ttttgtggat ggcaccagaa 900
gtcatcagaa tgcaagataa aaatccatac agctttcagt cagatgtata tgcatttggg 960
attgttctgt atgaattgat gactggacag ttaccttatt caaacatcaa caacagggac 1020
cagataattt ttatggtggg acgaggatac ctgtctccag atctcagtaa ggtacggagt 1080
aactgtccaa aagccatgaa gagattaatg gcagagtgcc tcaaaaagaa aagagatgag 1140
agaccactct ttccccaaat tctcgcctct attgagctgc tggcccgctc attgccaaaa 1200
attcaccgca gtgcatcaga accctccttg aatcgggctg gtttccaaac agaggatttt 1260
agtctatatg cttgtgcttc tccaaaaaca cccatccagg cagggggata tggtgcgttt 1320
cctgtccacg ggcatgcatt agcctatgga agtcagggtg atcttaatcc attaattaat 1380
gaaatcagca aaatcatttc agctgcaggt agcttcgatg ttaaagagga aagaactgca 1440
gcttctttat tgcagttgtc cggtaatgcc agtgattttt catatggacg gaactcaata 1500
accctgacca catcagcata a 1521
<210>39
<211>2169
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>39
atgacaacaa taaccactgc acaaattaaa agcacactgc agtctgcaaa gcaatccgct 60
gcaaataaat tgcactcagc aggacaaagc acgaaagatg catcacctca aaatattact 120
gatttgtgtg cagaatacca caacacacaa atacatacgc taaatgataa gatattttcg 180
tatacagaat ctctagctgg aaaaagagag atggctatca ttacttttaa gaatggtgca 240
acttttcaag tagaagtacc aggtagtcaa catatagatt cacaaaaaaa agcgattgaa 300
aggatgaagg ataccctgag gattgcatat cttactgaag ctaaagtcga aaagttatgt 360
gtatggaata ataaaacgcc tcatgcgatt gccgcaatgc ccatctgtca aatggagaaa 420
atagtgcttc tttttgcaat agtcagtctt gttaaaagtg atcagatttg cattggttac 480
catgcaaaca actcgacaga gcaggttgac acaataatgg aaaagaacgt tactgttaca 540
catgcccaag acatactgga aaagacacac aacgggaagc tctgcgatct agatggagtg 600
aagcctctaa ttttgagaga ttgtagtgta gctggatggc tcctcggaaa cccaatgtgt 660
gacgaattca tcaatgtgcc ggaatggtcc tacatagtgg agaaggccaa tccagtcaat 720
gacctctgtt acccagggga tttcaatgac tatgaagaat tgaaacacct attgagcaga 780
ataaaccatt ttgagaaaat tcagatcatc cccaaaagtt cttggtccag tcatgaagcc 840
tcattagggg tgagctcagc atgtccatac cagagaaagt cctccttttt cagaaatgtg 900
gtatggctta tcaaaaagaa cagtacatac ccaacaataa agaggagcta caataatacc 960
aaccaagaag atcttttggt actgtggggg attcaccatc ctaatgatgc ggcagagcag 1020
acaaagctct atcaaaaccc aaccacctat atttccgttg ggacatcaac actaaaccag 1080
agattggtac caagaatagc tactagatcc aaagtaaacg ggcaaagtgg aaggatggag 1140
ttcttctgga caattttaaa accgaatgat gcaatcaact tcgagagtaa tggaaatttc 1200
attgctccag aatatgcata caaaattgtc aagaaagggg actcaacaat tatgaaaagt 1260
gaattggaat atggtaactg caacaccaag tgtcaaactc caatgggggc gataaactct 1320
agtatgccat tccacaatat acaccctctc accatcgggg aatgccccaa atatgtgaaa 1380
tcaaacagat tagtccttgc gactgggctc agaaatagcc ctcaaagaga gagaagaaga 1440
aaaaagagag gattatttgg agctatagca ggttttatag agggaggatg gcagggaatg 1500
gtagatggtt ggtatgggta ccaccatagc aatgagcagg ggagtgggta cgctgcagac 1560
aaagaatcca ctcaaaaggc aatagatgga gtcaccaata aggtcaactc gatcattgac 1620
aaaatgaaca ctcagtttga ggccgttgga agggaattta acaacttaga aaggagaata 1680
gagaatttaa acaagaagat ggaagacggg ttcctagatg tctggactta taatgctgaa 1740
cttctggttc tcatggaaaa tgagagaact ctagactttc atgactcaaa tgtcaagaac 1800
ctttacgaca aggtccgact acagcttagg gataatgcaa aggaactggg taacggttgt 1860
ttcgagttct atcataaatg tgataatgaa tgtatggaaa gtgtaagaaa cggaacgtat 1920
gactacccgc agtattcaga agaagcaaga ctaaaaagag aggaaataag tggagtaggg 1980
catgcattag cctatggaag tcagggtgat cttaatccat taattaatga aatcagcaaa 2040
atcatttcag ctgcaggtag cttcgatgtt aaagaggaaa gaactgcagc ttctttattg 2100
cagttgtccg gtaatgccag tgatttttca tatggacgga actcaataac cctgaccaca 2160
tcagcataa 2169
<210>40
<211>12672
<212>DNA
<213>人工序列
<220>
<223>人工DNA序列
<400>40
gaattccaag cgaagtccat ccccctccct cttgattaca agggtgataa ttattattcg 60
catttgtgtg gtaatgggat agaaaggaat ggatagaaaa agaacaaaat tagtatagca 120
atagatatgc ccactgcatt gaatacttac agggcattat tttattatgt ttaaattgaa 180
gtggtctctg gtttgattta tttgttattc aagggggctg tttggagatc ggaaaattct 240
gtacgttaag tgtattattt aaccagtttc gatgcgtaac agattgattt tgcgtcagcg 300
gttatcgctt ttaagttgtt gctcttgcgc tatcgcgttt aggttatccg attaaagtca 360
aatttcctga aaatgctgta tagcgcggga gtgcacctta tagctgtagg taagtatgtt 420
caaaaaatag tcttgccgta caataatttt ccatatccaa actcactcct tcaagattct 480
ggtcccggtt tacgggtagt ttccggaagg gcggtagcat gctgattcaa actgcaagat 540
gaaacattgt cggagttgga tggaattaag tcatggctat agcatttggg cgtgcataac 600
aaaattggtc ctcatatttt agagtatgat tgcatattca ctaatatttt tactttctga 660
tgcgtggtgg catcatgctt tatgagataa acaatcctgg tagactagcc ccctgaatct 720
ccagacaacc aatatcactt atttaagtga tagtcttaat actagttttt agactagtca 780
ttggagaaca gatgattgat gtcttaggat cggagaaacg cagacggcgt actacacagg 840
aaaagatcgc tatcgttcag cagagctttg aaccgggaat gacggtctcc cttgttgccc 900
ggcaacatgg tgtggcagcc agccagctat ttctctggcg caagcaatac caggagggaa 960
gtcttactgc tgtggctgcc ggagaacagg tcgttcctgc ctctgaactt gctgccgcca 1020
tgaagcagat taaagagctc cagcgcctgc tcggcaaaaa aacgatggaa aatgaactcc 1080
ttaaagaagc cgttgaatat gggcgagcaa aaaagtggat agcgcacgcg cccttattgc 1140
ccggggatgg ggagtaagct tcgtcagccg ttgtctccgg gtgtcgcgtg cgcagttgca 1200
cgtcattctc agacgaaccg atgactggaa ggacggccgc cgcagccgtc acacggatga 1260
tacggatgtg cttcgccgta tacatcatgt tatcggagag ctgcccacat atggttatcg 1320
tcgggtatgg gcgctgcttc gcagacaaac agaacttgat ggtatgcctg cgatcaatgc 1380
caaatgtgtt taccggatca tgtgccagaa tgcgctgttg cttgagcgaa aacccgctgt 1440
accgccatcg aaacgggcac ataccggcag agtggctgtg aaagaaagta atcagcgatg 1500
gtgctctgac gggtttgagt tccgctgtga taacggagaa aaactgcggg tcacgttcgc 1560
gctggactgc tgtgatcgtg aggcactgca ctgggcggtc acaacgggtg gcttcaacag 1620
tgaaacagta caggacgtca tgctgggagc agtggaacgc cgctttggca gcgagcttcc 1680
ggcgtctcca gtggagtggc tgacggataa tggttcatgc taccgggcga atgaaacacg 1740
tcagttcgcc aggatgttgg gacttgaacc gaagaacacg gcagtgcgga gtccggagag 1800
taacggaata acagagagct tcgtgaaaac gataaagcgt gattacataa gtatcatgcc 1860
caaaccagac gggttaacgg cagcaaagaa ccttgcagag gcgttcgagc attataacga 1920
atggcatccg catagtgcgc tgggttatcg ctcgccacgg gaatatctgc ggcagcgggc 1980
cagtaatggg ttaagtgata acaggtatct ggaaatatag gggcaaatcc acctggtcat 2040
tatctggaat ttgacgaagt gtgataactg gtatagccag attaatctaa acctttgtct 2100
gacaaaatca gataaagaag agtagttcaa aagacaactc gtggactctc attcagagag 2160
ataggcgtta ccaaaatttg tttggaactg aacaagaaaa ttgtatttgt gtaactataa 2220
tcttaatgta aaataaaaga caccagttct gtagaatatg cttattgaag agagtgtaat 2280
aataatttta tatagatgtt gtacaaagaa caggaatgag taattattta tgcttgatgt 2340
tttttgactc ttgcttttta tagttattat ttttaagtta gtcagcgcaa taaaaacttg 2400
cttttaatat taatgcgagt tatgacatta aacggaagaa acataaaggc atatttttgc 2460
cacaatattt aatcatataa tttaagttgt agtgagttta ttatgaatat aaacaaacca 2520
ttagagattc ttgggcatgt atcctggcta tgggccagtt ctccactaca cagaaactgg 2580
ccagtatctt tgtttgcaat aaatgtatta cccgcaatac aggctaacca atatgtttta 2640
ttaacccggg atgattaccc tgtcgcgtat tgtagttggg ctaatttaag tttagaaaat 2700
gaaattaaat atcttaatga tgttacctca ttagttgcag aagactggac ttcaggtgat 2760
cgtaaatggt tcattgactg gattgctcct ttcggggata acggtgccct gtacaaatat 2820
atgcgaaaaa aattccctga tgaactattc agagccatca gggtggatcc caaaactcat 2880
gttggtaaag tatcagaatt tcatggaggt aaaattgata aacagttagc gaataaaatt 2940
tttaaacaat atcaccacga gttaataact gaagtaaaaa gaaagtcaga ttttaatttt 3000
tcattaactg gttaagaggt aattaaatgc caacaataac cactgcacaa attaaaagca 3060
cactgcagtc tgcaaagcaa tccgctgcaa ataaattgca ctcagcagga caaagcacga 3120
aagatgcatt agcctatgga agtcagggtg atcttaatcc attaattaat gaaatcagca 3180
aaatcatttc agctgcaggt agcttcgatg ttaaagagga aagaactgca gcttctttat 3240
tgcagttgtc cggtaatgcc agtgattttt catatggacg gaactcaata accctgacca 3300
catcagcata atatattaat ttaaatgata gcaatcttac tgggctgtgc cacataagat 3360
tgctattttt tttggagtca taatggattc ttgtcataaa attgattatg ggttatacgc 3420
cctggagatt ttagcccaat accataacgt ctctgttaac ccggaagaaa ttaaacatag 3480
atttgataca gacgggacag gtctgggatt aacgtcatgg ttgcttgctg cgaaatcttt 3540
agaactaaag gtaaaacagg taaaaaaaac aattgatcga ttaaacttta tttttctgcc 3600
cgcattagtc tggagagagg atggacgtca ttttattctg actaaaatca gcaaagaagt 3660
aaacagatat cttatttttg atttggagca gcgaaatccc cgtgttctcg aacagtctga 3720
gtttgaggcg ttatatcagg ggcatattat tcttattact tcccgttctt ctgttaccgg 3780
gaaactggca aaatttgact ttacctggtt tattcctgcc attataaaat acaggagaat 3840
atttattgaa acccttgttg tatctgtttt tttacaatta tttgcattaa taacccccct 3900
ttttttccag gtggttatgg acaaagtatt agtgcacagg gggttttcaa cccttaatgt 3960
tattactgtt gcattatctg ttgtagtggt gtttgagatt atactcagcg gtttaagaac 4020
ttacattttt gcacatagta caagtcggat tgatgttgag ttgggtgcca aactcttccg 4080
gcatttactg gcgctaccga tctcttattt tgagagtcgt cgtgttggtg atactgttgc 4140
gagggtaaga gaattagacc agatccgtaa ttttctgaca ggacaggcat taacatctgt 4200
tttggactta ttattttcac tcatattttt tgcggtaatg tggtattaca gcccaaagct 4260
tactctggtg atcttatttt cgctgccttg ttatgctgca tggtctgttt ttattagccc 4320
cattttgcga cgtcgccttg atgataagtt ttcacggaat gcggataatc aatctttcct 4380
ggtggaatca gtaacggcga ttaacactat aaaagctatg gcagtctcac ctcagatgac 4440
gaacatatgg gacaaacaat tggcaggata tgttgctgca ggctttaaag tgacagtatt 4500
agcaaccatt ggtcaacaag gaatacagtt aatacaaaag actgttatga tcatcaacct 4560
atggttggga gcacacctgg ttatttccgg ggatttaagt attggtcagt taattgcttt 4620
taatatgctt gctggtcaga ttgttgcacc ggttattcgc cttgcacaaa tctggcagga 4680
tttccagcag gttggtatat cagttacccg ccttggtgat gtgcttaact ctccaactga 4740
aagttatcat gggaaactga cattgccgga aattaatggt gatatcactt ttcgtaatat 4800
ccggtttcgc tataaacctg attctccggt tattttggac aatatcaatc ttagtattaa 4860
gcagggggag gttattggta ttgtcggacg ttctggttca ggaaaaagca cattaactaa 4920
attaattcaa cgtttttata ttcctgaaaa tggccaggta ttaattgatg gacatgatct 4980
tgcgttggct gatcctaact ggttacgtcg tcaggtgggg gttgtgttgc aggacaatgt 5040
gctgcttaat cgcagtatta ttgataatat ttcactggct aatcctggca tgtccgtcga 5100
aaaagttatt tatgcagcga aattagcagg cgctcatgat tttatttctg atttgcgtga 5160
ggggtataac accattgtcg gggaacaggg ggcaggatta tccggaggtc aacgtcaacg 5220
catcgcaatt gcaagggcgc tggtgaacaa ccctaaaata ctcatttttg atgaagcaac 5280
cagtgctctg gattatgagt cggagcatgt catcatgcgc aatatgcaca aaatatgtaa 5340
gggcagaacg gttataatca ttgctcatcg tctgtctaca gtaaaaaatg cagaccgcat 5400
tattgtcatg gaaaaaggga aaattgttga acagggtaaa cataaggagc tgctttctga 5460
accggaaagt ttatacagtt acttatatca gttacagtca gactaacaga aagaacagaa 5520
gaatatgaaa acatggttaa tggggttcag cgagttcctg ttgcgctata aacttgtctg 5580
gagtgaaaca tggaaaatcc ggaagcaatt agatactccg gtacgtgaaa aggacgaaaa 5640
tgaattctta cccgctcatc tggaattaat tgaaacgcca gtatccagac ggccgcgtct 5700
ggttgcttat tttattatgg ggtttctggt tattgctttt attttatctg ttttaggcca 5760
agtggaaatt gttgccactg caaatgggaa attaacacac agtgggcgta gtaaagaaat 5820
taaacctatt gaaaactcaa tagttaaaga aattatcgta aaagaaggag agtcagtccg 5880
gaaaggggat gtgttattaa agcttacagc actgggagct gaagctgata cgttaaaaac 5940
acagtcatca ctgttacagg ccaggctgga acaaactcgg tatcaaattc tgagcaggtc 6000
aattgaatta aataaactac ctgaactaaa gcttcctgat gagccttatt ttcagaatgt 6060
atctgaagag gaagtactgc gtttaacttc tttgataaaa gaacagtttt ccacatggca 6120
aaatcagaag tatcaaaaag aactgaattt ggataagaaa agagcagagc gattaacagt 6180
acttgcccgt ataaaccgtt atgaaaattt atcaagggtt gaaaaaagcc gtctggatga 6240
tttcagtagt ttattgcata aacaggcaat tgcaaaacat gctgtacttg agcaggagaa 6300
taaatatgtc gaagcagtaa atgaattacg agtttataaa tcacaactgg agcaaattga 6360
gagtgagata ttgtctgcaa aagaagaata tcagcttgtt acgcagcttt ttaaaaatga 6420
aattttagat aagctaagac aaacaacaga caacattggg ttattaactc tggaattagc 6480
gaaaaatgaa gagcgtcaac aggcttcagt aatcagggcc ccagtttcgg gaaaagttca 6540
gcaactgaag gttcatactg aaggtggggt tgttacaaca gcggaaacac tgatggtcat 6600
cgttccggaa gatgacacgc tggaggttac tgctctggta caaaataaag atattggttt 6660
tattaacgtc gggcagaatg ccatcattaa agtggaggca tttccttata cacgatatgg 6720
ttatctggtg ggtaaggtga aaaatataaa tttagatgca atagaagacc agagactggg 6780
acttgttttt aatgttatta tttctattga agagaattgt ttgtcaaccg ggaataaaaa 6840
cattccatta agctcgggta tggcagtcac tgcagaaata aagacaggta tgcgaagtgt 6900
aatcagttat cttcttagtc ctttagaaga gtcagtaaca gaaagtttac gtgagcgtta 6960
agtttcagaa gtccagtatt tgctgctata cgtgctgcgt ggcacttgcc gtctgaacgg 7020
cattgatccg gaagccaagt caaacaacag cgtgatgagc gtcagggcaa aacaccaagg 7080
ctctctcgat gacaccagaa caaattgaaa tacgtgagct gaggaaaaag ctaccgagtt 7140
cttgatgttg gactccctga acagttctct gtaatcggga aactcaggac gcgttatcct 7200
gtggtcacac tctgccatgt gtttagggtt catcacagca gctacagata ctggtaaaac 7260
cgtcctgaaa aaccagacgg cagacgggct gtattacgta gtcaggtact tgagctacat 7320
ggcatcagtc acggtttggc cggagcaaga cgtatcacca caatggcaac ccggagaggt 7380
gtcagcgcca gtgatataag acggttaacg gttaaaaatc gtggcgttga caacatccca 7440
gtggactgag gtcacacagg cctggcagca ttcctcttcc ggccggatga cccggatttc 7500
acggggaaag tacgccgata acagtttacg ggctgaagat tggcgtaggg aggatagcag 7560
acgttttgcc gcccccattg tctggagttg ggtgagaagg catcatttca ccaacaccaa 7620
catttcacag ttacacccca cagctacatg aagcgcttcc atgaattatc gctttgattt 7680
atcatgttaa aatagctcta cacggttggt tcaggattgc gcaccgaaac cctctaaaat 7740
ccactgacgc gcctgcgaat tatccagcac cgcgcctttc gagatcctct acgccggacg 7800
catcgtggcc ggcatcaccg gcgccacagg tgcggttgct ggcgcctata tcgccgacat 7860
caccgatggg gaagatcggg ctcgccactt cgggctcatg agcgcttgtt tcggcgtggg 7920
tatggtggca ggccccgtgg ccgggggact gttgggcgcc atctccttgc atgcaccatt 7980
ccttgcggcg gcggtgctca acggcctcaa cctactactg ggctgcttcc taatgcagga 8040
gtcgcataag ggagagcgtc gaccgatgcc cttgagagcc ttcaacccag tcagctcctt 8100
ccggtgggcg cggggcatga ctatcgtcgc cgcacttatg actgtcttct ttatcatgca 8160
actcgtagga caggtgccgg cagcgctctg ggtcattttc ggcgaggacc gctttcgctg 8220
gagcgcgacg atgatcggcc tgtcgcttgc ggtattcgga atcttgcacg ccctcgctca 8280
agccttcgtc actggtcccg ccaccaaacg tttcggcgag aagcaggcca ttatcgccgg 8340
catggcggcc gacgcgctgg gctacgtctt gctggcgttc gcgacgcgag gctggatggc 8400
cttccccatt atgattcttc tcgcttccgg cggcatcggg atgcccgcgt tgcaggccat 8460
gctgtccagg caggtagatg acgaccatca gggacagctt caaggatcgc tcgcggctct 8520
taccagccta acttcgatca ttggaccgct gatcgtcacg gcgatttatg ccgcctcggc 8580
gagcacatgg aacgggttgg catggattgt aggcgccgcc ctataccttg tctgcctccc 8640
cgcgttgcgt cgcggtgcat ggagccgggc cacctcgacc tgaatggaag ccggcggcac 8700
ctcgctaacg gattcaccac tccaagaatt ggagccaatc aattcttgcg gagaactgtg 8760
aatgcgcaaa ccaacccttg gcagaacata tccatcgcgt ccgccatctc cagcagccgc 8820
acgcggcgca tctcgggcag cgttgggtcc tggccacggg tgcgcatgat cgtgctcctg 8880
tcgttgagga cccggctagg ctggcggggt tgccttactg gttagcagaa tgaatcaccg 8940
atacgcgagc gaacgtgaag cgactgctgc tgcaaaacgt ctgcgacctg agcaacaaca 9000
tgaatggtct tcggtttccg tgtttcgtaa agtctggaaa cgcggaagtc agcgccctgc 9060
accattatgt tccggatctg catcgcagga tgctgctggc taccctgtgg aacacctaca 9120
tctgtattaa cgaagcgctg gcattgaccc tgagtgattt ttctctggtc ccgccgcatc 9180
cataccgcca gttgtttacc ctcacaacgt tccagtaacc gggcatgttc atcatcagta 9240
acccgtatcg tgagcatcct ctctcgtttc atcggtatca ttacccccat gaacagaaat 9300
cccccttaca cggaggcatc agtgaccaaa caggaaaaaa ccgcccttaa catggcccgc 9360
tttatcagaa gccagacatt aacgcttctg gagaaactca acgagctgga cgcggatgaa 9420
caggcagaca tctgtgaatc gcttcacgac cacgctgatg agctttaccg cagctgcctc 9480
gcgcgtttcg gtgatgacgg tgaaaacctc tgacacatgc agctcccgga gacggtcaca 9540
gcttgtctgt aagcggatgc cgggagcaga caagcccgtc agggcgcgtc agcgggtgtt 9600
ggcgggtgtc ggggcgcagc catgacccag tcacgtagcg atagcggagt gtatactggc 9660
ttaactatgc ggcatcagag cagattgtac tgagagtgca ccatatgcgg tgtgaaatac 9720
cgcacagatg cgtaaggaga aaataccgca tcaggcgctc ttccgcttcc tcgctcactg 9780
actcgctgcg ctcggtcgtt cggctgcggc gagcggtatc agctcactca aaggcggtaa 9840
tacggttatc cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc 9900
aaaaggccag gaaccgtaaa aaggccgcgt tgctggcgtt tttccatagg ctccgccccc 9960
ctgacgagca tcacaaaaat cgacgctcaa gtcagaggtg gcgaaacccg acaggactat 10020
aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc 10080
cgcttaccgg atacctgtcc gcctttctcc cttcgggaag cgtggcgctt tctcatagct 10140
cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg 10200
aaccccccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc 10260
cggtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga 10320
ggtatgtagg cggtgctaca gagttcttga agtggtggcc taactacggc tacactagaa 10380
ggacagtatt tggtatctgc gctctgctga agccagttac cttcggaaaa agagttggta 10440
gctcttgatc cggcaaacaa accaccgctg gtagcggtgg tttttttgtt tgcaagcagc 10500
agattacgcg cagaaaaaaa ggatctcaag aagatccttt gatcttttct acggggtctg 10560
acgctcagtg gaacgaaaac tcacgttaag ggattttggt catgagatta tcaaaaagga 10620
tcttcaccta gatcctttta aattaaaaat gaagttttaa atcaatctaa agtatatatg 10680
agtaaacttg gtctgacagt taccaatgct taatcagtga ggcacctatc tcagcgatct 10740
gtctatttcg ttcatccata gttgcctgac tccccatatg aatatcctcc ttagttccta 10800
ttccgaagtt cctattctct agaaagtata ggaacttcag agcgcttttg aagctggggt 10860
gggcgaagaa ctccagcatg agatccccgc gctggaggat catccagccg gcgtcccgga 10920
aaacgattcc gaagcccaac ctttcataga aggcggcggt ggaatcgaaa tctcgtgatg 10980
gcaggttggg cgtcgcttgg tcggtcattt cgaaccccag agtcccgctc agaagaactc 11040
gtcaagaagg cgatagaagg cgatgcgctg cgaatcggga gcggcgatac cgtaaagcac 11100
gaggaagcgg tcagcccatt cgccgccaag ctcttcagca atatcacggg tagccaacgc 11160
tatgtcctga tagcggtccg ccacacccag ccggccacag tcgatgaatc cagaaaagcg 11220
gccattttcc accatgatat tcggcaagca ggcatcgcca tgggtcacga cgagatcctc 11280
gccgtcgggc atgcgcgcct tgagcctggc gaacagttcg gctggcgcga gcccctgatg 11340
ctcttcgtcc agatcatcct gatcgacaag accggcttcc atccgagtac gtgctcgctc 11400
gatgcgatgt ttcgcttggt ggtcgaatgg gcaggtagcc ggatcaagcg tatgcagccg 11460
ccgcattgca tcagccatga tggatacttt ctcggcagga gcaaggtgag atgacaggag 11520
atcctgcccc ggcacttcgc ccaatagcag ccagtccctt cccgcttcag tgacaacgtc 11580
gagcacagct gcgcaaggaa cgcccgtcgt ggccagccac gatagccgcg ctgcctcgtc 11640
ctgcagttca ttcagggcac cggacaggtc ggtcttgaca aaaagaaccg ggcgcccctg 11700
cgctgacagc cggaacacgg cggcatcaga gcagccgatt gtctgttgtg cccagtcata 11760
gccgaatagc ctctccaccc aagcggccgg agaacctgcg tgcaatccat cttgttcaat 11820
catgcgaaac gatcctcatc ctgtctcttg atcagatctt gatcccctgc gccatcagat 11880
ccttggcggc aagaaagcca tccagtttac tttgcagggc ttcccaacct taccagaggg 11940
cgccccagct ggcaattccg gttcgcttgc tgtccataaa accgcccagt ctagctatcg 12000
ccatgtaagc ccactgcaag ctacctgctt tctctttgcg cttgcgtttt cccttgtcca 12060
gatagcccag tagctgacat tcatccgggg tcagcaccgt ttctgcggac tggctttcta 12120
cgtgttccgc ttcctttagc agcccttgcg ccctgagtgc ttgcggcagc gtgggggatc 12180
ttgaagttcc tattccgaag ttcctattct ctagaaagta taggaacttc gaagcagctc 12240
cagcctacac caaaaaaggg aataagggcg acacggaaat gttgaatact catactcttc 12300
ctttttcaat attattgaag catttatcag ggttattgtc tcatgagcgg atacatattt 12360
gaatgtattt agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcca 12420
cctgacgtct aagaaaccat tattatcatg acattaacct ataaaaatag gcgtatcacg 12480
aggccctttc gtcttcaaga attctcatgt ttgacagctt atcatcgatg gacattattt 12540
ttgtggagcc ggaggaaaca gaccagacgg ttcagatgag gcgcttacca ccagaaccgc 12600
tgttgtccca ccattctggc gattcccaaa cgctatttgg ataaaaagta gccttaacgt 12660
ggtttatttt cc 12672
Claims (20)
1.作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物,其包含下列组分:
(I)编码至少一个野生型或突变的蛋白的至少一个完整或部分抗原的至少一个核苷酸序列;和
(II)编码至少一个蛋白毒素和/或至少一个蛋白毒素亚基的至少一个核苷酸序列;和
(III)a)编码至少一个转运系统的至少一个核苷酸序列,所述的转运系统使得能够在微生物的外表面上表达组分(I)和组分(II)的表达产物和/或使得能够分泌组分(I)和组分(II)的表达产物;和/或编码使得能够分泌组分(I)和组分(II)的表达产物的至少一个信号序列的至少一个核苷酸序列;和/或
b)任选地,编码用于裂解哺乳动物细胞的胞质溶胶中的微生物且用于细胞内释放包含在裂解的微生物中的质粒或表达载体的至少一个蛋白的至少一个核苷酸序列;和
(IV)用于表达组分(I)至(III)的一个或多个的至少一个活化序列的至少一个核苷酸序列,其中所述的活化序列能够在微生物中活化和/或是组织细胞特异性的,肿瘤细胞特异性的,巨噬细胞特异性的,树突特异性的,淋巴细胞特异性的,功能特异性的或非细胞特异性的;
其中组分(I)至(IV)的任何一个能够以一倍或几倍存在并且如果组分(I)至(IV)的组分以几倍存在,则其相互独立地可以是相同的或不同的。
2.根据权利要求1的微生物,其中组分(I)和组分(II)不相同,即组分(I)不编码编码至少一个蛋白毒素和/或至少一个蛋白毒素亚基的至少一个核苷酸序列。
3.根据权利要求1至2中任一项的微生物,其中所述微生物选自“细菌,革兰氏阳性菌,革兰氏阴性菌,真核细胞”并且优选选自“埃希氏菌属的种,大肠杆菌,沙门氏菌属的种,伤寒沙门氏菌,鼠伤寒沙门氏菌,耶尔森氏菌属的种,小肠结肠炎耶尔森氏菌,弧菌属的种,霍乱弧菌,利斯特氏菌属的种,单核细胞增生利斯特氏菌,志贺氏菌属的种,弗氏志贺氏菌,耶尔森氏菌属的种,假单胞菌属的种”,其中优选微生物的毒力被减弱。
4.根据权利要求3的微生物,其中霍乱弧菌排除在所述微生物之外。
5.根据权利要求1至4中任一项的微生物,其中根据组分(I)的至少一个野生型或突变蛋白的至少一个完整或部分抗原选自下列野生型蛋白和它们已知的突变体:“受体;受体的胞外,跨膜或胞内部分;黏着分子;黏着分子的胞外,跨膜或胞内部分;信号转导蛋白;细胞周期蛋白;转录因子;分化蛋白;胚胎蛋白;病毒蛋白;过敏原;微生物病原体蛋白;真核病原体蛋白;癌-睾丸抗原蛋白;肿瘤抗原蛋白;和/或组织细胞特异性蛋白”,其中所述组织细胞选自“甲状腺,乳腺,唾液腺,淋巴结,乳腺,胃粘膜,肾,卵巢,前列腺,宫颈,膀胱浆膜和痣”。
6.根据权利要求5,其中根据组分(I)的至少一个野生型或突变蛋白的至少一个完整或部分抗原选自下列野生型蛋白和它们的已知的突变体:“Her-2/neu,雄激素受体,雌激素受体,肝素结合生长因子受体,EGF受体,ERBB2,ERBB4,TRAIL受体,FAS,TNFα受体,TGF-β受体,乳铁蛋白受体,碱性髓磷脂,α-乳清蛋白,GFAP,纤维酸性蛋白,酪氨酸酶,EGR-1,MUC1,c-Raf(Raf-1),A-Raf,B-Raf,B-Raf V599E,B-Raf V600E,B-Raf KD,B-Raf V600E激酶结构域,B-Raf V600E KD,B-Raf V600E激酶结构域KD,B-Raf激酶结构域,B-Raf激酶结构域KD,N-Ras,K-Ras,H-Ras,Bcl-2,Bcl-X,Bcl-W,Bfl-1,Brag-1,Mcl-1,A1,Bax,BAD,Bak,Bcl-Xs,Bid,Bik,Hrk,Bcr/abl,Myb,C-Met,IAP1,IAO2,XIAP,ML-IAP LIVIN,存活素,APAF-1,细胞周期蛋白D(1-3),细胞周期蛋白E,细胞周期蛋白A,细胞周期蛋白B,细胞周期蛋白H,Cdk-1,Cdk-2,Cdk-4,Cdk-6,Cdk-7,Cdc25C,p16,p15,p21,p27,p18,pRb,p107,p130,E2F(1-5),GAAD45,MDM2,PCNA,ARF,PTEN,APC,BRCA,Akt,PI3K,mTOR,p53和同源物,C-Myc,NFkB,c-Jun,ATF-2,Sp1,前列腺特异性抗原(PSA),癌胚抗原,甲胎蛋白,PAP;PSMA;STEAP;MAGE,MAGE-1,MAGE-3,NY-ESO-1,PSCA,MART,Gp100,酪氨酸酶,GRP,TCF-4,病毒HIV,HPV,HCV,HPV,EBV,CMV,HSV,流感病毒,A型流感病毒,A型流感病毒(H5N1)和(H3N2),B型流感病毒,C型流感病毒的病毒抗原;血凝素,血凝素H1,血凝素H5,血凝素H7,血凝素HA1(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12C(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),neuramidase,p60,LLO,脲酶,CSP,calflagin和/或CPB”或其中根据组分(I)的至少一个野生型或突变蛋白的至少一个完整或部分抗原选自由下列野生型蛋白和它们的已知的突变体组成的激酶(括号中是登录号):“AAK1(NM014911),AATK(NM 004920),ABL1(NM 005157),ABL2(NM 005158),ACK1(NM005781),ACVR1(NM 001105),ACVR1B(NM 020328),ACVR2(NM 001616),ACVR2B(NM 001106),ACVRL1(NM 000020),ADCK1(NM 020421),ADCK2(NM 052853),ADCK4(NM 024876),ADCK5(NM 174922),ADRBK1(NM001619),ADRBK2(NM 005160),AKT1(NM 005163),AKT2(NM 001626),AKT3(NM 005465),ALK(NM 004304),ALK7(NM 145259),ALS2CR2(NM 018571),ALS2CR7(NM 139158),AMHR2(NM 020547),ANKK1(NM 178510),ANKRD3(NM 020639),APEG1(NM 005876),ARAF(NM 001654),ARK5(NM 014840),ATM(NM 000051),ATR(NM 001184),AURKA(NM 003600),AURKB(NM004217),AURKC(NM 003160),AXL(NM 001699),BCKDK(NM 005881),BCR(NM 004327),BIKE(NM 017593),BLK(NM 001715),BMPR1A(NM 004329),BMPR1B(NM 001203),BMPR2(NM 001204),BMX(NM 001721),BRAF(NM004333),BRD2(NM 005104),BRD3(NM 007371),BRD4(NM 014299),BRDT(NM 001726),BRSK1(NM 032430),BRSK2(NM 003957),BTK(NM 000061),BUB1(NM 004336),BUB1B(NM 001211),CABC1(NM 020247),CAMK1(NM003656),CaMK1b(NM 198452),CAMK1D(NM 020397),CAMK1G(NM 020439),CAMK2A(NM 015981),CAMK2B(NM 001220),CAMK2D(NM 001221),CAMK2G(NM 001222),CAMK4(NM 001744),CAMKK1(NM 032294),CAMKK2(NM 006549),CASK(NM 003688),CCRK(NM 012119),CDC2(NM 001786),CDC2L1(NM 001787),CDC2L5(NM 003718),CDC42BPA(NM 014826),CDC42BPB(NM 006035),CDC7L1(NM 003503),CDK10(NM 003674),CDK11(NM 015076),CDK2(NM 001798),CDK3(NM 001258),CDK4(NM 000075),CDK5(NM 004935),CDK6(NM 001259),CDK7(NM 001799),CDK8(NM001260),CDK9(NM 001261),CDKL1(NM 004196),CDKL2(NM 003948),CDKL3(NM 016508),CDKL4(NM 001009565),CDKL5(NM 003159),CHEK1(NM 001274),CHUK(NM 001278),CIT(NM 007174),CLK1(NM 004071),CLK2(NM 003993),CLK3(NM 003992),CLK4(NM 020666),CRK7(NM 016507),CSF1R(NM 005211),CSK(NM 004383),CSNK1A1(NM 001892),CSNK1D(NM001893),CSNK1E(NM 001894),CSNK1G1(NM 022048),CSNK1G2(NM001319),CSNK1G3(NM 004384),CSNK2A1(NM 001895),CSNK2A2(NM001896),DAPK1(NM 004938),DAPK2(NM 014326),DAPK3(NM 001348),DCAMKL1(NM 004734),DCAMKL2(NM 152619),DCAMKL3(XM 047355),DDR1(NM 013993),DDR2(NM 006182),DMPK(NM 004409),DMPK2(NM 017525.1),DYRK1A(NM 001396),DYRK1B(NM 006484),DYRK2(NM 006482),DYRK3(NM 003582),DYRK4(NM 003845),EEF2K(NM 013302),EGFR(NM 005228),EIF2AK3(NM 004836),EIF2AK4(NM_001013703),EPHA1(NM 005232),EPHA10(NM 001004338),EPHA2(NM 004431),EPHA3(NM 005233),EPHA4(NM004438),EPHA5(NM 004439),EPHA6(XM 114973),EPHA7(NM 004440),EPHA8(NM 020526),EPHB1(NM 004441),EPHB2(NM 017449),EPHB3(NM004443),EPHB4(NM 004444),EPHB6(NM 004445),ERBB2(NM 004448),ERBB3(NM 001982),ERBB4(NM 005235),ERK8(NM 139021),ERN1(NM001433),ERN2(NM 033266),FASTK(NM 025096),FER(NM 005246),FES(NM002005),FGFR1(NM 000604),FGFR2(NM 022970),FGFR3(NM 000142),FGFR4(NM 022963),FGR(NM 005248),FLJ23074(NM 025052),FLJ23119(NM024652),FLJ23356(NM 032237),FLT1(NM 002019),FLT3(NM 004119),FLT4(NM 002020),FRAP1(NM 004958),FRK(NM 002031),FYN(NM 002037),GAK(NM 005255),GPRK5(NM 005308),GPRK6(NM 002082),GPRK7(NM 139209),GRK4(NM 005307),GSG2(NM 031965),GSK3A(NM 019884),GSK3B(NM002093),GUCY2C(NM 004963),GUCY2D(NM 000180),GUCY2F(NM 001522),H11(NM 014365),HAK(NM 052947),HCK(NM 002110),HIPK1(NM 152696),HIPK2(NM 022740),HIPK3(NM 005734),HIPK4(NM 144685),HRI(NM014413),HUNK(NM 014586),ICK(NM 016513),IGF1R(NM 000875),IKBKB(NM 001556),IKBKE(NM 014002),ILK(NM 004517),INSR(NM 000208),INSRR(NM 014215),IRAK1(NM 001569),IRAK2(NM 001570),IRAK3(NM 007199),IRAK4(NM 016123),ITK(NM 005546),JAK1(NM 002227),JAK2(NM 004972),JAK3(NM 000215),KDR(NM 002253),KIS(NM 144624),KIT(NM 000222),KSR(XM 290793),KSR2(NM 173598),LAK(NM 025144),LATS1(NM 004690),LATS2(NM 014572),LCK(NM 005356),LIMK1(NM 016735),LIMK2(NM005569),LMR3(XM 055866),LMTK2(NM 014916),LOC149420(NM 152835),LOC51086(NM 015978),LRRK2(XM 058513),LTK(NM 002344),LYN(NM002350),MAK(NM 005906),MAP2K1(NM 002755),MAP2K2(NM 030662),MAP2K3(NM 002756),MAP2K4(NM 003010),MAP2K5(NM 002757),MAP2K6(NM 002758),MAP2K7(NM 005043),MAP3K1(XM 042066),MAP3K10(NM002446),MAP3K11(NM 002419),MAP3K12(NM 006301),MAP3K13(NM004721),MAP3K14(NM 003954),MAP3K2(NM 006609),MAP3K3(NM 002401),MAP3K4(NM 005922),MAP3K5(NM 005923),MAP3K6(NM 004672),MAP3K7(NM 003188),MAP3K8(NM 005204),MAP3K9(NM 033141),MAP4K1(NM007181),MAP4K2(NM 004579),MAP4K3(NM 003618),MAP4K4(NM 145686),MAP4K5(NM 006575),MAPK1(NM 002745),MAPK10(NM 002753),MAPK11(NM 002751),MAPK12(NM 002969),MAPK13(NM 002754),MAPK14(NM001315),MAPK3(NM 002746),MAPK4(NM 002747),MAPK6(NM 002748),MAPK7(NM 002749),MAPK8(NM 002750),MAPK9(NM 002752),MAPKAPK2(NM 032960),MAPKAPK3(NM 004635),MAPKAPK5(NM 003668),MARK(NM018650),MARK2(NM 017490),MARK3(NM 002376),MARK4(NM 031417),MAST1(NM 014975),MAST205(NM 015112),MAST3(XM 038150),MAST4(XM291141),MASTL(NM 032844),MATK(NM 139355),MELK(NM 014791),MERTK(NM 006343),MET(NM 000245),MGC33182(NM 145203),MGC42105(NM153361),MGC43306(C9orf96),MGC8407(NM 024046),MIDORI(NM 020778),MINK(NM 015716),MKNK1(NM 003684),MKNK2(NM 017572),MLCK(NM182493),MLK4(NM 032435),MLKL(NM 152649),MOS(NM 005372),MST1R(NM 002447),MST4(NM 016542),MUSK(NM 005592),MYLK(NM 053025),MYLK2(NM 033118),MYO3A(NM 017433),MYO3B(NM 138995),NEK1(NM012224),NEK10(NM 152534),NEK11(NM 024800),NEK2(NM 002497),NEK3(NM 002498),NEK4(NM 003157),NEK5(MGC75495),NEK6(NM 014397),NEK7(NM 133494),NEK8(NM 178170),NEK9(NM 033116),NLK(NM 016231),NPR1(NM 000906),NPR2(NM 003995),NRBP(NM 013392),NRBP2(NM178564),NRK(NM 198465),NTRK1(NM 002529),NTRK2(NM 006180),NTRK3(NM 002530),OBSCN(NM 052843),OSR1(NM 005109),PACE-1(NM 020423),PAK1(NM 002576),PAK2(NM 002577),PAK3(NM 002578),PAK4(NM005884),PAK6(NM 020168),PAK7(NM 020341),PASK(NM 015148),PCTK1(NM 006201),PCTK2(NM 002595),PCTK3(NM 212503),PDGFRA(NM006206),PDGFRB(NM 002609),PDK1(NM 002610),PDK2(NM 002611),PDK3(NM 005391),PDK4(NM 002612),PDPK1(NM 002613),PFTK1(NM 012395),PHKG1(NM 006213),PHKG2(NM 000294),PIK3R4(NM 014602),PIM1(NM002648),PIM2(NM 006875),PIM3(NM 001001852),PINK1(NM 032409),PKE(NM 173575),PKMYT1(NM 004203),pknbeta(NM 013355),PLK(NM 005030),PLK3(NM 004073),PRKAA1(NM 006251),PRKAA2(NM 006252),PRKACA(NM002730),PRKACB(NM 002731),PRKACG(NM 002732),PRKCA(NM 002737),PRKCB1(NM 002738),PRKCD(NM 006254),PRKCE(NM 005400),PRKCG(NM002739),PRKCH(NM 006255),PRKCI(NM 002740),PRKCL1(NM 002741),PRKCL2(NM 006256),PRKCM(NM 002742),PRKCN(NM 005813),PRKCQ(NM 006257),PRKCZ(NM 002744),PRKD2(NM 016457),PRKDC(NM 006904),PRKG1(NM 006258),PRKG2(NM 006259),PRKR(NM 002759),PRKWNK1(NM018979),PRKWNK2(NM 006648),PRKWNK3(NM 020922),PRKWNK4(NM032387),PRKX(NM 005044),PRKY(NM 002760),PRPF4B(NM 003913),PSKH1(NM 006742),PSKH2(NM 033126),PTK2(NM 005607),PTK2B(NM004103),PTK6(NM 005975),PTK7(NM 002821),PTK9(NM 002822),PTK9L(NM 007284),PXK(NM 017771),QSK(NM 025164),RAD53(NM 007194),RAF1(NM 002880),RAGE(NM 014226),RET(NM 020975),RHOK(NM 002929),RIOK1(NM 031480),RIOK2(NM 018343),RIPK1(NM 003804),RIPK2(NM003821),RIPK3(NM 006871),RIPK5(NM 015375),RNASEL(NM 021133),ROCK1(NM 005406),ROCK2(NM 004850),ROR1(NM 005012),ROR2(NM004560),ROS1(NM 002944),RPS6KA1(NM 002953),RPS6KA2(NM 021135),RPS6KA3(NM 004586),RPS6KA4(NM 003942),RPS6KA5(NM 004755),RPS6KA6(NM 014496),RPS6KB1(NM 003161),RPS6KB2(NM 003952),RPS6KC1(NM 012424),RPS6KL1(NM 031464),RYK(NM 002958),SBK(XM370948),SCYL1(NM 020680),SCYL2(NM 017988),SGK(NM 005627),SgK069(SU SgK069),SgK085(XM 373109),SgK110(SU SgK110),SGK2(NM 016276),SgK223(XM 291277),SgK269(XM 370878),SgK424(CGP SgK424),SgK493(SU_SgK493),SgK494(NM 144610),SgK495(NM 032017),SGKL(NM 013257),SK681(NM 001001671),SLK(NM 014720),SMG1(NM 015092),SNARK(NM030952),SNF1LK(NM 173354),SNF1LK2(NM 015191),SNK(NM 006622),SNRK(NM 017719),SRC(NM 005417),SRMS(NM 080823),SRPK1(NM003137),SRPK2(NM 003138),SSTK(NM 032037),STK10(NM 005990),STK11(NM 000455),STK16(NM 003691),STK17A(NM 004760),STK17B(NM004226),STK18(NM 014264),STK19(NM 032454),STK22B(NM 053006),STK22C(NM 052841),STK22D(NM 032028),STK23(NM 014370),STK24(NM003576),STK25(NM 006374),STK3(NM 006281),STK31(NM 031414),STK32B(NM 018401),STK33(NM 030906),STK35(NM 080836),STK36(NM015690),STK38(NM 007271),STK38L(NM 015000),STK39(NM 013233),STK4(NM 006282),STLK5(NM 001003787),STYK1(NM 018423),SUDD(NM003831),SYK(NM 003177),TAF1(NM 138923),TAF1L(NM 153809),TAO1(NM004783),TAOK1(NM 020791),TAOK3(NM 016281),TBCK(NM 033115),TBK1(NM 013254),TEC(NM 003215),TEK(NM 000459),TESK1(NM 006285),TESK2(NM 007170),TEX14(NM 031272),TGFBR1(NM 004612),TGFBR2(NM003242),TIE(NM 005424),TIF1(NM 003852),TLK1(NM 012290),TLK2(NM006852),TNIK(NM 015028),TNK1(NM 003985),TOPK(NM 018492),TP53RK(NM 033550),TRAD(NM 007064),TRIB1(NM 025195),TRIB2(NM 021643),TRIB3(NM 021158),TRIM28(NM 005762),TRIM33(NM 015906),TRIO(NM007118),TRPM6(NM 017662),TRPM7(NM 017672),TRRAP(NM 003496),TSSK4(NM 174944),TTBK1(NM 032538),TTBK2(NM 173500),TTK(NM003318),TTN(NM 003319),TXK(NM 003328),TYK2(NM 003331),TYRO3(NM006293),ULK1(NM 003565),ULK2(NM 014683),ULK3(NM 015518),ULK4(NM017886),VRK1(NM 003384),VRK2(NM 006296),VRK3(NM 016440),WEE1(NM 003390),Wee1B(NM 173677),YANK1(NM 145001),YES1(NM 005433),ZAK(NM 016653),和/或ZAP70(NM 001079)”。
7.根据权利要求1至6中任一项的微生物,其中组分(II)选自“细菌毒素,肠毒素,外毒素,I型毒素,II型毒素,III型毒素,IV型毒素,V型毒素,RTX毒素,AB毒素,A-B毒素,A/B毒素,A+B毒素,A-5B毒素和/或AB5毒素”。
8.根据权利要求7的微生物,其中组分(II)选自“腺苷酸环化酶毒素,炭疽毒素,炭疽毒素(EF),炭疽毒素(LF),肉毒杆菌毒素,霍乱毒素(CT,Ctx),霍乱毒素B亚基(CTB,CtxB),白喉毒素(DT,Dtx),大肠杆菌LT毒素,大肠杆菌热不稳定肠毒素(LT),大肠杆菌热不稳定肠毒素B亚基(LTB),大肠杆菌ST毒素,大肠杆菌热稳定肠毒素(ST),红斑毒素,表皮剥脱毒素,外毒素A,产气荚膜菌肠毒素,百日咳毒素(PT,Ptx),志贺菌毒素(ST,Stx),志贺菌毒素B亚基(STB,StxB),志贺样毒素,葡萄球菌肠毒素,破伤风毒素(TT),中毒性休克综合征毒素(TSST-1),Vero细胞毒素(VT),艰难梭菌的毒素A(TA)和毒素B(TB),索氏梭菌的致死毒素(LT)和出血毒素(HT),诺氏梭菌的α毒素(AT)”。
9.根据权利要求1至8中任一项的微生物,其中组分(I)和组分(II)连接在一起使得能够表达和/或分泌由两个组分编码的融合蛋白。
10.根据权利要求9的微生物,其中所述融合蛋白选自“CtxB-PSA,CtxB-B-Raf V600E KD,CtxB-B-Raf V600E激酶结构域,CtxB-B-RafV600E激酶结构域KD,CtxB-B-Raf,CtxB-B-Raf KD,CtxB B-Raf激酶结构域KD,CtxB-HA1,CtxB-HA12C”。
11.根据权利要求1至10中任一项的微生物,其中组分(III)a)选自“I型分泌系统,II型分泌系统,III型分泌系统,IV型分泌系统,V型分泌系统,大肠杆菌溶血素转运系统(信号)(在hly特异性启动子控制下的包含HlyA,HlyB和HlyD的核苷酸序列),大肠杆菌溶血素转运系统(信号)(在非hly特异性细菌启动子的控制下的包含HlyA,HlyB和HlyD的核苷酸序列),新月柄杆菌的S层(Rsa A)蛋白的转运信号,大肠杆菌的TolC蛋白的转运信号,分泌信号Vtgss和/或源自利斯特菌溶胞素,p60和/或ActA的分泌信号”并且其中组分(III)b)选自“细胞内溶素,革兰氏阳性菌的裂解蛋白,单核细胞增生利斯特菌的裂解蛋白,单核细胞增生利斯特菌的PLY551和/或单核细胞增生利斯特菌的穿孔素”。
12.根据权利要求11的微生物,其中组分(III)a)为仅编码一个转运系统的至少一个核苷酸序列,所述的转运系统使得能够在微生物的外表面上共表达组分(I)和组分(II)的表达产物和/或使得能够共分泌组分(I)和组分(II)的表达产物,其中此类组分(III)a)优选为编码大肠杆菌的溶血素转运系统(信号)(在hly特异性启动子的控制下的包含HlyA,HlyB和HlyD的核苷酸序列)或大肠杆菌的溶血素转运系统(信号)(在非hly特异性细菌启动子控制下的包含HlyA,HlyB和HlyD的核苷酸序列)的至少一个核苷酸序列。
13.根据权利要求1至12中任一项的微生物,其中根据组分(III)a),组分(I)和组分(II)的表达产物被分泌。
14.根据权利要求1至13中任一项的微生物,其中
组分(I)选自“B-Raf V600E,B-Raf V600E激酶结构域,B-Raf V600EKD,B-Raf V600E激酶结构域KD,B-Raf KD,B-Raf激酶结构域,B-Raf激酶结构域KD,前列腺特异性抗原(PSA),血凝素HA1(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1),血凝素HA12C(优选来自A型流感病毒(A/泰国/1(KAN-1)2004(H5N1)”;
组分(II)选自“霍乱毒素B亚基(CTB,CtxB),大肠杆菌热不稳定肠毒素B亚基(LTB),破伤风毒素(TT)”;
组分(III)a)选自“与Hly分泌系统的组分一起的大肠杆菌HlyA溶血素转运信号(在hly特异性启动子的控制下的包含HlyA,HlyB和HlyD的核苷酸序列)”;
组分(IV)选自“大肠杆菌hly基因座的内源启动子”;
其中组分(I)和组分(II)连接在一起以使得能够表达由两个组分编码的融合蛋白并且其中该融合蛋白被分泌。
15.药物组合物,其包含至少一种根据权利要求1至14中任一项的微生物,优选至少一种冻干的根据权利要求1至14中任一项的微生物,和药学上可接受的载体,优选胶囊。
16.包含至少一种根据权利要求1至14中任一项的微生物或至少一种根据权利要求15的药物组合物的药物。
17.根据权利要求1至14中任一项的微生物用于制备用于治疗和/或预防生理学和/或病理生理学的病况的药物的用途,所述病况选自“不受控制的细胞分裂,恶性肿瘤,良性肿瘤,实体瘤,肉瘤,癌,过度增殖性疾病,类癌,尤文肉瘤,卡波西肉瘤,脑肿瘤,源自脑和/或神经系统和/或脑脊膜的肿瘤,神经胶质瘤,神经母细胞瘤,胃癌,肾癌,肾细胞癌,前列腺癌,前列腺癌变,结缔组织肿瘤,软组织肉瘤,胰腺肿瘤,肝肿瘤,头部肿瘤,颈部肿瘤,食管癌,甲状腺癌,骨肉瘤,视网膜母细胞瘤,胸腺瘤,睾丸癌,肺癌,支气管癌,乳腺癌,乳癌,肠癌,结直肠肿瘤,结肠癌,直肠癌,妇科肿瘤,卵巢肿瘤/卵巢的肿瘤,子宫癌,宫颈癌,宫颈癌变,子宫体癌,子宫体癌变,子宫内膜癌,尿膀胱癌,膀胱癌,皮肤癌,基底细胞瘤,肌脊瘤,黑色素瘤,眼内黑色素瘤,白血病,慢性白血病,急性白血病,淋巴瘤,感染,病毒性或细菌性感染,流行性感冒,慢性炎症,器官排斥和/或自身免疫性疾病”。
18.包含根据权利要求1至14中任一项的组分(I)至(IV)的质粒或表达载体。
19.用于制备根据权利要求1至14中任一项的微生物的方法,其中制备根据权利要求18的质粒或表达载体,并且用该质粒或表达载体转化微生物。
20.药物试剂盒,其包含至少一种根据权利要求1至14中任一项的微生物或根据权利要求15的药物组合物或根据权利要求16的药物以及药学上可接受的缓冲剂,优选碳酸盐缓冲剂。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86548406P | 2006-11-13 | 2006-11-13 | |
EP06123974A EP1921149A1 (en) | 2006-11-13 | 2006-11-13 | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
EP06123974.5 | 2006-11-13 | ||
US60/865,484 | 2006-11-13 | ||
US93914007P | 2007-05-21 | 2007-05-21 | |
US60/939,140 | 2007-05-21 | ||
PCT/EP2007/062237 WO2008058944A1 (en) | 2006-11-13 | 2007-11-13 | Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101595219A true CN101595219A (zh) | 2009-12-02 |
CN101595219B CN101595219B (zh) | 2016-01-27 |
Family
ID=37846081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200780044576.6A Expired - Fee Related CN101595219B (zh) | 2006-11-13 | 2007-11-13 | 作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物,其制备方法和用途 |
Country Status (30)
Country | Link |
---|---|
US (1) | US8669091B2 (zh) |
EP (2) | EP1921149A1 (zh) |
JP (1) | JP5479102B2 (zh) |
KR (1) | KR101505413B1 (zh) |
CN (1) | CN101595219B (zh) |
AR (1) | AR063795A1 (zh) |
AT (1) | ATE469971T1 (zh) |
AU (1) | AU2007321266B2 (zh) |
BR (1) | BRPI0719003A2 (zh) |
CA (1) | CA2669219A1 (zh) |
CY (1) | CY1111035T1 (zh) |
DE (1) | DE602007006985D1 (zh) |
DK (1) | DK2092067T3 (zh) |
ES (1) | ES2347019T3 (zh) |
HK (1) | HK1138314A1 (zh) |
HR (1) | HRP20100466T1 (zh) |
IL (1) | IL198736A0 (zh) |
ME (1) | ME01846B (zh) |
MX (1) | MX2009005038A (zh) |
NO (1) | NO20092278L (zh) |
NZ (1) | NZ576947A (zh) |
PL (1) | PL2092067T3 (zh) |
PT (1) | PT2092067E (zh) |
RS (1) | RS51416B (zh) |
RU (1) | RU2447145C2 (zh) |
SI (1) | SI2092067T1 (zh) |
TW (1) | TWI394834B (zh) |
UA (1) | UA94974C2 (zh) |
WO (1) | WO2008058944A1 (zh) |
ZA (1) | ZA200903022B (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104066447A (zh) * | 2011-11-23 | 2014-09-24 | 拜奥文斯瑞有限公司 | 重组蛋白及其治疗用途 |
CN104619841A (zh) * | 2012-07-26 | 2015-05-13 | 日本国立癌症研究中心 | Cep55基因与ret基因的融合基因 |
CN105473609A (zh) * | 2013-04-17 | 2016-04-06 | 杜塞尔多夫海因里希·海涅大学 | 用于表达肽和蛋白的方法 |
CN105601753A (zh) * | 2016-02-22 | 2016-05-25 | 潍坊医学院 | 结核杆菌噬菌体双组份融合溶菌蛋白及其制备方法和应用 |
CN107001431A (zh) * | 2014-05-21 | 2017-08-01 | 巴塞尔大学 | 基于细菌的蛋白质递送 |
CN107427565A (zh) * | 2014-12-19 | 2017-12-01 | 宾夕法尼亚大学理事会 | 使用重组李斯特菌菌株的组合疗法 |
CN107708713A (zh) * | 2015-04-28 | 2018-02-16 | 阿尔伯特爱因斯坦医学院公司 | 使用由减毒细菌递送的回忆抗原治疗癌症 |
CN107858430A (zh) * | 2017-11-20 | 2018-03-30 | 薛守海 | 甲基化基因组合物及制备诊断预示Her‑2过表达型乳腺癌骨转移试剂盒的用途 |
CN109486832A (zh) * | 2018-12-29 | 2019-03-19 | 中国农业科学院棉花研究所 | 一种创建有限生长株型棉花的方法 |
CN110237240A (zh) * | 2019-07-03 | 2019-09-17 | 上海市肺科医院 | 可溶性受体酪氨酸激酶sAxl在治疗结核病中的应用 |
CN111349099A (zh) * | 2015-03-19 | 2020-06-30 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
CN113721030A (zh) * | 2021-08-30 | 2021-11-30 | 河南中医药大学 | 用于桥本甲状腺炎不同证候特征性自身抗体检测的生物标志物及其应用 |
CN114921546A (zh) * | 2022-05-13 | 2022-08-19 | 核工业总医院 | circHIPK2作为乳腺癌生物标志物的应用 |
CN115976033A (zh) * | 2022-12-14 | 2023-04-18 | 西南大学 | 瓜实蝇tssk1和tssk3基因及其应用 |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2331271B1 (es) * | 2007-06-29 | 2010-10-14 | Universidad Del Pais Vasco | Metodo para la internalizacion de bacterias no invasivas en celulas eucariotas. |
US8877201B2 (en) | 2007-10-25 | 2014-11-04 | Wake Forest University Health Sciences | Bordetella outer-membrane protein antigens and methods of making and using the same |
AR070568A1 (es) * | 2008-02-05 | 2010-04-21 | Aeterna Zentaris Gmbh | Bacterias recombinantes con un sistema de secrecion de hemolisina de e. coli y expresion y /o secrecion incrementada de hlya, proceso para producirlas, y sus usos |
US20120020996A1 (en) * | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
KR101104077B1 (ko) * | 2008-10-14 | 2012-01-11 | 건국대학교 산학협력단 | Egr-1의 발현을 증가시키는 활성을 갖는 신규한 엔터로박테리아속에 속하는 신규균주 및 그 균주를 포함하는 조성물의 항암제로서의 용도 |
CN101480489B (zh) * | 2008-12-03 | 2012-07-04 | 中国人民解放军第三军医大学 | 疟原虫环子孢子蛋白抗肿瘤增殖和迁移的新用途 |
US8524220B1 (en) | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
US8771669B1 (en) | 2010-02-09 | 2014-07-08 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
GB2478734A (en) * | 2010-03-15 | 2011-09-21 | Sense Proteomic Ltd | Auto-antibody biomarkers of prostate cancer |
KR101229596B1 (ko) * | 2010-05-13 | 2013-02-04 | 한국외국어대학교 연구산학협력단 | 사람 락토페리신 펩티드의 대장균 발현 플라스미드 및 그 용도 |
WO2012028741A1 (en) | 2010-09-03 | 2012-03-08 | Intercell Ag | Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof |
US9856492B2 (en) * | 2011-03-02 | 2018-01-02 | Futuragene Israel Ltd. | Bacterial resistant transgenic plants having dysfunctional T3SS proteins |
CN103687611A (zh) | 2011-03-11 | 2014-03-26 | 阿德瓦希斯公司 | 基于李斯特菌属的佐剂 |
CN103987396A (zh) * | 2011-09-06 | 2014-08-13 | 新加坡科技研究局 | 多肽疫苗 |
US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
EP3760226A1 (en) | 2011-09-23 | 2021-01-06 | Loma Linda University | Bacterial strains expressing methylase genes and uses thereof |
EP2583975A1 (en) * | 2011-10-21 | 2013-04-24 | Heinrich-Heine-Universität Düsseldorf | Agents and methods for the expression and secretion of peptides and proteins |
JP2015511602A (ja) | 2012-03-12 | 2015-04-20 | アドバクシス, インコーポレイテッド | リステリアワクチン処理後のサプレッサー細胞機能抑制 |
US9499856B2 (en) | 2012-04-02 | 2016-11-22 | The Board Institute, Inc. | DDR2 mutations in squamous cell lung cancer |
CN104470537B (zh) * | 2012-05-23 | 2017-04-26 | 美国政府(由卫生和人类服务部的部长所代表) | 表达鼠疫耶尔森氏菌F1‑V融合蛋白的伤寒沙门氏菌Ty21a及其用途 |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
CA2904506A1 (en) * | 2013-03-15 | 2014-09-18 | Bioven 3 Limited | Self-assembling synthetic proteins |
LT2988762T (lt) | 2013-04-25 | 2018-09-25 | Vaximm Ag | Vektoriai, sukonstruoti salmonella pagrindu, skirti vėžio imunoterapijai, nukreiptai į vilmso naviko geną wt1 |
CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
EP3166637B1 (en) | 2014-07-10 | 2020-01-29 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
WO2016019379A1 (en) * | 2014-08-01 | 2016-02-04 | Northwestern University | Bacterial toxins and uses thereof as ras specific proteases |
US9717745B2 (en) | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
JP7266834B2 (ja) | 2015-12-28 | 2023-05-01 | 北海道公立大学法人 札幌医科大学 | 腫瘍抗原ペプチド |
SI3432916T1 (sl) | 2016-09-13 | 2020-01-31 | Allergan, Inc. | Stabilizirani ne-protein klostridijski toksin sestavki |
CA3037813A1 (en) | 2016-09-21 | 2018-03-29 | The Governors Of The University Of Alberta | Hepatitis c virus immunogenic compositions and methods of use thereof |
GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
TW201922256A (zh) | 2017-10-27 | 2019-06-16 | 中國大陸商浙江導明醫藥科技有限公司 | 治療淋巴樣惡性疾病之方法 |
CN109593771B (zh) * | 2018-07-27 | 2022-03-29 | 四川大学华西医院 | 一种人类map2k5第1100位碱基突变基因及其检测试剂盒 |
CN110330548B (zh) * | 2019-06-28 | 2021-03-09 | 哈尔滨医科大学 | 一种抗肿瘤多肽及其在制备抗肿瘤药物中的应用 |
WO2021026335A1 (en) * | 2019-08-08 | 2021-02-11 | The Trustees Of Indiana University | Methods for identifying and treating urinary tract infections |
AU2020329191A1 (en) | 2019-08-12 | 2022-03-31 | Regeneron Pharmaceuticals, Inc. | Macrophage stimulating 1 receptor (MST1R) variants and uses thereof |
CN113694202B (zh) * | 2020-06-29 | 2023-03-31 | 江苏省中医院 | Ass1或bckdk抑制剂在制备治疗溃疡性结肠炎的药物中的应用 |
WO2022098213A1 (ko) * | 2020-11-09 | 2022-05-12 | 전남대학교 산학협력단 | 암의 예방 및 치료용 살모넬라 균주 및 이의 용도 |
KR102547393B1 (ko) * | 2021-04-19 | 2023-06-23 | 엠브릭스 주식회사 | 보툴리늄 독소 전위 도메인 및 엔도라이신을 포함하는 단백질 복합체 및 이를 포함하는 항균 조성물 |
GB202209115D0 (en) * | 2022-06-21 | 2022-08-10 | Chain Biotechnology Ltd | Compositions and methods |
WO2024054673A1 (en) * | 2022-09-09 | 2024-03-14 | Texas Tech University System | Listeria monocytogenes as a vector for tumor-specific delivery of chemotherapeutic agents |
CN116875520A (zh) * | 2023-07-12 | 2023-10-13 | 吉林农业大学 | 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02170053A (ja) * | 1988-12-23 | 1990-06-29 | Meiji Seika Kaisha Ltd | 微生物の検出方法及び装置 |
RU2092556C1 (ru) * | 1995-08-29 | 1997-10-10 | Научно-исследовательский институт микробиологии Министерства обороны Российской Федерации | Способ введения чужеродных генов в геномы грамотрицательных микроорганизмов, плазмидный вектор ркс47м для введения чужеродных генов в геномы грамотрицательных микроорганизмов, способ конструирования плазмидного вектора ркс47м |
AU4070097A (en) * | 1996-08-16 | 1998-03-06 | Uab Research Foundation, The | Mucosal immunogens for novel vaccines |
US6036953A (en) * | 1996-11-29 | 2000-03-14 | The General Hospital Corporation | Heterologous antigens in live cell V. cholerae strains |
US20030235594A1 (en) * | 1999-09-14 | 2003-12-25 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
WO2001029233A2 (en) * | 1999-10-20 | 2001-04-26 | The Johns Hopkins University School Of Medicine | Chimeric immunogenic compositions and nucleic acids encoding them |
GB0030067D0 (en) * | 2000-12-11 | 2001-01-24 | Univ Bristol | Therapeutic agent |
RU2216590C1 (ru) * | 2002-02-26 | 2003-11-20 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Рекомбинантный аттенуированный штамм бактерий salmonella typhimurium t10/pkhbc - продуцент корового антигена вируса гепатита в |
DE10208653A1 (de) | 2002-02-28 | 2003-09-18 | Medinnova Ges Med Innovationen | Mikroorganismus als Träger von Nukleotidsequenzen kodierend für Zellantigene zur Behandlung von Tumoren |
-
2006
- 2006-11-13 EP EP06123974A patent/EP1921149A1/en not_active Withdrawn
-
2007
- 2007-11-13 EP EP07822513A patent/EP2092067B1/en active Active
- 2007-11-13 RU RU2009122560/10A patent/RU2447145C2/ru active
- 2007-11-13 KR KR1020097012089A patent/KR101505413B1/ko active IP Right Grant
- 2007-11-13 AR ARP070105040A patent/AR063795A1/es unknown
- 2007-11-13 PT PT07822513T patent/PT2092067E/pt unknown
- 2007-11-13 ME MEP-2010-387A patent/ME01846B/me unknown
- 2007-11-13 DE DE602007006985T patent/DE602007006985D1/de active Active
- 2007-11-13 CA CA002669219A patent/CA2669219A1/en not_active Abandoned
- 2007-11-13 DK DK07822513.3T patent/DK2092067T3/da active
- 2007-11-13 SI SI200730328T patent/SI2092067T1/sl unknown
- 2007-11-13 CN CN200780044576.6A patent/CN101595219B/zh not_active Expired - Fee Related
- 2007-11-13 US US11/939,254 patent/US8669091B2/en not_active Expired - Fee Related
- 2007-11-13 RS RSP-2010/0387A patent/RS51416B/en unknown
- 2007-11-13 BR BRPI0719003-4A patent/BRPI0719003A2/pt not_active Application Discontinuation
- 2007-11-13 MX MX2009005038A patent/MX2009005038A/es active IP Right Grant
- 2007-11-13 NZ NZ576947A patent/NZ576947A/en unknown
- 2007-11-13 UA UAA200906068A patent/UA94974C2/uk unknown
- 2007-11-13 AU AU2007321266A patent/AU2007321266B2/en not_active Ceased
- 2007-11-13 PL PL07822513T patent/PL2092067T3/pl unknown
- 2007-11-13 ES ES07822513T patent/ES2347019T3/es active Active
- 2007-11-13 JP JP2009536716A patent/JP5479102B2/ja not_active Expired - Fee Related
- 2007-11-13 WO PCT/EP2007/062237 patent/WO2008058944A1/en active Application Filing
- 2007-11-13 TW TW096142857A patent/TWI394834B/zh not_active IP Right Cessation
- 2007-11-13 AT AT07822513T patent/ATE469971T1/de active
-
2009
- 2009-05-04 ZA ZA200903022A patent/ZA200903022B/xx unknown
- 2009-05-13 IL IL198736A patent/IL198736A0/en active IP Right Grant
- 2009-06-12 NO NO20092278A patent/NO20092278L/no not_active Application Discontinuation
-
2010
- 2010-01-21 HK HK10100634.0A patent/HK1138314A1/zh not_active IP Right Cessation
- 2010-08-19 CY CY20101100767T patent/CY1111035T1/el unknown
- 2010-08-25 HR HR20100466T patent/HRP20100466T1/hr unknown
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11198716B2 (en) | 2011-11-23 | 2021-12-14 | In3Bio Ltd. | Recombinant proteins and their therapeutic uses |
CN108864261A (zh) * | 2011-11-23 | 2018-11-23 | 拜奥文斯瑞有限公司 | 重组蛋白及其治疗用途 |
CN108864291A (zh) * | 2011-11-23 | 2018-11-23 | 拜奥文斯瑞有限公司 | 重组蛋白及其治疗用途 |
CN104066447A (zh) * | 2011-11-23 | 2014-09-24 | 拜奥文斯瑞有限公司 | 重组蛋白及其治疗用途 |
CN104619841A (zh) * | 2012-07-26 | 2015-05-13 | 日本国立癌症研究中心 | Cep55基因与ret基因的融合基因 |
US10443081B2 (en) | 2013-04-17 | 2019-10-15 | Numaferm Gmbh | Methods for the expression of peptides and proteins |
CN105473609A (zh) * | 2013-04-17 | 2016-04-06 | 杜塞尔多夫海因里希·海涅大学 | 用于表达肽和蛋白的方法 |
CN107001431A (zh) * | 2014-05-21 | 2017-08-01 | 巴塞尔大学 | 基于细菌的蛋白质递送 |
CN107427565A (zh) * | 2014-12-19 | 2017-12-01 | 宾夕法尼亚大学理事会 | 使用重组李斯特菌菌株的组合疗法 |
CN111349099A (zh) * | 2015-03-19 | 2020-06-30 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
CN107708713A (zh) * | 2015-04-28 | 2018-02-16 | 阿尔伯特爱因斯坦医学院公司 | 使用由减毒细菌递送的回忆抗原治疗癌症 |
CN105601753A (zh) * | 2016-02-22 | 2016-05-25 | 潍坊医学院 | 结核杆菌噬菌体双组份融合溶菌蛋白及其制备方法和应用 |
CN107858430B (zh) * | 2017-11-20 | 2019-01-04 | 武汉迈特维尔生物科技有限公司 | 一种用于诊断预示Her-2过表达型乳腺癌骨转移的基因诊断试剂盒 |
CN107858430A (zh) * | 2017-11-20 | 2018-03-30 | 薛守海 | 甲基化基因组合物及制备诊断预示Her‑2过表达型乳腺癌骨转移试剂盒的用途 |
CN109486832A (zh) * | 2018-12-29 | 2019-03-19 | 中国农业科学院棉花研究所 | 一种创建有限生长株型棉花的方法 |
CN109486832B (zh) * | 2018-12-29 | 2021-11-23 | 中国农业科学院棉花研究所 | 一种创建有限生长株型棉花的方法 |
CN110237240A (zh) * | 2019-07-03 | 2019-09-17 | 上海市肺科医院 | 可溶性受体酪氨酸激酶sAxl在治疗结核病中的应用 |
CN113721030A (zh) * | 2021-08-30 | 2021-11-30 | 河南中医药大学 | 用于桥本甲状腺炎不同证候特征性自身抗体检测的生物标志物及其应用 |
CN113721030B (zh) * | 2021-08-30 | 2024-02-13 | 河南中医药大学 | 用于桥本甲状腺炎不同证候特征性自身抗体检测的生物标志物及其应用 |
CN114921546A (zh) * | 2022-05-13 | 2022-08-19 | 核工业总医院 | circHIPK2作为乳腺癌生物标志物的应用 |
CN115976033A (zh) * | 2022-12-14 | 2023-04-18 | 西南大学 | 瓜实蝇tssk1和tssk3基因及其应用 |
CN115976033B (zh) * | 2022-12-14 | 2024-05-17 | 西南大学 | 瓜实蝇tssk1和tssk3基因及其应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101595219A (zh) | 作为编码抗原和蛋白毒素的核苷酸序列的载体的微生物,其制备方法和用途 | |
US20090208461A1 (en) | Recombinant bacteria with e.coli hemolysin secretion system and increased expression and/or secretion of hlya, process of manufacturing and uses thereof | |
DK2942391T3 (en) | PROCEDURES FOR THE MANUFACTURE OF ANTIBIOTICS-RESISTANCE-FREE VACCINES | |
SA93130462B1 (ar) | طوافر mutants مزالة السمية مولدة للمناعة من سم الكوليرا ومن سم غير ثابت حراريا , تحضيرها واستحدامها لتحضير اللقاحات | |
US9402889B2 (en) | Live, oral vaccine for protection against Shigella dysenteriae serotype 1 | |
CN107073094A (zh) | 表达异源性抗原融合蛋白的重组李斯特菌菌株及其使用方法 | |
CN110564751A (zh) | 微环dna疫苗设计及应用 | |
Seidel et al. | 4 Identification of a novel arabinofuranosyltransferase AftB involved in a terminal step of cell wall arabinan biosynthesis in Corynebacterianeae, such as Corynebacterium glutamicum and Mycobacterium tuberculosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1138314 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1138314 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160127 Termination date: 20211113 |
|
CF01 | Termination of patent right due to non-payment of annual fee |